<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-12-29 09:23:09 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>94</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="Severe SARS-CoV-2 infection is characterized by lung hyperinflammation, impaired interferon responses, and defective T-cell activation, yet the molecular drivers of these immune dysregulations remain incompletely understood. Caspase-11 (CASP11), a key mediator of the non-canonical inflammasome, has been shown to mediate an innate hyperinflammatory response and cytokine release in a non-severe, non-lethal SARS-CoV-2 infection model. However, the role played by CASP11 in severe SARS-CoV-2 disease and how it impacts adaptive immunity is not identified. Here, we newly discover that CASP11 exacerbates severe SARS-CoV-2 pathogenesis by amplifying early innate immune responses while concurrently impairing antiviral CD8 T-cell immunity. Using global knockouts, reciprocal bone marrow chimeras, and phagocyte-monocyte system (PMS) cell-specific CASP11 deletion models, we show that CASP11 deletion in monocyte-derived cells reduces lung inflammation, enhances type I and II interferon signaling, and promotes robust virus-specific effector CD8⁺ T-cell response. This was associated with enhanced viral clearance and improved survival, even under lethal infection conditions. Importantly, CASP11 KO mice also exhibited faster resolution of post-viral inflammation, suggesting a role in long-term immune remodeling. These findings position CASP11 as a promising immunomodulatory target for acute and delayed manifestations of severe SARS-CoV-2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fa0d09c722147bd759ef9cedc307b8c6a5fb7718" target='_blank'>
              Caspase-11 Mediated Hyperinflammation Impairs CD8+ T Cell Immunity and Viral Clearance in Severe SARS-CoV-2 Infection
              </a>
            </td>
          <td>
            Mostafa Eltobgy, Mohamed M. Shamseldin, Owen Whitham, Heba M Amer, Jeffery Atkinson, Asmaa Badr, Jesse Hall, Jihad Omran, Gauruv A. Gupta, Yara Hassan, Rabab Abdelaleem, Richard Perez, Sarah Faber, Maciej Pietrzak, Amy Webb, Xiaoli Zhang, A. Kenney, Destiny Bissel, Shady Z K Estfanous, Kylene P. Daily, Andrew Mcnamara, Mahesh Kc, M. Peeples, Emily A. Hemann, Shahid M. Nimjee, E. Cormet-Boyaka, Jianrong Li, P. Boyaka, Jacob S. Yount, Benjamin M. Segal, Purnima Dubey, Amal O Amer
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, , Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Aging is a major risk factor for increased morbidity and mortality following acute respiratory virus infections. To elucidate the immune determinants underlying viral pathogenesis and delayed lung repair in the aged lung, a comprehensive time-course study was conducted. Single-cell RNA sequencing (scRNAseq) and high-dimensional flow cytometry were utilized to compare lungs from young and aged mice infected with influenza A virus (IAV). Aged hosts displayed diminished alveolar macrophage (AM) and dendritic cell (DC) but elevated monocyte-derived macrophage (MoM) and interstitial macrophage (IM) presence following infection. Additionally, enhanced accumulation of adaptive immune cells, including CD4+ tissue-resident helper (TRH) cells, CD8+ tissue-resident memory (TRM) cells, and a B cell subset resembling age-associated B cells, was observed in the memory phase. Pathway analysis revealed that elevated type I and II interferon (IFNα/γ) signaling, especially in MoM/IM subsets, distinguished the aged hosts from the young. Inhibition of IFNα/γ signaling after viral clearance improved long-term respiratory outcomes and reduced both IM and TRH populations in aged mice. These findings highlight the pivotal role of IFNα/γ signaling, likely within MoM/IM subsets, in driving the exuberant persistence of adaptive immune cells and chronic immunopathology in the aged lung following acute viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/79fbb4abcb1eeb6127549b886296b47a4c3b2fa0" target='_blank'>
              Temporal single-cell analysis reveals age-associated delay in immune resolution after respiratory viral infection
              </a>
            </td>
          <td>
            Yue Wu, Chaofan Li, Jinyi Tang, Xiaochen Gao, I. Cheon, Bibo Zhu, Ruixuan Zhang, C. Fain, S. Hu, H. Narasimhan, Gislane de Almeida Santos, K. Ayasoufi, , Hui Zong, Chongzhi Zang, Haidong Dong, Jie Sun
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therapy, yet the underlying mechanisms driving this potentiation remain poorly defined. This study aimed to elucidate how pomalidomide enhances CAR-T cell function and remodels the immune microenvironment to overcome therapeutic limitations. Methods In vitro assays (CCK-8, LDH, qPCR, ELISA, flow cytometry) and bulk RNA-seq assessed pomalidomide’s effects on human CAR-T cells. In vivo efficacy was evaluated in myeloma xenograft models. Single-cell RNA sequencing (scRNA-seq) of PBMCs from a lymphoma patient post-CAR-T/pomalidomide assessed immune microenvironment remodeling. Results Pomalidomide significantly enhanced CAR-T cell proliferation and cytotoxicity in an activation-dependent manner. It upregulated effector molecules (IL-2, IFN-γ) and chemokines (CXCL9-CXCL11), promoted central memory T cells (Tcm), and induced metabolic reprogramming while reducing exhaustion markers. In xenografts, combination therapy induced tumor regression and extended survival vs. CAR-T alone. scRNA-seq revealed pomalidomide-driven remodeling, characterized by increased T/NK cell proportions/activity and reduced myeloid-derived suppressor cell (MDSC) signatures. Conclusions Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04247-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6abcb94332697bc83ab93d4c224183daa93951d7" target='_blank'>
              Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
              </a>
            </td>
          <td>
            Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li
          </td>
          <td>2025-12-18</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong C. Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/457d4de587553b09db9c04406c900e3b240f5c8f" target='_blank'>
              CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration
              </a>
            </td>
          <td>
            Eleftheria Maranou, Gayoung Park, Pauline Weinzettl, Jonna Alanko, Otto I. Pulkkinen, Sarah E. Coupland, Marko Salmi, Carlos R. Figueiredo
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/561fc69832beac4c1e41655e3f435bfb03fefa41" target='_blank'>
              Oncogene c-Myc Regulates Upper Respiratory Epithelial Repair for Host Immunity During Acute Influenza Infection
              </a>
            </td>
          <td>
            Alexander G. Foote, Le Xu, J. Verheyden, Belle Pan, Nikita Katoch, Xin Sun
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Myelodysplastic syndrome (MDS) is characterized by bone marrow failure, clonal evolution and leukemic progression, but the pathophysiologic processes driving these events remain incompletely understood. Here, by establishing a comprehensive single-cell transcriptional taxonomy of human MDS, we reveal that inflammatory remodeling of bone marrow stromal niches is a common early feature, irrespective of the genetic driver landscape. We identify an activated CD8-T-cell subset as a source of stromal inflammation via TNF-receptor signaling, which prompts the inflammatory rewiring and loss of repopulating ability of residual normal hematopoietic stem/progenitor cells (HSPC). Mutant HSPCs display relative resistance to this inflammatory stress and reside predominantly in a transcriptional ‘high output’ state, providing a biological framework to their competitive advantage in an inflammatory microenvironment. Consistent with this, stromal inflammation associates with leukemic progression and reduced survival. Our data thus support a model of immune-stromal inflammatory signaling driving tissue failure and clonal evolution in the hematopoietic system. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, we provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human MDS. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, authors provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human myelodysplastic syndrome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d21dc014f548d4524dba3eed50e502490dcae8e" target='_blank'>
              An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome
              </a>
            </td>
          <td>
            Lanpeng Chen, Yujie Bian, Eline Pronk, Claire van Dijk, Tim V.D. van Tienhoven, R. Hoogenboezem, E. Bindels, Dennis Bosch, Sadaf Fazeli, A. D. de Graaf, Theresia M. Westers, M. Kholmatov, Judith B. Zaugg, Pedro L. Moura, Eva Hellström-Lindberg, A. A. van de Loosdrecht, J. Jansen, M. Sanders, M. H. Raaijmakers
          </td>
          <td>2025-11-18</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>48</td>
        </tr>

        <tr id="Abstract Objectives Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant, yet their functions remain incompletely understood. This study aimed to comprehensively analyze the role of G-MDSCs in MM patients undergoing CAR-T therapy. Methods Single-cell transcriptomic data from seven MM patients before and after CAR-T therapy were analyzed to characterize G-MDSCs. Functional enrichment and gene set enrichment analysis (GSEA) were performed to identify signaling pathways. A risk prediction model was constructed using RNA-seq and survival data from 713 MM patients, and validated by Kaplan–Meier analysis. In vitro experiments were conducted to assess the immunosuppressive functions of G-MDSCs. Results The findings, though exploratory due to limited sample size and inter-patient heterogeneity, suggested pathological activation and immunosuppressive roles of G-MDSCs potentially linked to patient prognosis. G-MDSCs were identified as key modulators of immune responses within the TME, with GSEA indicating regulation via IFN-α/γ signaling. They may facilitate immune evasion of MM cells by promoting proliferation through the IGF1–IGF1R axis and inhibiting T cells and other immune cells via the SIRPA–CD47 pathway. The risk prediction model based on G-MDSC gene signatures demonstrated high prognostic accuracy (AUC = 0.94). PTGS1 was identified as a key marker associated with high-risk groups, and functional assays confirmed its role in mediating G-MDSC immunosuppressive activity. Conclusions This study provides preliminary insights into the functional role of G-MDSCs in the MM TME and highlights their impact on CAR-T therapy outcomes. The findings suggest potential therapeutic strategies, including targeting PTGS1, to enhance CAR-T efficacy. Larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-02</td>
          <td>Immunopharmacology and Immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly immunosuppressive malignancy characterized by limited therapeutic options and a poor prognosis. Within the CRC tumor immune microenvironment (TIME), tumor-associated macrophages (TAMs) represent the predominant immune cell population. This study aimed to characterize the specific macrophage subsets contributing to CRC progression and resistance to immunotherapy. Single-cell RNA sequencing (scRNA-seq) was used to identify the key macrophage marker genes. The clinical significance of death-associated protein kinase 1 (DAPK1), was evaluated in clinical CRC cohorts using immunohistochemistry, immunofluorescence, Kaplan-Meier plots and Cox Proportional Hazards Models. Cytometry by time-of-flight, RNA-seq, flow cytometry and an in vitro co-culture system were performed to explore the functional role of macrophage-derived DAPK1 in the TIME. Subcutaneous tumor models and splenic-liver metastasis models were constructed to assess the potential of DAPK1 inhibition to enhance immune checkpoint blockade (ICB) efficacy. scRNA-seq analysis revealed predominant DAPK1 expression in intratumoral macrophages of CRC TIME. Elevated macrophage-specific DAPK1 level was significantly associated with worse prognosis. DAPK1+TAMs exhibited immunosuppressive properties and inhibit CD8+T cells cytotoxicity. Pharmacological inhibition of DAPK1 enhanced the efficacy of anti-PD-1 therapy in murine models. DAPK1+TAMs infiltration was an independent risk factor for overall survival in patients with CRC. These DAPK1+TAMs exhibit an immunosuppressive phenotype and promote the establishment of the TIME with immune evasion. Targeting DAPK1 may represent a potential strategy for synergizing immunotherapy in CRC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d25841457c8b6bc5218514a8ce08f04c9f270986" target='_blank'>
              DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer
              </a>
            </td>
          <td>
            Jiang Chang, Yuxu Niu, Shizhao Zhou, Ziqi Zhang, Weiying Zhu, Junchang Zhu, Haoran Xiu, Ke Shang, Q. Feng, Ye Wei
          </td>
          <td>2025-11-04</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6015d74c03081f1756895ea39d8fb38a3dc11ac" target='_blank'>
              Tissue-embedded CD4⁺ plasticity defines mucosal immunity in Inflammatory Bowel Disease
              </a>
            </td>
          <td>
            Q. Jiang, V. Merkus, C. Lindelauf, Nannan Guo, L. Ouboter, T. Höllt, P. Voorneveld, C. Meijer-Boekel, F. Koning, A.E. van der Meulen-de Jong, M. F. Pascutti, Vincent van Unen
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/938f1648314d21b17f5602b7a84c055f9ef0d7b2" target='_blank'>
              Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays§
              </a>
            </td>
          <td>
            Miriam Kelm, Nourhan Nasr, S. Bendig, Dieter Kabelitz, M. Lustig, H. Trautmann, A. Laqua, Christian Peters, D. Wesch, Heiner Oberg, Ottmar Janssen, T. Valerius, C. Baldus, A. Scheffold, M. Brüggemann, G. Chitadze
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96d3861c110e5ae3f35e700cedd4412c7f059c98" target='_blank'>
              T-cell Multiomic Analysis Identifies Subsets and Mechanisms of Interaction with Epithelial Cells in Idiopathic Pulmonary Fibrosis
              </a>
            </td>
          <td>
            A. Serezani, Julia M. R. Bazzano, B. Pascoalino, Ludmilla da Silva, Abigail J. Dietrich, Chase J. Taylor, T. Sherrill, C. Calvi, Paula I. Gonzalez-Ericsson, E. Wilfong, Matthew D Bacchetta, C. Shaver, Lorraine B. Ware, M.L. Salisbury, Luc Van Kaer, N. Banovich, JA Kropski, Timothy S. Blackwell
          </td>
          <td>2025-11-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I-/MHC-II+), we can cure mice with a regimen that includes radiotherapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan V. Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 antibodies are used to induce an immune response against many types of tumors. However, ICIs often also induce autoimmune responses, referred to as immune-related adverse events (irAEs), which occur unpredictably and at varying levels of severity in ICI-treated patients. The immunologic factors that predispose patients to the development of severe irAE are largely unclear. Here, we utilized high dimensional mass cytometry immunophenotyping of longitudinal blood samples from patients with metastatic melanoma treated with combination anti-PD-1/CTLA4 ICI therapy in the context of a clinical trial to characterize alterations in immune profiles induced by combination ICI therapy and to identify immune features associated with development of severe irAEs. Deep T cell profiling highlighted that ICI therapy induces prominent expansions of activated, CD38hi CD4+ and CD8+ T cells, which are frequently bound by the therapeutic anti-PD-1 antibody, as well as substantial changes in regulatory T cell phenotypes. However, neither the baseline frequency nor the extent of expansion of these cell populations was associated with development of severe irAEs. Rather, single cell-association testing revealed naïve CD4+ T cell abundance pre-treatment as significantly associated with the development of severe irAEs. Biaxial gating of naïve CD4+ T cells confirmed a significant positive association of naïve CD4+ T cell proportion and development of a severe irAE and with the number of irAEs developed in this cohort. Results from this broad profiling study indicate the abundance of naïve CD4+ T cells as a predictive feature for the development of severe irAEs following combination anti-PD-1/CTLA4 ICI therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b62cfec8fd4211059f5e6293956cd71228dc3135" target='_blank'>
              Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.
              </a>
            </td>
          <td>
            K. Marks, Alice Horisberger, M. Elahee, I. Adejoorin, Nilasha Ghosh, M. Postow, L. Donlin, Anne R Bass, Deepak A. Rao
          </td>
          <td>2025-11-25</td>
          <td>JCI insight</td>
          <td>1</td>
          <td>94</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 antibodies are used to induce an immune response against many types of tumors. However, ICIs often also induce autoimmune responses, referred to as immune-related adverse events (irAEs), which occur unpredictably and at varying levels of severity in ICI-treated patients. The immunologic factors that predispose patients to the development of severe irAE are largely unclear. Here, we utilized high dimensional mass cytometry immunophenotyping of longitudinal blood samples from patients with metastatic melanoma treated with combination anti-PD-1/CTLA4 ICI therapy in the context of a clinical trial to characterize alterations in immune profiles induced by combination ICI therapy and to identify immune features associated with development of severe irAEs. Deep T cell profiling highlighted that ICI therapy induces prominent expansions of activated, CD38hi CD4+ and CD8+ T cells, which are frequently bound by the therapeutic anti-PD-1 antibody, as well as substantial changes in regulatory T cell phenotypes. However, neither the baseline frequency nor the extent of expansion of these cell populations was associated with development of severe irAEs. Rather, single cell-association testing revealed naïve CD4+ T cell abundance pre-treatment as significantly associated with the development of severe irAEs. Biaxial gating of naïve CD4+ T cells confirmed a significant positive association of naïve CD4+ T cell proportion and development of a severe irAE and with the number of irAEs developed in this cohort. Results from this broad profiling study indicate the abundance of naïve CD4+ T cells as a predictive feature for the development of severe irAEs following combination anti-PD-1/CTLA4 ICI therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a25d1a5423c9c1eef83bca0be3e66901f651d912" target='_blank'>
              Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma
              </a>
            </td>
          <td>
            K. Marks, Alice Horisberger, M. Elahee, I. Adejoorin, Nilasha Ghosh, M. Postow, L. Donlin, Anne R Bass, Deepak A. Rao
          </td>
          <td>2025-10-31</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="Abstract Introduction Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study was to describe systemic versus local inflammatory changes of NK cell subsets as well as their physical cell-cell interactions in arthritis patients. Methods Spectral flow cytometry was used to compare paired peripheral blood (PB) and synovial fluid (SF) immune cells from patients with active inflammatory arthritis and healthy controls. Physical cell-cell interactions within tissues were studied by applying a recently developed cellular interaction mapping framework. Results Our paired approach revealed significant local enrichment of immature and activated NK cells in SF, characterized by elevated markers of early differentiation, immune-checkpoint regulation, and tissue-residency, highlighting tightly controlled immune activation at inflamed sites. Single-cell analysis confirmed heterogeneity within SF-NK cells, suggesting multiple co-existing activation states and developmental stages. PB-NK cells from patients differed profoundly compared to healthy controls, showing less immature NK cell subsets and an enrichment of mature, pro-inflammatory subsets indicative of systemic immune activation. Cellular interaction mapping revealed mainly NK/neutrophil interactions of patients’ NK cells, while interactions with B-cells, T-cells, or monocytes were negligible. T-cells also displayed profound local and systemic alterations. Cellular interaction mapping revealed that next to NK/neutrophil interactions, interactions between B-cells with monocytes and T-cells with neutrophils characterize joint inflammation. Conclusion This paired high-dimensional analysis revealed systemic and local alterations in NK cell subsets shaped by co-existing developmental stages and immune regulatory mechanisms. Cellular interaction mapping indicated that neutrophils are a main interaction-partner of NK cells in inflamed joints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33e0fc210c968311a194a2ca7566f89ed217a080" target='_blank'>
              Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis
              </a>
            </td>
          <td>
            F. Deicher, T. Exner, Maren Claus, S. Yousefian, Lea Rodon, Sophie Elisabeth Leonhardt, J. H. Distler, Carsten Watzl, Hanns-Martin Lorenz, Simon Haas, Daniel Hübschmann, Wolfgang Merkt
          </td>
          <td>2025-10-31</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC. Methods Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments assessed macrophage-intrinsic effects. Human studies included analysis of CD300e expression in matched tumor and normal tissue from patients with CRC and in vitro co-culture of patient-derived colon tumor organoids with monocytes to study CD300e induction and TAM polarization. Results In vivo, CD300e deficiency led to reduced tumor burden, enhanced major histocompatibility complex expression on TAMs, and improved T-cell responses. CD300e-deficient macrophages exhibited increased phagocytic activity, antigen presentation, and support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. In patients with CRC, CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. Tumor-derived signals in vitro induce CD300e expression and promote a protumorigenic macrophage profile. Conclusions Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/16c56c500ab6751223d28c46c0f7327dc521a283" target='_blank'>
              CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming
              </a>
            </td>
          <td>
            Annica Barizza, Stefania Vassallo, L. Masatti, Mattia Laffranchi, Sofia Giacometti, S. Lonardi, Mattia Bugatti, Sara Coletta, C. Della Bella, M. D’Elios, Simone Pizzini, A. Rosato, W. Vermi, Matteo Fassan, G. Spolverato, Silvano Sozzani, E. Calura, R. Sommaggio, Gaia Codolo
          </td>
          <td>2025-07-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3bbdd9bcc92736e4b8070a3a41a9e7c618c1a80" target='_blank'>
              ILC2s govern imprinting of alveolar macrophage-mediated immunity upon secondary helminth infection in the lung
              </a>
            </td>
          <td>
            Jonathan Pollock, , Lisa-Marie Graf, Andreas Ruhl, Daniel Radtke, David Voehringer
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="ABSTRACT Chronic antigen exposure drives CD4⁺ T cell senescence, yet how autoimmunity and persistent viral infections differentially shape T cell differentiation and function remains unclear. Using cytomegalovirus (CMV) and rheumatoid arthritis (RA) as models of chronic immune activation, we performed high‐dimensional mass cytometry and functional assays to define their impact on CD4⁺ T cells. In CMV‐seropositive individuals, CD27−CD28− CD4⁺ T cells were abundant and exhibited a predominantly cytotoxic, nonproliferative phenotype. Only a minor fraction was CMV‐reactive, suggesting that bystander‐driven differentiation contributes to this subset. In the absence of CMV, senescent CD4⁺ T cells were infrequent and phenotypically distinct, though they still exhibited low proliferative capacity. EBV and HSV did not independently increase CD27−CD28− CD4⁺ T cell frequency. Similarly, RA had little effect on their abundance but instead tuned the functional quality of senescent cells. In CMV‐seropositive RA patients, senescent CD4⁺ T cells produced less pro‐inflammatory cytokines and showed impaired cytotoxic degranulation. Central memory CD4⁺ and CD27−CD28− CD8⁺ T cell functions were preserved, with no evidence for CMV reactivation, suggesting maintained viral control by unaffected T cell responses. These findings highlight distinct, nonredundant effects of CMV and RA on CD4⁺ T cell senescence and reveal RA‐specific functional defects in senescent CD4⁺ T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3441dc9dbc45e96d9b0a98bad7c5d0ce97797b4d" target='_blank'>
              Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4+ T Cells
              </a>
            </td>
          <td>
            Lea Williams, Ali O Saber, Silina Awad, Xi Su, Asgar Ansari, Ruozhang Xu, Hannah Jung, Anupama Shahane, Joshua F. Baker, Laura F. Su
          </td>
          <td>2025-11-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Melanoma remains a major challenge in oncology because of its aggressive behavior and intricate immune interactions. Advances in immunophenotyping and single-cell atlas technologies have revealed heterogeneous regulatory T cell (Treg) subsets, among which peripheral blood CD39+PD-1+ Tregs have emerged as key mediators of systemic immunosuppression. This review summarizes current evidence on their immunoregulatory functions, emphasizing their role in suppressing anti-tumor immunity and contributing to poor clinical outcomes. By integrating immune atlas data with clinical observations, we outline the mechanisms by which this subset shapes both the tumor microenvironment and systemic immune responses. We further discuss their potential as prognostic biomarkers and therapeutic targets to optimize immunotherapy strategies. In addition, we highlight how this subset interacts with other immunosuppressive pathways, reinforcing resistance to immune checkpoint inhibitors. Despite these advances, challenges remain in fully characterizing this population and translating findings into clinical application. This review provides a comprehensive overview of the significance of CD39+PD-1+ Tregs in melanoma immunopathology and highlights future directions to advance precision immunotherapy and improve patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc33012596eab785fba7e6d8eba704e87044622b" target='_blank'>
              CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers
              </a>
            </td>
          <td>
            Guanlin Qiao, Hongxia He, Xiaobing Wang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors (ICIs) have transformed the treatment strategy for bladder cancer (BLCA), but primary resistance still occurs in most patients. Recent evidence suggests that neutrophil extracellular traps (NETs) play a key role in cancer therapy resistance, but their specific role in BLCA remains unclear. Methods An integrated analysis of multiple clinical cohorts receiving ICIs was performed to explore the link between NETs and patient outcomes. Immunofluorescence staining, in vitro co-culture system, scanning electron microscopy, and mouse lung metastasis model were used to evaluate the biological effects of NETs. Proteomics and single-cell transcriptomics analysis were further applied to elucidate the molecular mechanisms. Results Clinically, NETs abnormally accumulated in BLCA and promoted tumor metastasis and immunotherapy resistance in mice. Mechanistically, NETs upregulated the anti-phagocytic checkpoint STC1 in tumor cells through the TLR2-MAPK-FosL1 axis. Notably, STC1 inhibited antigen presentation by sequestering calreticulin, while its secreted form enhances NET formation, forming a self-reinforcing feedback loop. In addition, secreted STC1 impaired differentiation of CD14+ precursors into mature dendritic cells, further exacerbating immune suppression. Conclusion This study revealed the critical role of the NETs-STC1 feedback loop in BLCA immunoresistance. Targeting this axis could simultaneously enhance efficacy and safety of immunotherapy, providing a novel translational strategy for overcoming resistance in clinical settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1faa4fe50451eb7a16e8832d198e80df19796701" target='_blank'>
              Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer
              </a>
            </td>
          <td>
            Tingting Cai, Tao Feng, Wei Zhang, Qintao Ge, Liangju Peng, Yue Wang, Jindong Xie, Xinpei Deng, Wenkai Zhu, Shengming Jin, Jin Wang, Ding-Wei Ye, Yiping Zhu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Resistance to immune checkpoint blockade (ICB) remains a major challenge in lung adenocarcinoma (LUAD), with stromal mechanisms underlying CD8⁺ T cell exhaustion still poorly understood. By integrating single-cell, bulk, and spatial transcriptomic datasets using EcoTyper, we identified a distinct immunosuppressive ecotype, EC10, enriched for TGF-β signaling and epithelial–mesenchymal transition. EC10 exhibited spatial co-localization of fibroblasts, malignant epithelial cells, and exhausted CD8+ T cells, and was consistently associated with immune exclusion, poor progression-free survival, and elevated TIDE scores across four ICB-treated LUAD cohorts. Cell–cell communication analyses revealed a dominant TGFB1–SERPINE1 signaling axis originating from fibroblasts, linking stromal remodeling to T cell dysfunction. In contrast, EC12 represented an inflamed, ICB-responsive state enriched in interferon signaling. These findings define EC10 as a spatially organized, fibroblast-driven immunosuppressive ecosystem predictive of ICB resistance, and highlight the therapeutic potential of targeting the TGF-β axis in LUAD. This research identifies a fibroblast-driven immunosuppressive ecosystem in lung adenocarcinoma, linking TGF-β signaling to immune resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130525b051ffbdab87e5edbec0e75b95564de9c8" target='_blank'>
              Fibroblast TGF-β signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance
              </a>
            </td>
          <td>
            Seo-Young Lee, Youngjoo Lee
          </td>
          <td>2025-12-01</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Soft-tissue sarcomas (STS) are characterized by abundant extracellular matrix (ECM) deposition, yet the functional contribution of specific ECM components remains poorly understood. In this study, we identify periostin (POSTN), a matricellular protein, as a regulator of sarcoma progression and the tumor immune microenvironment. Analysis of human sarcoma datasets revealed that high POSTN expression correlates with poor prognosis and elevated expression of ECM-related and myeloid cell–associated genes. In murine genetic models of sarcoma, tumors expressing high levels of Postn displayed enhanced expression of ECM genes and monocyte-recruiting cytokines. Functional silencing of Postnin vivo reduced tumor growth without altering tumor cell proliferation or intrinsic signaling pathways, suggesting a noncell-autonomous mechanism. Instead, Postn-deficient tumors showed increased infiltration of CD4+ and CD8+ T cells and reduced proportions of immunosuppressive myeloid cells, including tumor-associated macrophages (TAM). Single-cell RNA sequencing revealed that Postn silencing reprograms the myeloid compartment, increasing IFN-responsive and proinflammatory subsets. Mechanistically, recombinant POSTN promoted monocyte migration and maturation into macrophages in vitro, supporting its role as a chemoattractant and differentiation cue. Therapeutic neutralization of POSTN partially recapitulated the immunologic remodeling but was insufficient to reduce tumor burden as monotherapy. Significance: Our findings position POSTN as a key stromal regulator in STS, linking tumor-derived ECM components to immune evasion via myeloid cell recruitment and education. These results open avenues for targeting POSTN as an adjuvant strategy to enhance the efficacy of immunotherapies and overcome the immune-excluded phenotype of sarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4fcb661ad1542d712f7aa5599bc104c08fe2694e" target='_blank'>
              Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and Differentiation
              </a>
            </td>
          <td>
            Jinfen Xiao, Kristin Ishaya, E. Ko, Annaliese Fowler, Marina T Broz, Jlenia Guarnerio
          </td>
          <td>2025-11-20</td>
          <td>Cancer Research Communications</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Background Glioblastoma (GBM) is the most aggressive form of cancer of the central nervous system. Despite advances in immunotherapies and standard-of-care treatments for GBMs, clinical outcomes remain limited—owing to the immunosuppressive tumor microenvironment and the intrinsic resistance of GBM to conventional approaches. As a result, there is growing interest in rational combination strategies, particularly those pairing oncolytic viruses with immune-based therapies or established treatment modalities. Oncolytic viruses, by displaying conditionally enabled tumor cell-restricted replication, while stimulating antitumor immune responses and leaving healthy tissue unharmed, have the potential to reshape the therapeutic landscape in GBM and aid in achieving more durable benefits for patients. This study investigates the use of infectious bursal disease virus (IBDV) as a potential virotherapy for GBM. Methods and results In vitro, IBDV infects and replicates within murine GBM cells and patient-derived GBM stem cells, inducing direct oncolysis and activating proinflammatory gene expression programs. IBDV also enhances the cytolytic activity of temozolomide (TMZ) in treated GBM cells, complementing TMZ chemotherapeutic activity. In vivo, treatment with IBDV in CT-2A GBM-bearing syngeneic mice significantly reduced tumor growth and improved survival compared with control mice. Intratumoral administration of IBDV induces a deep remodeling of the tumor immune microenvironment, reducing immunosuppressive M2-like macrophages and increasing the ratio of CD8+T cells to regulatory T cells. This reversion of immunosuppression linked to monocyte-derived macrophages has been confirmed on experimental ex vivo infections of explants derived from human GBM donors. Conclusion These findings support further consideration of IBDV as a novel virotherapeutic agent for GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3ac0ee04265515e91527e1407a5dbcbe315c0678" target='_blank'>
              Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma
              </a>
            </td>
          <td>
            Vicent Tur-Planells, Y. Bykov, Gloria O Dawodu, Noemí García-Romero, Sara Izpura-Luis, Leticia Pérez-Rodríguez, Sergio Rius-Rocabert, I. Palacín-Aliana, Javier Arranz-Herrero, Inmaculada Márquez-Leiva, Álvaro Monago-Sánchez, M. Del Río, J. Rodriguez-Barbosa, Jordi Cano-Ochando, Adolfo García-Sastre, Daniel Lozano-ojalvo, Estanislao Nistal-Villán, Á. Ayuso-Sacido, Sara Cuadrado-Castano
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Background Colorectal cancer (CRC) continues to represent a major cause of cancer-related mortality worldwide, with its progression and therapeutic outcomes strongly shaped by the complexity and heterogeneity of the tumor immune microenvironment (TME). This review critically examines the cellular and molecular mechanisms driving immune evasion in CRC, emphasizing the dual roles of immune cell populations—including tumor-associated macrophages, neutrophils, dendritic cells, T cells, B cells, and natural killer cells—as well as non-cellular elements such as the extracellular matrix and extracellular vesicles. Objective A key objective is to evaluate recent developments in immunotherapeutic approaches, including immune checkpoint inhibitors, tumor vaccines, adoptive cell transfer, and novel combinatorial regimens, while addressing their therapeutic promise and inherent limitations, especially in microsatellite-stable (MSS) tumors that exhibit primary resistance to standard immunotherapies. Further analysis integrates perspectives on metabolic reprogramming within the TME, epigenetic alterations, and advances in engineered cellular therapies, thereby providing a comprehensive framework for overcoming immunosuppressive mechanisms. Discussion and conclusion Special consideration is directed toward the translational value of targeting immune-metabolic interactions and spatial dynamics within the TME. Ultimately, this work synthesizes current knowledge and outlines forward-looking strategies to advance personalized, multi-target immunotherapy, with the potential to reshape clinical paradigms in CRC management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/03fb3a1b140db8c8ae9afa2ff97c1f40f6b8cd5d" target='_blank'>
              Cellular characteristics of the immune microenvironment of colorectal cancer and progress in immunotherapy research
              </a>
            </td>
          <td>
            Chunbaixue Yang, Jianchun Fan, Yixuan Zhang, Yixiao Zhang, Lei Xia, Xinran Cao, Xueliang Wu
          </td>
          <td>2025-11-30</td>
          <td>Annals of Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Tissue-resident memory T (TRM) cells persist long-term in non-lymphoid tissues and provide rapid local immune protection, yet emerging evidence shows they also act as key drivers of chronic inflammation and relapse in rheumatoid immune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and primary Sjögren’s syndrome (pSS). A systematic search of PubMed, Web of Science, and Google Scholar (through October 2025) identified studies on TRM cell biology, pathogenic roles, and therapeutic modulation in autoimmune diseases. This review summarizes the fundamental features of TRM cells, including their TGF-β and IL-15 dependent development, tissue-specific heterogeneity, and unique metabolic programs. It highlights disease-specific pathogenic mechanisms: promotion of osteoclastogenesis and chronic synovial inflammation via Granulocyte-macrophage colony stimulating factor (GM-CSF) and the IL-23/IL-17 axis in RA; amplification of type I interferon responses and autoantibody production in SLE; potential contribution to fibrosis through TGF-β secretion in SSc; and mediation of glandular injury through cytotoxicity in pSS. Therapeutic strategies targeting TRM cells—such as JAK inhibitors, IL-17/IL-23 blockade, disruption of residency signals, metabolic interventions, and microenvironmental remodeling via nanotechnology—are critically evaluated. Challenges remain in achieving tissue-specific targeting without compromising systemic immune memory. Future directions include spatial transcriptomics, organoid models, and artificial intelligence to support precision medicine. Targeting TRM cells presents a promising novel avenue for achieving long-term remission and potentially even a cure for rheumatoid immune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1201e244b31ebcc016319c4d8203919cb836f463" target='_blank'>
              Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies
              </a>
            </td>
          <td>
            Yu Tian, Jie Zhang, Lianying Wu, Chi Zhang, Fan Zheng, Yang Yang, Guanting Lu, Daoyuan Xie
          </td>
          <td>2025-11-30</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="


 Follicular lymphoma (FL) disease trajectory is characterized by a protracted preclinical stage, followed by iterative cycles of remission/relapse, suggesting that the elusive FL cancer precursor/persister cells (CPC) are not eradicated by current therapies and support early FL development and lymphoma recurrence. FL malignant B cells are dependent on a dynamic interplay with a heterogeneous tumor microenvironment (TME), dominated by amplified Treg, activated Tfh, and dysfunctional cytotoxic T cells. FL TME composition within invaded lymph nodes (LN) has been associated with clinical outcomes. However, neither CPC nor their specific supportive niches have been yet characterized, despite being the ultimate targets to cure FL. Compelling clinical evidence has identified the bone marrow (BM) as a permissive niche for FL CPC. Here, we analyze the BM T cell niche in low tumor burden FL patients treated by Rituximab monotherapy (FLIRT trial, NCT02303119), looking for the impact of malignant B cells on BM T cell profile and for the T-cell niche supporting drug-resistant persister cells.
 Paired BM aspirates were obtained from 19 low tumor-burden FL patients at diagnosis (M0) and in remission at one year (M12) of Rituximab monotherapy. BM aspirates from 5 age-matched healthy donors (HD) were incorporated as controls. We generated a single-cell dataset combining gene expression and BCR/TCR repertoires (10X Genomics) from purified B and T cells. Quantification of the t(14;18) frequency by QPCR revealed a systematic, yet variable, infiltration of FL BM at M0 and a dramatic depletion at M12, when few residual tumor cells could be detected and profiled.
 A total of 54,732 CD4 and 53,580 CD8 T cells were profiled. The BM T-cell landscape was highly heterogeneous across FL patients in contrast to the more uniform distribution in HD BM. Among the 15 T-cell clusters, 8 were differentially represented in FL BM at M0 vs HD BM with a decrease of cytotoxic CD8 T cells and naive CD4 T cells and an increase of IFN-responsive CD4 and CD8, Treg, Tfh-like, and memory CD8 T cells. Treg, IFN-responsive CD4, and CD8 EM were associated with a poorer clinical outcome, defined as a PFS<24 months and/or a time-to-next treatment (TTNT)<30 months (n=8/19 patients, P<0.05). Conversely, naive CD4 and naive CD8 T cells were associated with a favorable outcome. While exhausted CD8 T cells were not over-represented in FL BM, we identified a FL-specific subset of IL-10+ CD8 T cells co-expressing CD8 Treg markers. Furthermore, cytotoxic T cell transcriptional profile was characterized by a reduced expression of genes/pathways associated with T-cell activation and cytotoxicity, while the TGFb pathway was enriched, collectively highlighting a shift towards local immune suppression.
 At M12, IFN-responsive CD4, Treg, naive CD4 and CD8 T cells returned to levels similar to those found in HD BM, suggesting that their alteration at M0 was dependent on tumor B cell infiltration. However, M0 and M12 FL BM Treg retained a similar activated TNFRSF9hi Treg signature, which was associated with a poor prognosis when scored on bulk RNAseq of FLIRT FL LN biopsies at diagnosis (P=0.0048, n=122). Furthermore, the defective cytotoxic CD8 response persisted both quantitatively and qualitatively upon B-cell depletion.
 Finally, the Tfh-like cluster remained high at M12 in FL BM, regardless of the presence of residual tumor B cells. Analysis of BM malignant B cell heterogeneity using an unsupervised metaclustering approach identified 7 metaclusters (Mcl) co-occurring across FL patients and co-opting distinct gene expression programs, resembling the B cell developmental hierarchy in the LN from dark zone GC-like, light zone (LZ) GC-like, and memory-like FL B cells. Interactome analysis revealed a preferential interaction between BM Tfh-like cells and BM LZ GC-like tumor B cells. Interestingly, M12 residual tumor B cells were enriched for LZ GC-like Mcl, in agreement with the persistence of Tfh-like T cells.Our data describe the T-cell landscape within FL BM TME, unveiling a profound enrichment of regulatory T cell subsets and Tfh-like cells, alongside a defective cytotoxic immune response. Following B cell depletion using a B-cell targeted monotherapy, the tumor supportive T-cell niche persists within the BM. This preserved niche may support the survival of rare residual GC-like CPC and contribute to subsequent relapses, thereby identifying a new therapeutic vulnerability in FL.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d16f58ff8a6623ee2cd2b85985d1b1b79e14836" target='_blank'>
              Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma
              </a>
            </td>
          <td>
            Karin Tarte, A. Beyou, S. Léonard, J. Dulong, S. Rodriguez, N. Mossadegh-Keller, G. Brisou, Charles Brottier, L. Xerri, B. Nadel, Camille Laurent, Guillaume Cartron, Sandrine Roulland
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets. Methods Ccl7 myeloid cell-specific knockout mice and MC38 tumor-bearing mouse models were established to investigate the role of Ccl7 during CRC progression. Proteomic analysis, RNA-seq, and flow cytometry analysis were used to determine the role of Ccl7 in the tumor immune microenvironment. Results Herein, we found that elevated CCL7+ tumor-associated macrophages (TAMs) in tumors correlated with tolerance to ICIs blockage therapy in patients with CRC. Deletion of CCL7 in myeloid cells resulted in reduced accumulation of immunosuppressive TAMs and increased infiltration of activated CD8+ T cells within the tumor. Mechanistically, CCL7 modulates peroxisome biogenesis and fatty acid oxidation, thereby promoting the immunosuppressive functions of TAMs via the PI3K-AKT-PEX3 signaling pathway. Furthermore, CCL7 inhibits the expression of chemokine CXCL10 by suppressing the AKT2-STAT1 signaling pathway, which reduces the infiltration of activated CD8+ T cells in the tumor. Blocking CCL7 delays CRC progression and enhances the therapeutic efficacy of PD-L1. Conclusion Our study highlights the novel role and regulatory mechanisms of CCL7+ TAMs in ICIs immunotherapy resistance, suggesting that CCL7 may serve as a potential combined therapeutic target for ICIs immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53a194d2240d9d29b67527ded8020c64d8c9fb2a" target='_blank'>
              Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells
              </a>
            </td>
          <td>
            Yijiao Chen, Xudong Liu, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, Yongsheng Li, Lei Wu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Despite effective viral suppression with antiretroviral therapy (ART), people living with HIV (PLWH) experience persistent inflammation, immune dysfunction, and premature onset of cardiovascular and aging-related comorbidities. To define the underlying mechanisms, we performed longitudinal transcriptomic profiling in peripheral blood mononuclear cells (PBMCs) from a cohort of simian immunodeficiency virus (SIV)-infected rhesus macaques spanning four key stages: pre-infection, acute infection, short-term ART, and long-term ART. Bulk RNA sequencing revealed dynamic immune remodeling across infection and treatment. Acute SIV infection induced robust antiviral and inflammatory programs, with upregulation of interferon-stimulated genes (ISGs), IL-27, JAK/STAT, and NF-κB signaling, coupled with suppression of T- and B-cell activation pathways. Short-term ART effectively reversed these transcriptional perturbations, restoring adaptive immune gene expression and reducing innate antiviral responses to near-baseline levels. In contrast, chronic SIV infection on long-term ART maintained viral suppression but was characterized by reactivation of innate immune pathways, including TLR2/TLR4/MYD88, NF-κB, and inflammasome (NLRP3/or NLRP12, caspase-1) signaling, along with sustained macrophage activation, platelet/coagulation signaling, and senescence-associated secretory phenotype. Protein analyses confirmed persistent CASPASE-1 and NF-κB activation in spleen tissue. Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART– treated macaque revealed macrophage-rich plaques with p21⁺ senescent cells with intraluminal thrombus formation, recapitulating key features of HIV-associated atherogenesis. Together, these findings demonstrate that while ART normalizes acute infection–induced immune dysregulation, chronic SIV infection sustains a chronic, macrophage- and TLR-driven inflammatory state linked to vascular injury and aging process regardless of long-term suppression of viremia. Targeting inflammasome, NF-κB, and senescence pathways may mitigate non-AIDS comorbidities in PLWH.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7a8f96a2324d1327914a92bba9009e04dbf070e" target='_blank'>
              Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART
              </a>
            </td>
          <td>
            Yilin Chen, Xiaofeng Ding, Sonalika Ray, Siva Thirugnanam, Robert V. Blair, Ahmad Saied, S. Sukhanov, J. Kolls, Woong-ki Kim, P. Delafontaine, Jay Rappaport, Xuebin Qin, Namita Rout
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eac0fc7ba7c67303e9257f2a2d91aba7b28ddab" target='_blank'>
              Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis
              </a>
            </td>
          <td>
            Chao Guan, Xiangmin Li, Xiaoshan Zeng, Zhenguang Du, Zhicheng Zhou, Jungang Zhao, Lele Song, Li Yu
          </td>
          <td>2025-12-01</td>
          <td>Therapeutic Advances in Medical Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="ABSTRACT Staphylococcal enterotoxins (SE) crosslink the MHC‐II on antigen‐presenting cells (APC) with the T‐cell receptor, inducing a polyclonal T‐cell response. Although APCs are the initial targets of SE and are critical in shaping subsequent T‐cell activation, the effects of SE on APC function remain poorly understood. This study investigates the immunomodulatory effects of staphylococcal enterotoxin A (SEA) on monocytes and their differentiation into monocyte‐derived dendritic cells (moDC) or macrophages (MDM). Transcriptomic analyses of human monocytes via RNA sequencing revealed SEA‐induced enrichment of gene pathways associated with inflammation, infection, and dermatitis, effects that were amplified in the presence of T cells. Phenotypic and functional characterization showed that SEA‐primed monocytes differentiated into MDM with an altered polarization, deviating from classical M1/M2 pathways. SEA‐primed MDM exhibited downregulation of key markers, including HLA‐DR, CD80, CD86, and PD‐L1. Functional assays demonstrated that SEA‐primed MDM pushed hyperinflammatory T‐cell responses, with significantly enhanced proliferation and IFN‐γ secretion. In contrast, following SEA‐priming, moDC retained robust antigen‐presenting capabilities and displayed enhanced expression of molecules involved in T‐cell interactions. These findings provide mechanistic insights into SEA‐mediated immune modulation, illustrating how SEA reprograms MDM functions and amplifies proinflammatory T‐cell responses. This advances our understanding of superantigen‐driven immune interactions, offering a foundation for developing therapeutic strategies to mitigate superantigen‐mediated immune conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31b8b3bf0438451c3b982c5f615c660d9c3ce361" target='_blank'>
              Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation
              </a>
            </td>
          <td>
            C. Arasa, Khaleda Rahman Qazi, David Brodin, Manuel Mata Forsberg, E. Sverremark-Ekström
          </td>
          <td>2025-12-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Background Currently, immune checkpoint inhibitors (ICIs) and other immune-activating strategies represent the main approach to cancer treatment; however, immune resistance in many solid tumors limits the immune therapy response and can cause strong toxic side effects. In solid tumors, the development of effective anti-tumor immune responses is hindered by limited immune cell infiltration and an immunosuppressive tumor microenvironment (TME). To overcome current immunotherapy challenges, we proposed a novel approach providing local and stable treatment levels to activate or revitalize anti-tumor immunity, to achieve the effect of TME infiltration and sustained presence in solid tumors. Methods Using genetic engineering methods to synergistically activate immunity in the TME, we programmed macrophages to express therapeutic payloads, including interleukin (IL)-12 and the signal regulatory protein alpha-Fragment crystallizable fusion protein (SIRPα-Fc), a CD47 ICI. Co-culture studies were performed to evaluate the effects of the genetically engineered macrophages (GEMs) on the T cells and GEMs themselves in vitro. We evaluated the tumor response, cellular response, and cytokine response. The GEMs were administered to a mouse model of tumor-cell transplantation, where they were retained and expressed as lentiviral payloads. Results The IL-12 secreted by the GEMs provided effector signals for T cells, thereby enhancing the tumor resident anti-tumor macrophages and CD8+T-cell populations. In addition, the secretion of SIRPα-Fc enhanced the phagocytic activity of the macrophages toward tumor cells and promoted their antigen presentation function. The combination therapy of dual proteins produced significant synergistic effects in solid tumor models and further enhanced memory immunity. The GEMs also improved the efficacy of ICIs in the ICI-resistant gene engineering tumor models and demonstrated significant anti-tumor efficacy in the metastasis models. Conclusions Our study showed the potential clinical application of GEMs in the treatment of tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e54b7612ca10a019c14cb39b2232584f60b628c0" target='_blank'>
              Engineered macrophages accumulate in solid tumors and locally deliver immune-activating proteins to inhibit tumor progression
              </a>
            </td>
          <td>
            Yan Xu, Yan Zhou, Jiahe Wang
          </td>
          <td>2025-11-01</td>
          <td>Translational Cancer Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>171</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/58ad21f0ac78d5c82537932a36fb92c178b210c8" target='_blank'>
              Microenvironment-specific modulation of macrophage function and tumour progression by ADAMTS1 through Syndecan-4 shedding
              </a>
            </td>
          <td>
            Silvia Redondo-García, R. Caracuel-Peramos, F. J. Rodríguez-Baena, Salvador Muñoz-Mira, Ana García-Muñoz, R. López-Domínguez, María del Carmen Plaza-Calonge, Belén López-Millán, P. Carmona-Sáez, J. C. Rodríguez-Manzaneque
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="


 Introduction:
 Chronic Lymphocytic Leukemia (CLL) results in the expansion of immunosuppressive B-cells leading to risk for secondary malignancies, infection, and suboptimal T-cell based immunotherapeutic responses. Treatments that restore immune function (e.g. ibrutinib) may improve the efficacy of CD19 CAR T-cell (CART) therapies. We previously demonstrated that venetoclax (Ven) causes complex immunologic changes which broadly improve circulating immune cell (including T-cell) function. While we found that Ven appears to improve CD19 CART cytotoxicity in most patients, some CD19 CAR T-cells manufactured after Ven treatment did not perform as well in ex vivo cytotoxicity assays. We performed a multiomic correlation analysis to elucidate germane molecular features that may help predict and optimize Ven-enhanced CD19 CART cytotoxicity.
 Methods:
 We collected peripheral blood mononuclear cells (PBMCs) and serum from 13 consented CLL patients initiating standard of care Ven-based therapy (Ven-monotherapy N = 9, Ven+ɑCD20 N = 4; BDR-164122). Specimens were collected before treatment (D0) and after 30 days (D30) of therapy. CD19 CART were manufactured for 6 patients at both timepoints using an ɑCD19 construct (scFv/CD28/TCRζ via retroviral transduction). Cytotoxicity was measured against Raji-Luciferase cells. D0 and D30 specimens were analyzed by flow cytometry (including T-cell subsets and exhaustion markers) and RNA-seq (with xCell for cell-type deconvolution, rMATS for splicing, LISA for master regulator analysis). Enrichment analysis identified biological processes linked to cytotoxicity with statistical significance calculated as False Discovery Rate (FDR) adjusted P value. Metabolomics were performed with the Biocrates MxP Quant 500 XL assay. For each multiomic feature, magnitude change from D0 to D30 was calculated. These changes were correlated with changes in CD19 CART ytotoxicity across 7 effector-to-target ratios (1:8 through 8:1) using Spearman's correlation.
 Results:
 Enhanced CD19 CART cytotoxicity correlated with increased NK-cell frequency (CD56+/CD57+, CD56-/CD57+) determined by flow cytometry and cell-type deconvolution. In addition, RNA sequencing studies demonstrated that CD19 CART activity correlated with gene expression changes in interferon-ɑ (IFNA1, FDR<0.001) and interferon-ɣ (IFNG, FDR<0.002) response pathways. Specifically, an increase in key interferon signaling genes (GZMA, STAT1, CASP1) were associated with improved CD19 CART cytotoxicity. Moreover, a decrease in some interferon signaling genes (JAK2, STAT2, IFNAR2) was associated with a decrease in CD19 CART activity. LISA analysis identified POU2F2 and HDAC1 as key transcriptional regulators of genes associated with enhanced post-Ven CD19 CART killing. Elevated anti-inflammatory metabolites (cortisol, cortisone), as well as cysteine and phosphatidyl lipids correlated with improved CD19 CART cytotoxicity. Diminished CD19 CART cytotoxicity correlated with increased CD4+ LAG3+ T-cells coexpressing TIM3/TIGIT, and total CD3+ T-cells. Cell-type deconvolution demonstrated an inverse correlation between regulatory T-cells (T-regs) and CD19 CART cytotoxicity. Increase in NFκB signaling and splicing factor genes (e.g. RELA, RELB, NFKB1, NFKB2, TNF, U2AF1, U2AF2) were associated with a decrease in CD19 CART cytotoxicity (FDR<0.001). Alternative splicing by rMATS analysis identified a MAP3K7 (TAK1) event resulting in a TAK1 variant lacking its negative regulatory domain. This alternative splice form of TAK1 enhances NFκB signaling and impacts CD19 CART activity. Elevated serum triacylglycerols, GABA, spermine, and taurine detected by metabolic studies correlated with diminished CD19 CART cytotoxicity. Conclusion: Using a comprehensive multiomic approach we uncovered signaling pathways associated with improved CD19 CART activity following Ven-based therapy in CLL patients. The activation of the interferon-ɑ, interferon-ɣ and glucocorticoid signaling pathways enhance CART activity. In contrast, NFκB signaling and spliceosome-related pathways contribute to sustained immune activation and negative impacts on CAR T-cell function. Venetoclax treatment appears to alter T-cell (especially T-reg) and NK-cell subtypes, which influence the anti-tumor activity of CD19 CAR T-cells. Our work provides a foundation for further mechanistic inquiry into Ven-related immunologic impacts, which can improve synergistic combination treatments using CART for CLL patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be9262399f1e435c641b61481400c69897fe78fa" target='_blank'>
              Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Jacob P Wright, F. Hernandez-Ilizaliturri, C. Mavis, Joseph Tario, Alex Niu, Taylor K Mandeville, Dorothy C. Pan, Grant Schofield, Dae-Kyum Kim, Joseph Barbi, Hua-Hsin Hsiao, Spencer Rosario, M. Cortese
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 IntroductionChronic lymphocytic leukemia (CLL) is marked by profound immune dysregulation, which compromises both the numerical and functional integrity of the T cell compartment, posing significant challenges for chimeric antigen receptor (CAR) T-cell therapy. CLL patients often exhibit an elevated expression of inhibitory receptors such as PD-1 and CTLA-4 on their T cells. Additionally, the immunosuppressive microenvironment in these patients is marked by the predominance of effector and effector memory T cells, which are less capable of sustaining long-term immune responses. Prior studies, including work from our group (Fraietta JA et al., 2018), have highlighted the importance of early memory T cell subsets in promoting CAR T cell expansion, persistence, and anti-tumor efficacy. However, these subsets are intrinsically rare in CLL, limiting the success of manufacturing strategies that rely on their enrichment or ex-vivo expansion. Studies by Ludwig LM et al. (2021) and van Bruggen JAC et al. (2022) demonstrated that short-term Venetoclax treatment selectively depletes naive T cells, but prolonged therapy led to their numerical recovery along with upregulation of OXPHOS and glycolysis pathways. However, the effects of Venetoclax on T-cell functionality and its implications for CAR T-cell manufacturing remain uncertain. We aimed to study if treatment with Venetoclax could improve the qualitative and quantitative defects in the T cells in CLL patients ensuring better CAR T-cells and identify the ideal timepoint following treatment to collect T cells for CAR T manufacturing.
 MethodsWe analyzed peripheral blood samples from discovery (n=14) and validation (n=23) cohorts of CLL patients, with one or more prior lines of therapy, treated with Venetoclax monotherapy or in combination with the anti-CD20 antibody Obinutuzumab. Deep phenotyping of T cells and their response to activation with PMA and Ionomycin was performed using a spectral flow cytometry panel. CD19-directed CAR T cells (incorporating the 4-1BB costimulatory domain) were manufactured, and their proliferation and anti-tumor efficacy were assessed by flow cytometry and restimulation assays in vitro. Statistical analyses were performed using the Friedman test, 2-way ANOVA or Kruskal Wallis test, as appropriate.
 ResultsTreatment with Venetoclax improved the qualitative and quantitative T cell defects with a significant increase in the proportion of naïve (CD45RA+CD27+CCR7+) T cells (both CD4+ and CD8+) and decrease in the effector memory (CD45RA-CD27-CCR7-) compartment. Both manual gating and unsupervised clustering analysis showed a significant decrease in the frequency of regulatory T cells (Tregs) and T cells expressing markers of effector differentiation (KLRG1, CD244, EOMES) and inhibition/exhaustion markers (PD1, CD39, CTLA4, TIGIT). The differences were more pronounced after 1 year of treatment and the findings were confirmed in an independent validation cohort. Upon activation, the treatment-naive samples showed a significant increase (percentage or absolute) in the expression of activation-exhaustion markers (ICOS, PD1, TIM3, TIGIT, CTLA4) while the increase was more restrained after Venetoclax treatment. CAR T-cells were manufactured and functionally assessed through co-culture and repeated stimulation with the aggressive, MHC-deficient CD19+ leukemia cell line NALM6. CAR T-cells manufactured with samples one year post treatment with Venetoclax exhibited greater fold expansion and population doublings on repeat stimulation with NALM6 cells compared to their paired treatment-naive samples. Cytokine analysis and cytotoxicity assays are currently being performed to strengthen our findings.
 ConclusionOur findings strongly suggest that the BCL2 inhibitor Venetoclax exerts beneficial immunomodulatory effects beyond their primary anti-tumor activity. By reducing tumor burden and potentially directly influencing T cell biology, Venetoclax facilitates not only quantitative T cell recovery but also qualitative improvements. Such improvements include phenotypic shifts away from exhaustion and towards less differentiated states (potentially enriching for early memory precursors) and the restoration of key T cell functions like proliferation and cytokine production - factors that may significantly improve CAR T cell manufacturing and therapeutic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b0f58a6bf6fe69cb96d274bc1c6f4165ac0c965" target='_blank'>
              Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Arun Arunachalam, Beatriz Coutinho de Oliveira, Céline Grégoire, Ziran Zhao, Lily Simpson-Heavey, John C. Molina, A. Kater, F. Peters, A. Wiestner, J. Woyach, J. Melenhorst
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Besides its robust antiviral activity, type I interferon (IFN-I) also exerts immunomodulatory effects and can even drive pathology during chronic viral infections. Mechanisms that regulate IFN-I induction during virus infection, thus strongly affecting the outcome of disease, remain to be defined. Here, using the lymphocytic choriomeningitis virus (LCMV) Docile strain, we identified acid ceramidase (aCDase, Asah1) as a critical lipid-metabolic regulator of endosomal, nucleic acid-driven IFN-I responses and disease outcome during chronic virus infection. aCDase is highly expressed in plasmacytoid dendritic cells (pDCs) and required for robust early IFN-I production. aCDase deficiency resulted in ceramide accumulation, blunting IFN-α/β induction, impairing IFN-I-dependent upregulation of programmed death-ligand 1 (PD-L1) on antigen-presenting cells and preventing the exhaustion of virus-specific CD8+ T cells, leading to severe immunopathology. This pathology is abrogated by CD8+ T-cell depletion or by adoptive transfer of IFN-I-induced PD-L1-expressing macrophages. Conversely, limiting ceramide production in acid sphingomyelinase (Asm)-deficient mice prevented ceramide accumulation, and pDCs showed accelerated IFN-I induction. Mechanistically, ceramide abundance regulated IFN-I production by altering endosomal signaling microdomains. Collectively, our findings reveal ceramide homeostasis as a key determinant of IFN-I-driven CD8+ T-cell exhaustion and immunopathology during chronic viral infection and highlight aCDase as a potential therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3347a83451be199ba4cf611d6ba58e4cec09e11d" target='_blank'>
              Acid ceramidase regulates CD8+ T-cell exhaustion via type I interferon-mediated upregulation of PD-L1
              </a>
            </td>
          <td>
            Zhongwen Hu, Hossam Abdelrahman, Abdelrahman Elwy, F. Kuang, Swati Dhiman, Shafaqat Ali, Marcel Marson, Lisa Holnsteiner, Thamer A Hamdan, Justa Friebus-Kardash, Elisa Wiebeck, Wiebke Hansen, S. Scheu, Erich Gulbins, P. Lang, K. Lang, Judith Lang
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Immune checkpoints act like dimmer switches that keep immune responses in balance. In autoimmune disease, problems usually fall into four overlapping types: weak inhibitory signals, too much co-stimulation, metabolic or epigenetic rewiring of checkpoint pathways, and a mismatch between tissue and blood findings. This narrative review focused on human and translational studies from PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (Embase), Web of Science, and Scopus (to 2025), prioritizing tissue-based data, trials of checkpoint agonists or co-stimulation blockade, cell-based tolerance (low-dose interleukin-2 (IL-2), chimeric antigen receptor regulatory T cells (CAR-Tregs), and extracellular vesicle (EV) approaches. Tissue profiling tracks disease activity better than blood alone. Immunometabolic stress, especially lactate-driven protein lactylation and ferroptosis, can blunt programmed cell death protein-1/cytotoxic T-lymphocyte associated protein-4 (PD-1/CTLA-4) braking and destabilize regulatory T cells (Tregs). A practical biomarker panel pairs lesion immunohistochemistry/spatial maps of PD-1/programmed death-ligand-1 (PD-L1) and second-wave checkpoints with soluble PD-1, PD-L1, CTLA-4, and EV cargo under strict pre-analytical control. Therapy should be staged: first, lower the inflammatory and metabolic load, then restore inhibitory tone with checkpoint agonists or co-stimulation blockade, and add Treg support and EV-guided delivery when regulation is fragile. Safety needs vaccine timing, age-/sex-aware dosing, and composite panels that distinguish flare from over-suppression. The next step is endotype-first, spatially informed, biomarker-anchored trials to achieve durable, safer immune rebalancing.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc3b98a9c47abbacb791867bf6e6236a27247d00" target='_blank'>
              Immune Checkpoint Dysregulation in Autoimmune Disorders: A Narrative Review of Therapeutic Implications
              </a>
            </td>
          <td>
            Diwan Mahmood Khan, Rohit Kumar, Mahavadi Sriharsha, Srihita Mahavadi, Arnaw Kishore
          </td>
          <td>2025-11-01</td>
          <td>Cureus</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Radiation-induced skin injury (RISI) is a common and debilitating complication of radiotherapy, characterized by persistent inflammation and delayed wound healing. Macrophages play a central role in this process; however, the molecular mechanisms governing their dysfunction under radiation stress remain poorly understood. To elucidate the role of triggering receptor expressed on myeloid cells 2 (TREM2) in macrophage regulation after irradiation, we combined single-cell RNA sequencing, in vivo mouse models, and in vitro macrophage assays. Conditional knockout mice (LysMCreTrem2flox/flox) were used to selectively delete Trem2 in macrophages. Radiation induced a distinct TREM2+ macrophage subset; however, despite elevated Trem2 mRNA, protein levels declined due to ADAM17-mediated shedding driven by radiation-induced reactive oxygen species (ROS) accumulation and NRF2 activation. Inhibition or small interfering RNA (siRNA)-mediated knockdown of ADAM17 restored TREM2 protein expression, reduced soluble TREM2 release, improved macrophage survival, and promoted anti-inflammatory M2 polarization. Conversely, Trem2 deficiency enhanced apoptosis, sustained inflammation, and delayed wound healing, whereas Trem2 overexpression or local adoptive transfer of TREM2+ macrophages accelerated tissue repair. Mechanistically, TREM2 conferred radioprotection through extracellular signal-regulated kinase (ERK) pathway activation, linking the ROS–NRF2–ADAM17 axis to TREM2–ERK signaling in macrophage survival and polarization. Collectively, these findings identify a novel regulatory cascade, ROS–NRF2–ADAM17–TREM2–ERK, that governs macrophage fate under irradiation. Targeting this pathway or supplementing TREM2+ macrophages may offer promising therapeutic strategies for mitigating RISI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5e8bb0105bfc306e09e4c0af1d74cb3671e412a" target='_blank'>
              TREM2 Deficiency Regulates Macrophage Apoptosis and Repair in Radiation-Induced Skin Injury
              </a>
            </td>
          <td>
            Zijian Chen, siyuan cai, Pengfei Li, ziyi zhou, zhenxing huang, juntao deng, Linbo Jin, Zucheng Luo, Dongli Fan, Junli Zhou, Fazhi Qi, Yiming Zhang
          </td>
          <td>2025-11-13</td>
          <td>Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are central constituents of the tumor microenvironment (TME), recruited from circulating monocytes through chemotactic signals, and they execute complex, multifaceted functions throughout tumor progression. Functionally heterogeneous, TAMs are broadly classified into distinct subtypes that display a dynamic duality, capable of shifting between tumor-suppressive and tumor-promoting states, though the pro-tumorigenic functions tend to dominate across multiple cancer types. The polarization of TAMs is modulated by diverse cytokines and signaling networks within the TME. Key pro-tumor mechanisms include activating proliferative signaling pathways, enhancing invasive and metastatic potential, establishing an immunosuppressive TME through immune cell interactions, and conferring therapy resistance. The spatial heterogeneity of TAMs further underscores the predictive relevance. Translational research increasingly focuses on TAM-targeting strategies such as inhibiting recruitment, depleting subsets, or reprogramming function. Emerging approaches, including nanomedicine-based targeting, macrophage-mediated therapies, and novel drug formulations, highlight the importance of combining conventional treatments with immune checkpoint inhibitors (ICIs). Such combinations help overcome therapeutic resistance and improve clinical outcomes. This review systematically summarizes recent advances in TAM biology and plasticity, biomarkers from single-cell and spatial analyses for distinguishing TAM subsets, and their prognostic relevance in immunotherapy. It also discusses TAM-targeting strategies and their synergistic potential with existing therapies. Together, these insights lay the foundation for next-generation cancer treatments that precisely target TAMs to overcome therapy resistance and improve patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/364fbf1a7e99dd37bbe5b81db733d5ee958dbfae" target='_blank'>
              Tumor-associated macrophages in cancer: from mechanisms to application
              </a>
            </td>
          <td>
            Wan Tang, Xin Wang, Bing Han, Shuheng Jiang, Hongshi Cao
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Despite major advances in immunotherapy, respective treatments often show only limited benefit in patients with chronic lymphocytic leukemia (CLL). Immune checkpoint blockade, which has shown durable responses in multiple malignancies, has yielded inferior efficacy in CLL. Similarly, adoptive CAR-T cell therapy, which has achieved remarkable success in other B cell malignancies, resulted in lower response rates in CLL. The lack of success of these immunotherapies is likely due to the profound T cell dysfunction and immune suppressive microenvironment, typical characteristics of this disease. The so-called “exhaustion” of T cells is marked by impaired effector capacity, sustained inhibitory receptor expression, and loss of progenitor exhausted (TPEX) populations, cell subsets which are critical for responses to PD-1 blockade. This suggests that reversing T cell exhaustion could be key to improving outcomes.
 Emerging evidence implicates the immunoregulatory cytokine interleukin-10 (IL-10) as a context-dependent modulator of T cell exhaustion. While traditionally viewed as an immunosuppressive mediator that limits tissue damage during chronic inflammation and suppresses antiviral immunity, IL-10 may, in cancer, enhance tumor-infiltrating CD8⁺ T cell function, prolong their survival, and delay T cell exhaustion.
 Using the Eµ-TCL1 adoptive transfer (TCL1-AT) mouse model of CLL, we previously identified a role for IL-10 receptor (IL-10R)–STAT3 signaling in sustaining CD8⁺ TPEX cells, preventing terminal exhaustion, with loss of signaling accelerating CLL progression (Hanna et al., Immunity 2021). As IL-10 expression is linked to better outcome in CLL patients and IL-10R loss is associated with DLBCL development early in life, we hypothesize that IL-10 improves the fitness of cytotoxic T cells thereby preventing immune escape in CLL and likely other B cell malignancies.
 To test the potential of IL-10 in modulating T cell responses against CLL, we generated a stabilized IL-10 fusion protein (IL-10-Fc) and demonstrated that treatment of TCL1-AT mice with IL-10-Fc slowed CLL progression, reduced exhausted effector T cells, and preserved TPEX populations.
 To dissect T cell-intrinsic effects, we employed an in vitro exhaustion assay by repetitive antigen-specific stimulation of T cell receptor (TCR)-transgenic murine CD8⁺ T cells with peptide-loaded target cells. IL-10 treatment maintained effector T cells in these cocultures, reduced terminal exhaustion markers TIM-3 and CD39, and promoted a polyfunctional phenotype with robust cytokine production and CD107a expression, demonstrating a direct effect of IL-10 on T cell fitness.
 To gain a broader view of IL-10-mediated immune modulation in the TCL1-AT model, we performed spectral flow cytometry and single-cell RNA-sequencing following short-term IL-10-Fc treatment. Both T cell and myeloid compartments displayed therapy-induced alterations, including shifts in regulatory T cells, CD8⁺ T cells, neutrophils, and monocytes. Notably, IL-10-Fc reduced PD-L1⁺ patrolling monocytes, which were linked to immune suppression in CLL, and increased inflammatory monocytes, which suggests a reversal of pro-tumoral myeloid activity.
 Finally, a pilot combination treatment study revealed that IL-10-Fc synergized with the BTK inhibitor ibrutinib, achieving profound disease control in the TCL1-AT mouse model beyond either agent alone. These findings position IL-10 as a promising immunomodulatory therapy in CLL, capable of restoring T cell function and remodeling the suppressive tumor microenvironment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/189bf152f9c8c3a59e8922ef6b9ef1ab630e8fe4" target='_blank'>
              IL‑10 limits CLL progression by reprogramming T cell exhaustion and myeloid suppression
              </a>
            </td>
          <td>
            A. Floerchinger, M. Gao, Jan Philipp Schadendorf, Yuliia Borysovych, Nicolas Aubert, Hannah Briesch, L-M Pilger, Mei-Wen Peng, P. Lichter, Stella E. Autenrieth, M. Zapatka, L. Tang, M. Seiffert
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="The tumor microenvironment (TME) orchestrates tumor growth, immune evasion, and therapeutic response in head and neck squamous cell carcinoma (HNSCC). Current immune checkpoint inhibitors (ICIs) target the programmed death receptor-1/programmed death-ligand 1 (PD-1/PD-L1) axis and improve survival in recurrent, metastatic, and locally advanced HNSCC. Tumor cells produced exosomes directly suppress cytotoxic T-lymphocytes activity by modulating immune checkpoint pathways and disrupting T-cell receptor signaling. Cancer-associated fibroblast-derived exosomes (CAF-Exos) function indirectly by conditioning immune escape and tumor growth. Together, these exosomal populations cooperate to create an immunosuppressive niche that hinders the efficacy of immunotherapies. CAF-Exos induce TME changes that exclude CD8+ T-cells, promote regulatory T-cells (Tregs), and upregulate PD-L1 expression in tumor cells. The bidirectional transfer of microRNAs (miRNAs) between tumor cells and CAFs enhances epithelial–mesenchymal transition (EMT), suppresses cytotoxic lymphocytes, and undermines ICI efficacy. This review article summarizes recent publications about plasma-derived exosomes from HNSCC patients. These exosomes carry tumor and immune checkpoint markers, reflect tumor burden and treatment response, and strongly modulate immune cells by suppressing T- and B-cell activity and promoting immunosuppressive macrophages. We encourage functional and biomechanistic future studies in the field of HNSCC that examine how CAF subtypes exosomes achieve an immunoresistant TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/045447a931fd77543654643276c8475e775846e3" target='_blank'>
              Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Julia Federspiel, J. Dudas, B. Hofauer, B. Wollenberg, T. Steinbichler
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Maintaining tissue function while eliminating infected cells is a fundamental challenge to host defense. Innate inflammatory damage contributes to lethal influenza and COVID-19, yet other than steroids, immunomodulatory drugs have modest effects and delayed use of antivirals significantly dampens their efficacy. In this study we aimed to identify treatment strategies to prevent death from lethal influenza infection when antiviral treatment is suboptimal due to delayed dosing. However, use of more than 50 immunomodulatory reagents directed against innate inflammation failed to prevent death in infected mice. These data along with transcriptomic and tissue imaging studies led to a “tipping point” model in which early innate immune damage in the context of continued viral damage and late adaptive immunopathology leads to loss of viability. We hypothesized that rebalancing this system to maintain pulmonary function by either promoting the repair response or inhibiting late adaptive, not innate, tissue damage would enable survival. Here we report that limiting viral spread using oseltamivir (Tamiflu) in combination with enhancement of epithelial repair by blockade of type I interferon signaling or limitation of further epithelial cell loss mediated by cytotoxic CD8+ T cells rescued a large fraction of infected animals, providing new insight into the importance of repair processes and the timing of adaptive immune responses in survival of severe pulmonary infections.



 This work was supported by the Division of Intramural Research of NIAID, NIH.



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8113fe23eea75369234673c68cee6a1b474ff234" target='_blank'>
              Rebalancing viral and inflammatory damage versus tissue repair prevents death from lethal influenza infection 2480
              </a>
            </td>
          <td>
            Hiroshi Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin Chu, Anita Gola, Ronald Germain
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI). Methods Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated. Results In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells. Conclusion This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/854d707af7ff1d7731b63579e115f89b9c83b43b" target='_blank'>
              Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy
              </a>
            </td>
          <td>
            Salvatore Russo, Yvonne Giannoula, S. Feola, Justin Cerioni, Firas Hamdan, Jacopo Chiaro, Anja Thu Ha Dang, Paolo Bottega, Michaela Feodoroff, M. Fusciello, Virpi Stigzelius, Carmine D’Amico, Carmen Caiazza, Gabriella Antignani, Federica D'Alessio, Milda Sakalauskaite, Julia Petryk, J. Bell, C. Ilkow, M. Grönholm, Vincenzo Cerullo
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Renal cell carcinoma (RCC) evolves within a chronic inflammatory renal niche, where angiogenesis, metabolism, and immune programs synergize to reshape the tumor immune microenvironment (TIME). Recurrent renal damage and tissue hypoxia sustain NF-κB/STAT3 and HIF-VEGF signaling, while a sustained IFN-γ response enhances antigen presentation while inducing inhibitory checkpoints, promoting a state of “inflammation but constrained.” Single-cell and spatial studies reveal early microenvironment heterogeneity and the chemokine-checkpoint paradox: regions enriched in CXCL9/10 coexist with endothelial inertia, cancer-associated fibroblasts (CAFs)-mediated stromal barriers, and metabolic stress, which collectively exclude functional CD8+T cells. In advanced clear cell RCC, immuno-inflammatory, immuno-excluded, and immuno-desert phenotypes often coexist and undergo transitions during treatment, leading to heterogeneity in response to immune checkpoint blockade (ICB). We propose a modular perspective-the NF-κB/STAT3, HIF-VEGF, IFN-γ circuits and auxiliary regulatory factors-to link stage-specific biology with treatment matching. Integrative biomarkers couple IFN-γ characteristics with angiogenesis/stromal modules and spatial indicators, offering superior predictive power compared to single tests. These insights support the adoption of a combined strategy: integrating vascular normalization or stromal/myeloid cell reprogramming on the basis of ICB, and encouraging the use of longitudinal “immune snapshots” to guide intervention and precision immunotherapy for renal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2bd0a59026e4807122514617a7c05a2fad79de65" target='_blank'>
              From chronic inflammation to immune escape: mapping the tumor microenvironment evolution in renal cell carcinoma
              </a>
            </td>
          <td>
            Hanjun Xu, Baojun Tu, Hui Li, Yong Shan
          </td>
          <td>2025-11-04</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6–JAK–STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d49eb0cd9f9aa70be266360e0a4941b4deb7497" target='_blank'>
              Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies
              </a>
            </td>
          <td>
            Michael Rassner, T. Müller, Kirstyn Anne Crossley, G. Andrieux, Sabina Schaberg, Cornelia Endres, Lena Jakob, Teresa Poggio, N. Köhler, J. Kolter, Gerhard Müller-Newen, Katharina Schönberger, N. Cabezas-Wallscheid, I. González-Menéndez, Leticia Quintanilla-Martinez, Melissa Zwick, Driti Ashok, T. N. Hartmann, Olaf Groß, O. Gorka, M. Follo, A. Illert, M. Boerries, R. Zeiser, J. Duyster
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Abstract Apoptosis, a form of programmed cell death, is crucial for keeping homeostasis during and after infections. Cellular FLICE-inhibitory protein (c-FLIP) is an inhibitor of death receptor-mediated apoptosis, of which three isoforms have been characterized so far. While the isoforms c-FLIPlong and c-FLIPshort are well characterized, the function of c-FLIPR remains poorly understood. To study the role of c-FLIPR in influenza A virus (IAV) infection, we employed vavFLIPR transgenic mice that constitutively express murine c-FLIPR in all hematopoietic cells. Upon IAV challenge, vavFLIPR mice showed an altered viral dynamic with a higher viral load than wild-type mice, coinciding with a higher number of Natural Killer (NK) cells. IAV directly infected murine NK cells, but viral particles produced by NK cells did not infect other target cells. While NK cells from vavFLIPR and control mice were equally able to kill tumor cells in vitro, we detected reduced degranulation of c-FLIPR transgenic NK cells from infected mice compared to wild-type counterparts. Furthermore, TNFα and IFNg expression was reduced in c-FLIPR transgenic NK cells. We conclude that c-FLIPR impairs NK cell activity during IAV infection. Key messages Constitutive expression of the anti-apoptotic c-FLIPR in hematopoietic cells increases IAV titers. Accumulation of NK cells in vavFLIPR mice during IAV infection. IAV infects NK cells in a non-productive manner. IAV infection of NK cells impairs their function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2201ed3d7dca3eff038218bf0fd445634039c961" target='_blank'>
              The cell death regulator c-FLIPR impairs natural killer cell responses during influenza a virus infection
              </a>
            </td>
          <td>
            André Carmo-Fernandes, Neda Tafrishi, Clara Bessen, Konstantinos Katsoulis-Dimitriou, Marina C. Greweling-Pils, D. Bruder, C. Plaza-Sirvent, Ingo Schmitz
          </td>
          <td>2025-12-26</td>
          <td>Journal of Molecular Medicine (Berlin, Germany)</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Q. Han, Yuntao Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) represent a small subset of tumor cells populations characterized by their ability to self-renew and differentiate. These cells are often considered resistant to chemotherapy, radiotherapy, and immunotherapy, playing a crucial role in driving tumor progression and metastasis. To evade immune attacks, CSCs utilize various genetic and epigenetic strategies that diminish immune recognition, enhance tolerance to immune-induced cytotoxicity, and foster the development of a protective immunosuppressive microenvironment. This microenvironment is shaped by a group of key immunosuppressive cells, particularly myeloid-derived suppressor cells (MDSCs), which not only directly inhibit effector T cells and natural killer (NK) cells, facilitating the immune escape of CSCs, but also significantly contribute to the maintenance of tumor cell stemness and promote their metastasis. Conversely, the developmental signals of MDSCs are also regulated by CSCs. This complex interplay between MDSCs and CSCs adds layers of complexity to the cancer-immune cycle and the associated tumor treatment strategies. Therefore, understanding the detrimental interdependence between MDSCs and CSCs to effectively impede tumor progression has become heated topic in tumor immunology. In this review, we provide a timely summary of the latest studies on the reported characteristics of CSCs and MDSCs, discuss their interconnection during tumor progression, and evaluate various immunotherapeutic strategies targeting these cell populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f6883e12fe0f725487279c796b8b972017bb7c9" target='_blank'>
              Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy
              </a>
            </td>
          <td>
            Bo Wang, Xiaoguo Zhao, Shuxin Han, Yuekang Xu, Jinyao Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple Myeloma (MM) is the second most frequent hematologic malignancy in adults in the Western world. The bone marrow microenvironment plays a critical role in MM progression by supporting malignant plasma cell (PC) survival, immune evasion, and proliferation. Among immune checkpoints, TIGIT has recently emerged as a relevant immunoregulatory molecule, capable of dampening cytotoxic responses and enhancing immune suppression. We investigated the expression of TIGIT in the bone marrow of newly diagnosed MM patients and its correlation with disease characteristics and microenvironmental features. We enrolled 25 consecutive patients with newly diagnosed MM. Bone marrow samples were collected for cytomorphology, cytogenetics (FISH), and immunohistochemistry using the Cytomatrix system. TIGIT expression was analyzed in bone marrow-infiltrating immune cells. Histological evaluation and confocal microscopy assessed immune cell localization, neutrophil extracellular trap (NET) formation, and proinflammatory cytokine expression. Clinical parameters, staging (ISS, R-ISS, R2-ISS), cytogenetic risk, and laboratory values were correlated with TIGIT status. TIGIT was expressed in 86% (19/22) of evaluable samples. TIGIT-positive patients had a significantly higher frequency of advanced R-ISS stages (p = 0.01), high-risk cytogenetics (100%), and elevated LDH (> 220 mU/ml, 100% TIGIT+). Among patients with PC% >60% or FLC ratio > 100, 92% were TIGIT+. Morphological differences were evident between groups: TIGIT-negative PCs were larger and altered, while TIGIT-positive PCs showed polarized nuclei and proximity to neutrophils. TIGIT-positive samples displayed increased neutrophils undergoing NETosis, as confirmed by neutrophil elastase and Ly6b co-expression (p = 0.0067). Elevated IL-6 (p = 0.0003) and IL-8 (p = 0.004) in TIGIT-positive samples suggest a proinflammatory microenvironment promoting neutrophil recruitment and NETosis. TIGIT expression in the bone marrow of MM patients is associated with more aggressive disease features and an inflammatory microenvironment enriched with NET-forming neutrophils. These findings support TIGIT as a potential biomarker of disease severity and a therapeutic target in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2db043b94ebed36b09b59ae106115395215e9302" target='_blank'>
              Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma
              </a>
            </td>
          <td>
            V. Tomarchio, Francesca Arciprete, Monica Di Cecca, G. Maricchiolo, Viola Velardi, M. Tafuri, A. Bianchi, V. Morano, Barbara Mecorio, L. Rigacci, A. Crescenzi, M. Zingariello, O. Annibali
          </td>
          <td>2025-11-01</td>
          <td>Annals of Hematology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Abstract Immune-mediated glomerulonephritis (IMGN) is a major cause of kidney failure worldwide, yet the precise roles of T cells in its pathogenesis remain poorly understood. However, existing studies lack a comprehensive understanding of the characteristics and functional roles of IMGN T cells in the human context. Addressing this gap is crucial for advancing targeted therapies. By integrating single-cell RNA sequencing (sc-RNA-seq) data from three primary IMGN types—IgA nephropathy (IgAN), lupus nephritis (LN), and membranous nephropathy (MN)—we identified T cell subtype alterations at single-cell resolution. Utilizing advanced sc-RNA-seq computational pipelines, we constructed gene co-expression networks (GCNs), inferred T-cell differentiation trajectories, and assessed metabolic and intercellular signaling features. IMGN kidneys presented expanded T-cell compartments, with significant enrichment of cytotoxic natural killer T (NKT) cells and GZMK⁺ effector memory T (GZMK⁺ Tem) cells. Notably, LTB⁺ memory T cells (LTB⁺ Tm) were selectively elevated in IgAN and LN patients. A coexpression module centered on RGS1 was significantly correlated with 24-h proteinuria (p < 0.001). Metabolic profiling revealed subtype-specific disruptions in the glutathione (GSH) and 3-phospho-D-glyceroyl phosphate (3PD) pathways. Interaction analysis highlighted endothelial cells, mesangial cells, and fibroblasts as key mediators of pathogenic T-cell activation via defined ligand‒receptor pairs. This study provides the first comprehensive single-cell atlas of human IMGN T cells, revealing disease-specific T-cell states, metabolic signatures, and activation mechanisms. Our findings offer new insights into human renal immunopathology and identify promising therapeutic targets for IMGN.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/355e0f6ab7752fce8d41720415bcb57b5ac71157" target='_blank'>
              Single-cell transcriptomic analysis reveals T cell heterogeneity and metabolic reprogramming in human immune-mediated glomerulonephritis
              </a>
            </td>
          <td>
            Jianbo Qing, Yiting Zhao, W. Cheungpasitporn, Jing Miao, C. Thongprayoon, Henglan Wu, Junnan Wu
          </td>
          <td>2025-11-16</td>
          <td>Autoimmunity</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Dendritic cells (DCs), as pivotal antigen-presenting cells (APCs), play crucial roles in initiating T cell-mediated antitumor immune responses, bridging innate and adaptive immunity while maintaining immune tolerance. With an in-depth understanding of DC biology and functions, numerous DC-targeted therapeutic approaches have been developed. An enhanced understanding of DC heterogeneity and DC cross-talk with other cells within the tumor microenvironment (TME), along with functional and metabolic remodeling mechanisms, may optimize DC-based cancer immunotherapies. This review focuses on the heterogeneity of the individual occurrence and function of DCs in tumors, elucidates the cross-talk between DCs and other cells in the TME, provides an in-depth understanding of the dysfunction and metabolic reprogramming of DCs in the TME, and summarizes existing DC-based anticancer therapies and novel therapeutic strategies, with the aim of providing new insight into the emerging role of DCs in future cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/faa2235fef7e2070a903bcb396ad65abaccb1f93" target='_blank'>
              The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy
              </a>
            </td>
          <td>
            Zhiyuan Xie, Yingjun Fang, Xinhao Zhang, Yingshuai Fang, Ruiqi Li, Ying Guo, Yabing Yang, Shuaixi Yang, Lijie Song
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00ed13bb7acb39c5e98a4fa14592f332d5a91492" target='_blank'>
              A narrative review of therapy-induced senescence in cancer: mechanisms, immune interplay, and therapeutic opportunities
              </a>
            </td>
          <td>
            Henry Sutanto, Alfan Ahkami, D. Fetarayani, P. Z. Romadhon
          </td>
          <td>2025-12-01</td>
          <td>Journal of the Egyptian National Cancer Institute</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Infected skin tumors are challenging to treat and frequently result in tumor progression, relapses, and post-surgical complications. Moreover, bacterial infections significantly contribute to tumor therapy resistance as they release tumor microenvironment (TME)-modulating molecules. Immune or cancer cells can recognize these pathogen-associated molecular patterns (PAMPs), initiating signaling and pro- or antitumoral response. Hence, understanding PAMPs in tumor therapy may improve the understanding and efficacy of cancer treatment. Cold gas plasma treatment has shown promise in treating infected, ulcerative head and neck cancers. Here, we elucidated gas plasma-induced bacterial PAMP release and their combination with direct gas plasma exposure in skin cancer cells in vitro. Evaluating metabolic activity and viability of tumor cells revealed a significantly stronger growth-inhibitory effect of the combinatory treatment, suggesting a relevant contribution of bacterial molecules to tumor toxicity. A synergistic effect was found regarding the oxidative damage marker γH2AX that was elevated in response to the combination treatment. Cancer cells subjected to gas plasma and provoked PAMPs exhibited an altered phenotype that displayed a strikingly different chemokine and cytokine profile. Mass spectrometry analysis showed improved bacterial cell lysis by gas plasma treatment, increasing intracellular protein release of all three tested bacterial strains.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/293a30a89e7025c1bd7e6b159297e4ac34cc91f2" target='_blank'>
              Gas plasma-induced bacterial PAMP release promotes skin cancer cell death
              </a>
            </td>
          <td>
            Julia Berner, Malin Sieben, Eric Freund, P. Schulan, L. Miebach, S. Bekeschus
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Eosinophils, once primarily considered strictly end-stage effector cells in parasitic infections and allergic inflammation, are now emerging as vital immunoregulatory cells. This review focuses on eosinophil contributions to cell-mediated adaptive immunity by exploring the multifaceted interactions between eosinophils and T cells that underlie their unique contributions to immune modulation in allergic diseases. We begin by reviewing key features of eosinophil immunobiology within the context of their relevance to the development, differentiation, and function of CD4+ and CD8+ T cells in homeostasis and immunity. Building on this framework, we review recent literature revealing new roles for eosinophils in homeostatic immunosuppression, adaptive immune initiation, and immunomodulation within the context of an active immune response. We further explore the significance of eosinophil functionality impacting the structure and function of primary and secondary lymphoid organs, including thymic involution and regeneration, on cell-mediated immunity. This review presents an evolving paradigm that positions eosinophils as essential players in shaping multiple layers of the immune landscape in allergic diseases and beyond.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ab0b85536608c33ecf22448310bbb151d779835e" target='_blank'>
              Innate Immune Pairing: Eosinophils as Hidden Architects of T Cell Immunity
              </a>
            </td>
          <td>
            Kriti Gupta, Natalie A. Falta, Lisa A. Spencer
          </td>
          <td>2025-11-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="This research elucidates a novel strategy wherein CD8⁺ T cells overcome tumor immune evasion by initiating ferroptosis and establishing a self-sustaining positive feedback loop. Unlike traditional cytolytic pathways employed by CD8⁺ T cells (e.g., Fas-L/Fas and perforin/ granzyme mechanisms), the interferon-gamma (IFN- γ)-facilitated ferroptosis pathway unveils a distinct immunoregulatory role. Ferroptosis is an iron-dependent, non-apoptotic form of cell death driven by excessive lipid peroxidation, loss of mitochondrial membrane integrity, and eventual plasma membrane disruption. Crucially, beyond direct tumor cell killing, the process leads to emission of damage-associated molecular patterns (DAMPs), which potently stimulate dendritic cell maturation and enhance antigen-specific T cell responses. This establishes a cyclic “immune activation--ferroptosis- -immune reactivation” cascade, effectively alleviating immunosuppression within the tumor microenvironment (TME). Our comprehensive analysis demonstrates that CD8⁺ T cell-secreted IFN-γ downregulates SLC7A11, limiting cystine uptake and impairing glutathione (GSH) biosynthesis, thereby inactivating GPX4. Concurrently, IFN-γ upregulates ACSL4, promoting esterification of polyunsaturated fatty acids (PUFAs) into phospholipids and increasing susceptibility to lipid peroxidation. Together, these synergistic changes induce robust ferroptosis. This mechanism offers a transformative therapeutic perspective for tackling resistance to immune checkpoint inhibitors, with considerable theoretical and clinical implications for next-generation cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc592830024c2ef74ca04dbb64f75f144610d41c" target='_blank'>
              CD8⁺ T Cell-Induced Ferr optosis via a Positive Feedback Mechanism to Overcome Immune Resistance
              </a>
            </td>
          <td>
            Jiaqi Mou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Circular RNAs (circRNAs) have recently emerged as critical regulators of tumor–immune interactions. Owing to their covalently closed structure, remarkable stability, and tissue-specific expression, circRNAs not only serve as molecular sponges and protein regulators but also play multifaceted roles in shaping the tumor immune microenvironment. Accumulating evidence indicates that circRNAs drive immune suppression by stabilizing PD-L1 through post-translational modifications and RNA-binding protein interactions, transmitting suppressive signals via exosomes to T cells and myeloid-derived suppressor cells, reprogramming glucose and lipid metabolism to deprive effector lymphocytes, and reinforcing cancer stemness and therapy resistance. In striking contrast, a subset of circRNAs has been shown to sensitize tumors to immunotherapy by activating innate immune pathways such as RIG-I/MAVS and STING, inducing immunogenic cell death, and overcoming resistance to endocrine therapy or ferroptosis inducers, thereby enhancing the efficacy of immune checkpoint blockade. Beyond their mechanistic functions, circRNAs also hold promise as stable and accessible biomarkers for prognosis, patient stratification, and therapeutic monitoring, particularly when enriched in circulating exosomes. Advances in antisense oligonucleotides, RNA interference, and nanomedicine provide new opportunities to therapeutically target oncogenic circRNAs or deliver engineered pro-immunogenic circRNAs. While significant challenges remain in detection accuracy, functional annotation, delivery specificity, and clinical validation, circRNAs represent a new frontier in immuno-oncology. Harnessing their dual roles may unlock innovative biomarker platforms and next-generation RNA-based therapeutics, ultimately improving the efficacy of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4d997c9720e9890b039f09060198c82b2dba63d" target='_blank'>
              From immune suppression to immunotherapy sensitization: the dual roles of circRNAs in cancer progression
              </a>
            </td>
          <td>
            Quan Dai, Xiaoli Yuan, Hang Dong, Haiyi Xue
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 CAR-T cells have emerged as a therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus (SLE). One open question is the impact of preconditioning on therapeutic responses. In preliminary experiments using pre-irradiated lupus-prone New Zealand Black/New Zealand White (NZB/W) mice, second-generation anti-mCD19 CAR-T cells positively impacted many disease features. Significant bone marrow (BM) B-cell depletion and lower proteinuria were observed across irradiated groups, suggesting an immunosuppressive effect. Based on these findings, we aimed to demonstrate the impact of CAR-T cells over irradiation on various immunologic and clinical features by modifying the conditioning regimen in these mice. Twenty two-week-old pre-irradiated mice were treated with PBS or CAR-T cells+IL-2. Lymphocytes were assessed in blood, BM, and spleen 4-weeks post treatment. The engraftment of CAR-T cells was documented in all samples. CAR-T cell-treated mice showed persistent B cell decrease in various subsets (marginal zone/naïve B cells and plasma cells). Furthermore, increases in CD4+ and CD8+ T cells, with a lower percentage of effector/central memory T cells and higher naïve T cells were observed as an outcome of CAR-T treatment. CAR-T treated mice also displayed lower anti-dsDNA antibodies and proteinuria. Thus, CAR-T cells showed a differential impact on lupus beyond irradiation. Other disease features to ascertain CAR-T cell efficacy for SLE are being explored.



 Supported by Kyverna Therapeutics, Inc., Emeryville, CA.



 Therapeutic Approaches to Autoimmunity (THER)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48e017f60a3235e38047b172faeb8b5872f707d" target='_blank'>
              Efficacy and engraftment of anti-CD19 CAR-T cells in murine lupus 4343
              </a>
            </td>
          <td>
            J. Romo-Tena, Shouvonik Sengupta, William Ambler, S. Nakabo, C. Carmona-Rivera, Eduardo Patino Martinez, L. P. Blanco, Shairaz Shah, Jennifer Zeng, Ashley E. Mahne, Joseph K Cheng, T. Van Blarcom, Mariana J. Kaplan
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="ABSTRACT Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8+ T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863d3f6179309aee5c3016baab1955820d8c1527" target='_blank'>
              The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
              </a>
            </td>
          <td>
            Soyoung Kim, IkJoon Han, Suin Lee, Sujin Park, Jae-Won Jeon, Hyunsu Bae
          </td>
          <td>2025-11-25</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Gastric cancer (GC) remains a major global health burden with persistently high mortality despite therapeutic advances. Accumulating evidence highlights the pivotal role of tumor-associated macrophages (TAMs) in orchestrating gastric tumor progression through immune suppression, angiogenesis, extracellular matrix remodeling, and metastasis. Within the tumor microenvironment (TME), TAMs exhibit functional plasticity, often polarizing toward an M2-like phenotype that promotes immunosuppression and tumorigenicity. These cells actively participate in immune evasion via immune checkpoint expression and cytokine-mediated T cell inhibition, while also facilitating lymphovascular invasion and chemoresistance through exosome-mediated crosstalk. The density and phenotype of TAMs have been associated with prognosis and therapeutic response in GC. Recent studies have proposed TAMs as promising targets for therapy, with strategies focusing on depleting M2 subsets, reprogramming toward M1 phenotypes, and blocking TAM-driven oncogenic signaling. Targeted interventions, including MENK, paclitaxel, and NF-κB inhibitors, have shown potential in preclinical models. This review comprehensively discusses the mechanistic roles of TAMs in GC and evaluates emerging TAM-targeted therapeutic strategies that may enhance the efficacy of immunotherapy and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/913bc3f4af4f9d7fed06d178714e6cfa582ea213" target='_blank'>
              Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy
              </a>
            </td>
          <td>
            Chang Wang, Xu Fan, Xiaomeng Sun, Yi Xu, Yanna Sun, Jidong Liu
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0895fbd19269fbdc4298e324e79791c8a18caebd" target='_blank'>
              CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.
              </a>
            </td>
          <td>
            J. Boldison, P. Leete, E. Robinson, Wendy Powell, Joanne Davies, Conor McMullan, Sophie L Walker, Noel G. Morgan, S. Hanna, F. S. Wong
          </td>
          <td>2025-11-22</td>
          <td>Diabetologia</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background Bystander activation has primarily focused on conventional antigen-specific T cells (TMEM) and other innate immune cell types. However, the role of virtual memory T cells (TVM) has been largely overlooked, despite their numerical superiority and highly cytotoxic phenotype. Bystander activation is particularly relevant in infections caused by intracellular pathogens. In this study, we aimed to compare the bystander activation potential of TVM cells versus TMEM cells during the early days following T. cruzi infection. Methodology/Principal Findings Our results demonstrate that TVM and TMEM cells, evaluated by flow cytometry, are present but do not undergo significant changes in frequency during the first four days post-infection (p.i.). In an in vitro co-culture system, TVM or TMEM cells pre-incubated with IL-12 and IL-18 (effector cells) were cultured with T. cruzi-infected enriched peritoneal macrophages (Tc-PM, target cells). Immunofluorescence assays revealed that both TVM and TMEM cells exhibit a highly efficient capacity to kill the parasite and induce degranulation, in contrast to naïve T cells (TN), which showed almost no cytotoxic activity. Furthermore, intracellular flow cytometry assays confirmed that both TVM and TMEM cells produce substantial amounts of IFNγ up to 4 days p.i. when stimulated in vitro with IL-12 and IL-18, whereas TN cells fail to produce this cytokine. Accordingly, TVM and TMEM cells exert their cytotoxic effects via IFNγ production, rather than NKG2D, which subsequently activates reactive oxygen species (ROS) and Nitric Oxide (NO) pathways in Tc-PM. Additionally, we demonstrate that in TVM cells, IFNγ signaling occurs through STAT1 in Tc-PM. Finally, analysis of human TVM cells within PBMCs, revealed increased expression of the functional marker granzymes in Chagas disease patients compared to healthy controls. Conclusions/Significance These results challenge the view that only TMEM cells dominate early infection control. The equivalency of TVM and TMEM cells in parasite clearance suggests TVM cells are valuable innate-like contributors, providing rapid protection. Their numerical prevalence in unprimed individuals indicates TVM cells may be an underestimated component of early immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49e47d58d53ce22ebb1eb8471770bd5352dc5158" target='_blank'>
              Bystander CD8+ conventional memory versus virtual memory T cells in the initial days post-Trypanosoma cruzi infection
              </a>
            </td>
          <td>
            M. E. Viano, R. E. Baigorrí, Gastón Bergero, M. Aoki, N. L. Lidon, Maria Guadalupe Teixeira, Melisa Rocío Herrera, C. Motran, F. Cerbán, C. Stempin, M. C. Rodriguez-Galán
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Cancer is a disease with a very high fatality rate. immunotherapy is a promising way to treating cancers, of which CTLs are important for the host immune system against tumor, directly killing tumor cells. However, the relative immunotherapy is limited by many factors that suppress the function and activity of CD8+ CTLs. This review aims to study the mechanisms by which CD8+ CTLs are suppressed in the tumor microenvironment. By collecting preclinical and clinical studies, this paper summarized the main factors that suppress CD8+ CTLs including the following factors: immune cells like regulatory T cell (Tregs), tumor-associated macrophage (TAM), myeloid-derived suppressor cells (MDSCs); metabolic factors like hypoxia, lactic acid accumulation, glucose competition, and immune checkpoints molecules (ICM) PD-1 and CTLA-4. The complex mechanisms of suppressing CD8+ CTLs in the tumor microenvironment are discussed in these findings, which may give clues to the relative treatment and help overcome these suppression effects on CD8+ CTLs in tumorigenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0a3c8667fb5c07636fc20ce12f9301e91ee0bab" target='_blank'>
              Suppressed Factors to CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Zeyu Zhou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a clonal malignancy of plasma cells that remains largely incurable despite major advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Chimeric antigen receptor (CAR)-engineered immune cells have transformed the therapeutic landscape, but CAR-T cell therapy faces challenges such as severe cytokine release syndrome (CRS), neurotoxicity, limited persistence, and logistical complexity. In recent years, natural killer (NK) cells have emerged as a promising platform for next-generation cellular immunotherapy, offering innate antitumor activity, a reduced risk of graft-versus-host disease (GvHD), and the feasibility of “off-the-shelf” allogeneic production. This review summarizes current advances in CAR-NK cell therapy for MM, focusing on two major aspects: the diversity of cell sources—including NK-92, peripheral (PB) and cord blood (CB), and induced pluripotent stem cell (iPSC)-derived NK cells—and the expanding repertoire of target antigens such as BCMA (B-cell maturation antigen), NKG2D, CD38, CD70, SLAMF7, CD138, and GPRC5D. We highlight preclinical and early clinical studies demonstrating potent cytotoxicity, favorable safety profiles, and innovative multi-targeting strategies designed to overcome antigen escape and enhance persistence. Emerging clinical data suggest that CAR-NK cell therapy may combine the specificity of CAR recognition with the inherent safety and versatility of NK biology, offering a potential paradigm shift in the treatment of relapsed or refractory MM. Further clinical validation will determine whether CAR-NK cell therapy can achieve durable remission and complement or surpass current CAR-T modalities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6c564648f2cac8ed7d5dc089469d07120d75f71b" target='_blank'>
              State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens
              </a>
            </td>
          <td>
            Asya Bastrich, Kamilla Vinogradova, D. Mokrousova, Anna Efremova, O. Makhnach, D. Goldshtein
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Introduction: Aging impairs immune function and leads to increased vulnerability to infection, malignancy, and vaccine failure.Immunosenescence, marked by reduced thymic output, naive T cell attrition, and progenitor exhaustion, undermines vaccine responses and anti-tumor immunity in aged individuals. While cytokine-based and stem cell-modifying therapies have attempted to reverse this decline, they remain limited by toxicity, durability, or translational feasibility. Here, we present an mRNA approach that transiently reconstitutes thymic signaling pathways in an unrelated organ. By expressing Delta-like ligand 1 (DLL1), Fms-like tyrosine kinase 3 ligand (FLT3-L), and interleukin-7 (IL-7) - collectively termed DFI - in the liver, we observed rejuvenated aged immunity via coordinated modulation of thymopoiesis, lymphoid progenitors, and immune function.
 Methods: We identified age-related decline of Notch, IL-7, and FLT3-L signaling in thymic epithelial cells and peripheral T cells using spatial transcriptomics (Slide-seq v2) and single-cell RNA-seq across the human and murine lifespan. Modified mRNAs encoding DFI were encapsulated in SM-102 lipid nanoparticles (LNPs) and administered to aged mice (72 weeks). Hepatic expression, pharmacokinetics, and tissue specificity were assessed via RIBOmap and immunofluorescence. Functional impact on thymopoiesis, hematopoiesis, and immune function was assessed via flow cytometry, V(D)J sequencing, TREC analysis, peptide vaccination, tumor challenge (B16-OVA and MC38-OVA), and immune checkpoint inhibitor (ICI) therapy. Autoimmune safety was evaluated in NOD, Act-mOVA, and EAE models.
 Results: DFI mRNA was selectively translated in hepatocytes, yielding membrane-bound DLL1 and secreted IL-7 and FLT3-L without off-target organ expression. This induced expansion of naïve CD4⁺ and CD8⁺ T cells, increased TRECs, and restored thymic cellularity in aged mice. Mechanistically, DFI did not reprogram hematopoietic stem cell (HSC) fate or reverse myeloid bias but significantly expanded common lymphoid progenitors (CLPs) in the bone marrow. These CLPs exhibited increased CCR9 expression and thymus-homing potential, consistent with peripheral DLL1-mediated Notch signaling and improved thymic seeding. Early thymocyte subsets (DN1-DN3) were selectively enriched, accompanied by rapid induction of Rag2 and Nur77 in thymocytes, supporting enhanced de novo thymopoiesis. Despite HSC aging signatures remaining intact, DFI circumvented upstream deficits by expanding committed lymphoid progenitors and reinvigorating thymic output.
 Beyond the T cell compartment, DFI restored conventional dendritic cell type 1 (cDC1) populations and boosted co-stimulatory molecule expression (CD40, CD83, CD86). In parallel, it decreased dysfunctional age-associated B cells and increased follicular B cells, resulting in more robust antigen-specific IgG responses and IgM-to-IgG class-switching after peptide vaccination.
 Functionally, DFI pre-treatment doubled vaccine-specific CD8⁺ T cells in aged mice and improved antigen recall cytokine production (IFN-γ, IL-2). In tumor models, DFI conditioning enhanced spontaneous rejection of MC38-OVA and B16-OVA tumors and improved survival. It restored intratumoral CD8⁺ T cell infiltration and diversity and reversed age-associated T cell exhaustion signatures. When combined with ICI, DFI synergistically enhanced tumor control and survival in aged mice with established tumors.
 Importantly, DFI did not trigger autoimmune responses. In NOD mice, DFI did not accelerate type 1 diabetes or increase autoreactive TCRs. In Act-mOVA mice, tolerance to endogenous OVA was preserved. In the EAE model, DFI increased peripheral MOG-specific T cells but did not worsen CNS inflammation or clinical scores. DFI's immunostimulatory effects were strictly transient, dissipating 4 weeks post-treatment without long-term adverse effects.
 Conclusions: Transient hepatic expression of DLL1, IL-7, and FLT3-L safely and effectively reactivates thymopoiesis, expands functional T cell pools, and enhances antigen-specific immune responses in aged hosts. By bypassing stem cell-intrinsic defects and rejuvenating the thymic niche via liver-derived trophic cues, DFI overcomes major roadblocks of immune aging. This mRNA-based, non-integrating platform supports scalable, cyclic immunostimulation without autoimmunity, suggesting a viable strategy to enhance vaccine efficacy and cancer immunotherapy in elderly patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ca64b5c3c124926369d482741b8ee751943695e" target='_blank'>
              Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts
              </a>
            </td>
          <td>
            M. Friedrich, Julie Pham, Jiakun Tian, Hongyu Chen, Jiahao Huang, N. Kehl, Sophia Liu, Blake Lash, Fei Chen, Xiao Wang, Rhiannon K. Macrae, Feng Zhang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Long COVID has emerged as a major global health concern, yet the long-term trajectory of immune recovery and its contribution to persistent symptoms remain to be elucidated. Here, we conducted a three-year longitudinal follow-up of the 47 COVID-19 patients and applied single-cell RNA sequencing (scRNA-seq) and multiplex cytokine profiling to comprehensively characterize the peripheral immune landscape during convalescence. We observed persistent immune dysregulation up to three years post-infection, characterized by chronic inflammation and impaired restoration of naïve CD4⁺ T cells, naïve CD8⁺ T cells, and SLC4A10⁺ MAIT cells—features reminiscent of immunosenescence. Notably, Th17 cells, rather than monocytes, emerged as key drivers of chronic inflammation beyond one year. We identified two distinct Th17 subsets: RORC⁺ Th17 cells and LTB⁺ Th17 cells. While RORC⁺ Th17 cells were negatively correlated with inflammatory cytokine levels, LTB⁺ Th17 cells showed proinflammatory features and were positively associated with long COVID symptoms. Sustained elevation of S100A8 and IL-16 in follow-up patients may contribute to the persistent presence of LTB⁺ Th17 cells. Together, our study provides an in-depth longitudinal map of immune remodeling in COVID-19 convalescents, revealing key cellular and molecular drivers of sustained inflammation up to three years post-infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f682ef5df5972e318b0093c3cf2459508e92d089" target='_blank'>
              T cell-driven sustained inflammation and immune dysregulation mimicking immunosenescence for up to three years post-COVID-19
              </a>
            </td>
          <td>
            Tian Zheng, Ru Gao, Yiwei Liu, Ye-ming Wang, Chao Wu, Li Guo, Lan Chen, Xinming Wang, Yan Xiao, Jingchuan Zhong, Rongling Zhang, Ying Wang, Xianwen Ren, Bin Cao, Lili Ren, Jianwei Wang
          </td>
          <td>2025-11-20</td>
          <td>Immunity & Inflammation</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="


 Background: Treatment resistance and relapse in myeloma and lymphoma are driven by diverse immunosuppressive mechanisms within the tumor microenvironment (TME), including expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells, upregulation of immune checkpoints, and suppression of antigen presentation, which collectively impair cytotoxic T and natural killer (NK) cell function. Heat shock protein 70 (HSP70), highly expressed in many hematologic malignancies, including multiple myeloma and lymphoma, plays a central role in these processes by stabilizing oncoproteins, inhibiting apoptosis, and promoting immune escape. Extracellular HSP70 released from tumor cells, often bound to tumor-derived antigens, can induce pro-tumorigenic inflammation and facilitate recruitment of immunosuppressive cells, and interfere with antigen processing and stress-induced cell death. Prior attempts at HSP70–based vaccination showed limited clinical efficacy due to challenges in purifying material and efficiently targeting APCs, highlighting the need for novel strategies to leverage this pathway in myeloma and lymphoma immunotherapy.
 Methods: We developed a panel of murine monoclonal antibodies to HSP70 by immunizing BALB/c mice with murine fibroblast L-cells expressing human HSP70 fused to green fluorescent protein. This panel was then screened in immune-competent BALB/c mice injected with luciferase (luc)-expressing MOPC315.BM murine myeloma cells, selected due to the 95% homology between murine and human HSP70. Clone 77A was identified from this screen as showing the most robust in vivo anti-tumor activity and subjected to further in vitro and in vivo testing.
 Results: Clone 77A enhanced antigen-presenting cell (APC) uptake of HSP70 tumor antigen complexes, promoted cross-priming of antigen-specific T cells, and engaged FcγRIII on NK cells and antigen presenting cells and thus modulated both innate and adaptive immunity.
 In immunocompetent myeloma models (MPC11 and Vk*MYC), 77A remodeled the immunosuppressive TME by inhibiting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). Also, 77A promoted dendritic cell (DC) infiltration and expanded central memory CD4+ and CD8+ T- and NK-cell populations, subsequently generating a potent anti-tumor activity. Bulk RNA-seq and pathway analysis confirmed activation of antigen processing/presentation and NK cell-mediated cytotoxicity pathways.
 In the EG7.OVA (chicken ovalbumin) lymphoma model, 77A reshaped the TME to favor tumor-specific immune activation, including expansion of OVA presenting DCs and proliferation of OVA323–339-specific CD4+ T cells and OVA257-264- specific CD8+ T cells with enhanced effector function. These antigen specific T cells from 77A-treated tumor bearing mice exerted significant ex vivo cytotoxicity against EG7.OVA cells. Moreover, 77A augmented proliferation and effector function of OVA257-264- specific CD8+ T cells administered into the EG7.OVA lymphoma bearing mice, supporting its potential for a combined regimen with adoptive T cell therapy (ACT). We also found that HSP70 subcutaneous co-administration into established lymphoma tumors enhanced 77A's therapeutic efficacy in the EG7.OVA model. Additionally, 77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib), radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. Its activity extended to solid tumors, including 4T1 breast cancer, and was further potentiated by tumor expression of immunogenic antigen hemagglutinin. or PD-1 immune checkpoint blockade.
 In the MM1.S xenograft model, 77A retained activity under NK cell depletion, likely due to myeloid polarization toward an M1 phenotype. The activity was more modest compared with that seen in more immune competent models, highlighting its long-term efficacy relied on T cell priming and effector function. Finally, 77A directly enhanced human immune function by boosting MART-1 specific CD8+ T cell expansion and enhancing NK cell cytotoxicity in healthy donor samples.
 Conclusion: 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridge innate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic and solid tumor models, and synergizes with multiple immunomodulatory and standard therapies, supporting its clinical translation as a novel immunotherapy platform.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a887ea64b847a742d0e834756a184372d82443b" target='_blank'>
              First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models
              </a>
            </td>
          <td>
            Jun Wei, Richard J. Jones, I. Kuiatse, Hua Wang, R. Orlowski
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>93</td>
        </tr>

        <tr id="


 Tumor-associated myeloid populations contribute significantly to immunosuppression and treatment resistance in glioblastoma (GBM). While the pro-tumorigenic influence of tumor-associated neutrophils (TANs)—including their role in promoting angiogenesis, immunosuppression, and immune checkpoint expression—is well documented, their potential anti-tumoral functions remain insufficiently investigated.



 This study employed CT2A syngeneic murine models of GBM to investigate the immunological and oncological consequences of systemic neutrophil depletion. Anti-Ly6G antibodies were administered intraperitoneally to selectively eliminate circulating neutrophils. Tumor progression was monitored through in vivo bioluminescence imaging (IVIS), while immune profiling was conducted using flow cytometry on samples from the brain, blood, and spleen.



 Over a 21-day period, IVIS imaging revealed signficantly elevated radiance in neutrophil-depleted mice relative to controls, indicating enhanced tumor burden (mean radiance fold-change: 2.7; p = 0.042). Kaplan-Meier analysis showed that neutrophil-depleted animals had significantly shortened survival (median: 19 vs. 24 days; log-rank p = 0.0058). Importantly, this reduction in survival was not observed in neutrophil-depleted mice lacking tumors, suggesting that the neutrophil effect is context-dependent within the GBM tumor microenvironment (TME). Flow cytometric analysis confirmed effective peripheral neutrophil depletion, with CD45⁺Ly6G⁺CD11b⁺ cells reduced from 3.1% to 0.03% (p < 0.001). Additionally, a trend toward reduced brain-infiltrating CD8⁺ T cells was observed in the absence of neutrophils (p = 0.0553).



 Our findings present one of the first reported pre-clinical evidence that TANs may exert protective, anti-tumoral effects within the GBM TME. Neutrophil depletion not only accelerated tumor progression and impaired survival but also disrupted immune equilibrium in the brain. These data support a paradigm shift in which TANs may be leveraged or reprogrammed as therapeutic agents in future GBM immunotherapies. Continued investigation is warranted to delineate the molecular basis of TAN plasticity and their potential role in reshaping anti-GBM immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/225247f6ba2e8abda8f3fd79dd3a30a5922e4a2d" target='_blank'>
              TMIC-43. Tumor-Associated Neutrophils: A Double-Edged Sword in Glioblastoma Progression
              </a>
            </td>
          <td>
            Matthew A Abikenari, John Choi, Ravi Medikonda, Lily H Kim, Rohit Verma, Andrew Tran, Shreyas Annagiri, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Introduction: Emerging evidence suggests that the immunosuppressive tumor microenvironment is a major limiting factor impairing CAR-T cell function. Recent studies have identified immunosuppressive erythroid precursor cells (EPCs) – a novel cell population that accumulates in pathological contexts (including neonates, cancer-bearing hosts, and infected individuals) – which potently suppress immune responses and diminish upon maturation. In this study, we aim to investigate the impact of these immunomodulatory EPCs on CAR-T cell function and explore potential strategies to overcome their suppressive effects, thereby enhancing CAR-T cell efficacy.
 Methods: We established KA539 lymphoma models in irradiated C57BL/6 mice and collected clinical peripheral blood samples from hematologic malignancy patients to quantify EPCs accumulation in extramedullary tissues. Functional profiling was performed via RNA-seq on FACS-sorted CD45⁺ versus CD45⁻ EPCs, validated by scRNA-seq. To assess EPCs-mediated CAR-T cell suppression, CD19 CAR-T cells were co-cultured with EPCs followed by multiparameter analysis including proliferation, cytokine secretion, exhaustion, and tumor-killing capacity of CAR-T cells. Mechanistically, we performed RNA-seq and Cut&Tag with erythroid precursors upon BRD4 inhibition, and genetic validation in erythroid-specific BRD4 cKO mice to demonstrate that BRD4 regulates the immunity of CD45+ EPCs.
 Results: We confirmed that both tumor-bearing mice and patients with hematologic malignancies showed significantly increased EPCs proportions in extramedullary tissues, including peripheral blood, spleen, and liver. RNA-seq analysis revealed that CD45+ EPCs exhibited elevated expression of immunosuppressive genes, including VISTA, PD-L1, LGALS3. Notably, tumor-bearing mice exhibited increased EPCs levels following CAR-T treatment, particularly in the poor-response group, suggesting a potential link between EPCs expansion and therapeutic resistance. Coculture with CD45+ EPCs significantly impaired CAR-T cell function, reducing both TNF-α secretion and proliferative capacity. Consistent with our previous findings on BRD4's role in blocking erythroid maturation, we observed that BRD4 similarly impeded EPCs' maturation in tumor-bearing mice and patient-derived samples. Furthermore, BRD4 inhibition downregulated immune-related genes and pathways in EPCs. Integrated analysis of Cut&Tag and RNA-seq data revealed that BRD4 directly transcriptionally activated immune regulatory genes in EPCs, including PD-L1 and VISTA. Besides, experiments with BRD4conditional knockout mice further confirmed that BRD4 inhibition promoted maturation of CD45+ EPCs and repressed expression of novel immune checkpoint VISTA. Importantly, flow cytometry analysis demonstrated that BRD4 inhibition significantly alleviated EPCs-induced CAR-T cell exhaustion, as evidenced by reduced expression of the exhaustion markers PD-1 and LAG-3, supporting BRD4 inhibition as a viable strategy to potentiate CAR-T cell function by modulating EPCs' immunosuppressive activity.
 Conclusion: Our study establishes that immunosuppressive EPCs directly impair CAR-T cell function. We demonstrate that BRD4 transcriptionally activates VISTA expression in EPCs, and targeting BRD4 reverses EPC-mediated CAR-T suppression. These findings unveil a novel mechanism of the immunosuppressive microenvironment in CAR-T therapy and provide a potential approach to enhance clinical efficacy against hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c440cfd119e2a331ecd6f4081b0a4605fb549576" target='_blank'>
              BRD4 sustains immunosuppressive erythroid precursors to compromise CAR-T cell function
              </a>
            </td>
          <td>
            Meng Zhang, Mengmeng Huang, Yijin Chen, Haiqiong Zheng, Yanjuan Liu, Dawei Huo, Yong-xian Hu, Pengxu Qian, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="The roles of eosinophil extracellular traps (EETs) in cancer have not been investigated. This research aims to unearth the association between EETs and clinical outcomes in pan-cancer. From the Cancer Genome Atlas (TCGA) program, a 28-gene EETs score was constructed. Overall, higher EETs scores indicated shorter overall survival. EETs were significantly correlated to various pro-tumor processes, including extracellular matrix remodeling, IL-17 signaling, M2 macrophage polarization, and Treg differentiation. Immune suppressive M2 macrophages infiltrated more in the tumor microenvironment (TME), while cytotoxic cells (CD8 T and NK cells) were fewer. EETs-gene expression correlated with multiple T cell co-inhibitors. Target molecules of immune checkpoint inhibitors (ICIs) were not in proximity to the EETs disease module. Drugs against IL-5, IL-5RA, CCL-11 and IL-33 scored highly in perturbation of the disease module. Therefore, the EETs formation was coordinated with the adverse clinical outcomes and TME alternations in cancer. The role of EETs and anti-eosinophil therapy in cancer deserve further investigation in the era of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b598a846eb03bb4801110e2bd62531abd6b5070" target='_blank'>
              Eosinophil extracellular traps formation is correlated with cancer prognosis by tumor microenvironment remodeling
              </a>
            </td>
          <td>
            Jingdai Zhang, Yu Qiu, Yifan Liu, Shengwei Mo, Muwen Nie, Hui Zhang, Xiaohang Liu, Wei Chen
          </td>
          <td>2025-11-17</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 CD19-targeted Chimeric Antigen Receptor (CAR) T cell therapy is a leading treatment for B-cell malignancies, achieving complete remission rates of ~50% in pediatric non-Hodgkin's lymphoma. However, relapse remains a major barrier, driven by immune evasion, T-cell exhaustion and/or dysfunction, and limited persistence. These challenges highlight the need for innovative CAR vector designs to improve durability and efficacy.
 One strategy is to enhance recruitment of the T cell kinase LCK to the immune synapse, thereby strengthening proximal signaling (Feucht et al., 2019; Hartl et al., 2020; James, 2018). This compensates for the absence of co-receptor–MHC interactions in native T cell receptor (TCR) signaling, which position LCK near the immunoreceptor tyrosine-based activation motifs (ITAMs) of CD3ζ. Optimizing LCK-mediated ITAM phosphorylation may yield next-generation CARs with cytotoxic potency approaching that of the native TCR.
 We engineered an optimized CAR incorporating a 37-amino-acid segment (TIP) of the Herpesvirus saimiri tyrosine-protein kinase–interacting protein that binds LCK with high specificity and modulates its activity. Incorporation of the TIP co-stimulation motif into the CAR-BB-CD3ζ domain produced several notable effects:
 The TIP motif altered early CAR T cell activation, with antigen-independent recruitment of LCK and other proximal signaling mediators to the CAR–CD3ζ complex, indicating ligand-independent priming of signaling. Despite elevated basal phosphorylation, cytokine secretion was absent and downstream transcription remained inactive, thereby preserving antigen specificity while accelerating early activation kinetics.
 Ex vivo expansion revealed a consistent enrichment of CD8⁺ T cells in TIP-CAR cultures (72% vs 35% in BBζ-CAR, p<0.0001), accompanied by higher Ki67 (46% vs 28%, p<0.05) and CD38 (85% vs 64%, p<0.01) expression in CD8+ subset across eight donors. Phenotyping also showed a skew toward a CCR7⁻CD45RA⁺ effector phenotype within the CD8⁺ compartment (59% vs 41%, p<0.01), suggesting distinct TIP-driven memory imprinting patterns across T cell lineages.
 Integrated transcriptomic profiling and flow cytometric phenotyping demonstrated that TIP co-stimulation reprograms T cell transcriptional landscape relative to BBζ-CARs, with upregulation of key TCR signaling genes (TCR variants, ZAP70, LAT) and the transcription factor TCF7, while showing no changes in exhaustion-associated transcripts, including PD1, LAG3 and TIGIT. These findings suggest that TIP co-stimulation reinforces T cell activation programs while restraining terminal differentiation and exhaustion.
 The functional performance of TIP-CAR T cells, evaluated through standard in vitro assays, demonstrated that TIP-CAR T cells showed a statistical increase in target-cell killing (p<0.0001) with robust proliferation comparable to that of BBζ-CAR T cells. To assess in vivo efficacy, we conducted a xenograft study using NSG mice engrafted with luciferase-Raji lymphoma cells. Mice (n = 6–7/group) received TIP-CAR T cells, BBζ-CAR T cells, or no treatment, using cells manufactured from two healthy donors. Bioluminescent imaging revealed a statistically significant reduction of tumor burden in TIP-CAR–treated mice compared to BBζ-CAR (p < 0.05), with rapid and sustained tumor clearance. Survival analysis showed significantly prolonged overall survival in the TIP-CAR-treated group (log-rank p < 0.001); mice treated with BBζ-CAR T cells succumbed to progressive disease, while TIP-CAR treated mice survived long-term. Notably, upon rechallenge with Raji cells several weeks after initial clearance, TIP-CAR-treated mice resisted tumor re-engraftment, indicating durable antitumor immunity and memory formation. Flow cytometric analysis of peripheral blood and bone marrow of rechallenged mice confirmed enhanced persistence and expansion of TIP-CAR T cells, enriched for CD8⁺effector-memory phenotypes.
 These findings demonstrate that the TIP co-stimulation motif enhances in vivo CAR T cell function by improving synapse formation, sustaining cytotoxic competence, and enabling long-term immune surveillance. Altogether, this study introduces a modular, virus-derived co-stimulatory motif that rewires early CAR signaling and programs durable, high-functioning T cell responses. TIP co-stimulation motif offers a broadly translatable strategy to enhance CAR T cell efficacy, persistence, and memory in hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/66fd44f99beda94bebf5c7b3f684bfc12d2c3e14" target='_blank'>
              Signaling role of viral protein motif and its application in CAR T cell therapy
              </a>
            </td>
          <td>
            Wooram Jung, Kunho Chung, Jude Franklin, David N. Wald, J. Melenhorst, Jae U. Jung
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bcfd3df2c5d1e60c0a8518093894d3b787fd6a7" target='_blank'>
              Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.
              </a>
            </td>
          <td>
            Limin Jia, Zhaoyang Wang, Jinfa Du, Zhigang Ren, Jiandong Jiang, Pan Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers of medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glucocorticoid (GC)-resistant, acute graft-versus-host-disease (GVHD) is a major cause of mortality following allogeneic hematopoietic stem cell transplantation. Second line treatment with Ruxolitinib (RUX) can be effective, but only a minority of patients attain durable complete remissions. Biopsies from the gut in patients with refractory GVHD are frequently characterised by large clonal expansions of CD8+ T cells. Experimental models of GVHD have suggested that these T cell effector expansions may be sustained by progenitor-type T cells expressing the transcription factor TCF1, which possess greater inherent proliferative and self-renewal potential than effector cells. We hypothesised that a similar progenitor-type population can be found in humans and is resistant to GC treatment.
 Using clinically relevant concentrations of methylprednisolone and several independent methods for human T cell stimulation, we determined output population architecture and function with a combination of multiparameter flow cytometry, bulk and single cell transcriptional profiling. Under conditions of repetitive anti-CD3/CD28 stimulation over a three-week period, GC-treated CD8+ T cells showed greater proliferation and overall expansion than control cells. GC-treated CD8+ T cells showed greater retention of cell markers (e.g., IL-7RA, CD27) and transcriptional profiles (e.g., KLF2, LTB, BCL2) associated with a 'less-differentiated’ state. In vitro assays indicated intact cytokine-generating function and killing capacity of the GC-resistant CD8+ T cells versus controls. These GC-driven changes to T cell proliferation and phenotype were largely restricted to CD8+T cells and occurred independently of the presence of CD4+ T cells.
 To track the population architecture of GC-treated CD8+ T cells compared to controls, we performed scRNAseq of 3-week expanded cultures. The GC-treated CD8+ T cell population showed a distinct differentiation trajectory composed primarily of two IL7RA-expressing clusters: a major effector memory-like cluster expressing cytotoxic genes (e.g., PRF1) as well as known GC-regulated genes (e.g., GILZ); and a smaller cluster composed of progenitor-like cells, expressing TCF7 (encoding TCF1) and LEF1. To test how this GC-induced shift in population architecture emerged during culture, we tracked cell proliferation and cellular state according to the individual input differentiation status of CD8+ T cells (TN, TCM, and TEM(RA)) prior to activation; these experiments showed that GC-induced changes in proliferation and cell state were primarily derived from the expanding TN-origin cells. To test the clinical relevance of these findings in vivo, we interrogated patient scRNAseq data derived from n=19 biopsies of acute lower gut GVHD, treated with (n=14) or without GC (n=5) at the time of biopsy. We identified strong enrichment for our TCF-1+ progenitor-like cluster in patients with severe GVHD treated with GC (median 35.1% versus 9.5% of CD8+ T cells, p<0.05).
 To address how JAK1/2 inhibition would influence the GC-resistant phenotype, we applied RUX at clinically relevant concentrations and showed that its addition blocked proliferation in GC-treated cultures to a greater extent than control cells. However, RUX simultaneously further enriched for the TCF-1hi IL-7Rahi progenitor-like population which additionally displayed elevated expression of the anti-apoptotic molecule, BCL-2. We reasoned that BCL-2 inhibition would have the potential to separately target the progenitor population. To test this hypothesis, we treated control and GC-treated T cell cultures with clinically relevant concentrations of Venetoclax (VEN), alone or in combination with RUX. VEN treatment alone did not block proliferation but led to reduced frequencies of progenitor-like cells arising in the presence of GC. When combined, VEN and RUX led to both reduced proliferation and reduced progenitor frequency in parallel to increased activated Caspase-3 expression by CD8+ T cells, particularly in the presence of GC.
 Taken together, these data show that treatments used for GVHD including GC and RUX may select for progenitor-like CD8+ T cells with the potential to sustain tissue injury and lead to refractory disease. Strategies combining drug targets which can inhibit T cell proliferation whilst preventing the retention of multipotent and proliferative progenitor populations may be required to overcome the limitations of current GVHD treatment strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5de99b6fdb68f489811020a31ec532757463d4e2" target='_blank'>
              T cell resistance to glucocorticoids in graft-versus-host disease
              </a>
            </td>
          <td>
            Andrew McIntyre, Lisanne Schoutens, Elisa Armbrecht, Andrew Gravett, Nicolas Sanschagrin, Callum Wright, Matthew Collin, R. Chakraverty
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Purpose Cancer immunotherapy aims to enhance the immune system’s ability to recognize and eliminate cancer cells, providing a sustained and effective immune response. However, the tumor microenvironment (TME), characterized by an abundance of tumor-associated M2 macrophages and the presence of exhausted or naïve T cells (non-effector T cells), remains a major barrier to effective immunotherapy. Herein, inflammatory M1 macrophage-derived extracellular vesicles (M1EV) were surface-modified to display interleukin-2 (M1EV_IL2), aiming to develop a multifunctional cancer immunotherapeutic agent capable of modulating both innate and adaptive immune responses. Methods We engineered M1EV to label the surface with azide groups through metabolic glycoengineering and developed M1EV_IL2 that displayed IL-2 via bioorthogonal chemistry. M1EV_IL2 were purified by size-exclusion chromatography (SEC) and characterized through comprehensive analyses, including nanoparticle tracking analysis (NTA). In vitro macrophage repolarization and T cell activation were evaluated at the gene-expression level, followed by ex vivo assays assessing T-cell proliferation, cytokine secretion, and activation marker expression. Results M1EV_IL2 effectively retained the intrinsic physicochemical properties of EVs while displaying IL-2 stably on its surface. It upregulated M1 macrophage markers, IL-1β and CXCL10, while downregulating the M2 macrophage marker CD206, thereby inducing M2-to-M1 macrophage repolarization. In addition, M1EV_IL2 also activated CD4+ T cells and induced the activation of naïve CD8+ T cells to effector T cells, leading to enhanced cell proliferation and secretion of antitumor cytokines. Conclusion These results indicate that M1EV_IL2 has the potential to reshape the tumor immune landscape by simultaneously activating macrophages and T cells, thereby enhancing both innate and adaptive immune responses. Unlike conventional cancer therapies, which directly target tumor cells, M1EV_IL2 is expected to enhance immune responses, potentially mitigating adverse effects while improving therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b118249d7b0665de4875eb1da2d46b5bd10b41f" target='_blank'>
              Interleukin-2 Surface Displayed M1 Macrophage-Derived Extracellular Vesicles for Modulating the Tumor Microenvironment
              </a>
            </td>
          <td>
            Kyeong Tae Kim, Jeong Hyun Lee, S. Kang, W. Rhee
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Immune thrombocytopenia (ITP) is an autoimmune disease where premature destruction of platelets as well as inhibition of platelet production leads to thrombocytopenia and associated bleeding. It has long been considered a disease primarily caused by B cells, but the role of T lymphocytes in its pathogenesis is now better understood and deserves elucidation. Two types of T cells will be discussed: (1) splenic T follicular helper cells (TFH) that participate in differentiation of B cells within germinal centres (GC) and stimulate the production of antiplatelet antibodies, thus supporting the humoral autoimmune response; and (2) antibody‐independent mechanisms of action of cytotoxic T lymphocytes (CTL) that may directly participate in platelet destruction as well as inhibit their production by targeting megakaryocytes. To date, most novel therapies target antibody‐mediated disease, but targeting either TFH or CTL may provide new therapeutic opportunities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d17d8c8f8416f78e330a2a60fac51b7eba070e10" target='_blank'>
              T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells
              </a>
            </td>
          <td>
            S. Audia, Nichola Cooper
          </td>
          <td>2025-11-04</td>
          <td>British Journal of Haematology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid proliferation, diffuse infiltration, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis remains dismal, with median survival rarely exceeding 15 months. The immunosuppressive and heterogeneous tumor microenvironment (TME), along with profound tumor-intrinsic resistance mechanisms, contributes significantly to treatment failure. Cardiotonic steroids (CTS), such as ouabain, have recently gained attention for their pleiotropic effects beyond Na+/K+-ATPase inhibition, including modulation of intracellular signaling, induction of cell death, and immune regulation. In GBM, ouabain has been shown to reduce tumor cell viability, impair migration, disrupt angiogenesis, and alter different signaling pathways. Although direct evidence of ouabain’s effects on the GBM immune microenvironment is limited, findings from other models suggest that it can modulate both innate and adaptive immune responses, affecting T cells, regulatory T cells, dendritic cells, monocytes, and NK cells. While previous reviews have explored the anticancer and pharmacological aspects of cardiotonic steroids, the immunological dimension of ouabain’s activity remains underrepresented. This review integrates current evidence on ouabain’s dual actions in tumor biology and immune regulation, emphasizing its emerging therapeutic potential and the need for deeper investigation within high-grade glioma models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c73049935628c7b64bd22cf222eb78736095626" target='_blank'>
              From hormonal immunomodulation to glioblastoma therapy: the emerging role of Ouabain
              </a>
            </td>
          <td>
            Arthur Gomes de Andrade, D. Carvalho, Daniel Wilson Arruda Magalhaes, A. C. de Queiroz, M. S. Alexandre-Moreira, Sandra Rodrigues-Mascarenas, L. H. A. Cavalcante-Silva
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="


 Background: Signal-induced proliferation-associated gene 1 (Sipa1), a RAP1 GTPase-activating protein, is expressed in both hematopoietic cells and stromal cells. It negatively regulates G-protein signaling pathways involving in cell adhesion and proliferation. We have demonstrated that Sipa1loss induces bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs, CD45-TER119-CD31-CD44-CD51+SCA1+ and SCA1- subsets) alterations that drive the development of myeloproliferative neoplasm. Meanwhile, we have observed reduced Sipa1 expression in the BM MSPCs in mice with acute myeloid leukemia (AML) (Blood Adv. 2018, 2(5):534-548). However, the impact of the Sipa1 reduction on AML progression remains unclear.
 Methods: We have here explored the impact of Sipa1 expression in the host BM mesenchymal and immune cell niche by, 1) analyzing AML progression in Sipa1-/- and Sipa1+/+ recipient mice transplanted with MLL-AF9 AML cells with or without prior irradiation; 2) in vivo depletion of specific lymphoid subsets using neutralizing antibodies to determine their contributions; 3) immune and mesenchymal niche characterization using RNA sequencing and flow cytometry; 4) determining clinical correlation between Sipa1 expression in hematopoietic cells and treatment outcomes in patients with AML.
 Results: Remarkably, Sipa1 deficiency in host microenvironment led to delayed or no AML development, reflected in that 30% of the Sipa1-/- recipient mice did not develop AML while all Sipa1+/+ mice did after AML cell injection without prior irradiation. Notably, such a difference in AML development was not observed in lethally irradiated Sipa1-/- and Sipa1+/+ recipient mice where their immune cells were eliminated, indicating the critical involvement of Sipa1-/- immune cells in the AML inhibition. Further, in vivo depletion of NK cells by antibody neutralization could completely reverse the difference in AML development kinetics in the Sipa1-/- mice, suggesting that Sipa1 deficiency may boost NK cells anti-AML immune response. The enhanced anti-AML activity of Sipa1-/- NK cells was consistent with the increased maturation and activation of Sipa1-/- NK cells derived from spleen and blood. Furthermore, RNA sequencing suggested significant enrichment of the inflammatory genes associated with NK cell cytoxicity in Sipa1-/- BM MSCs (CD45-TER119-CD31-CD44-CD51+SCA1+) relative to that in Sipa1+/+ mice, providing another potential mechanism contributing to the increased anti-AML activity of Sipa1-/- NK cells, driven by the inflamed Sipa1-/- BM MSCs. Most importantly and notably, in line with these findings in mice, low SIPA1 expression in bone marrow mononuclear cells is associated with better survival and therapy responses to BET and mTOR inhibitors in AML patients (TCGA LAML dataset, and unpublished data from Prof. Caroline Heckman's lab in Helsinki University).
 Conclusions: Altogether, our study suggests that Sipa1 loss boosts anti-AML response of NK cells, possibly triggered by enhanced inflammatory host microenvironment. These findings along with the clinical correlation between low SIPA1 expression and better survival in AML patients point to the translational potential of these discoveries, meriting further investigation of therapeutic potential of Sipa1 deficient NK cells for AML and the underlying mechanisms.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f8871824fe2ad8aaef916abb388f27c2c0036c5" target='_blank'>
              Sipa1 loss in host niche boosts anti-AML immune response
              </a>
            </td>
          <td>
            Runqing Zhang, L. Sandhow, H. Cai, Hong Qian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Trained immunity (TI) represented a unique state of innate immune activation, characterized primarily by persistent epigenetic modifications in immune cells. This phenomenon was first observed during pathogen infections and vaccinations, where it manifested as enhanced defensive responses in innate immune effector cells—such as those of the mononuclear phagocyte system and natural killer cells—upon re-stimulation. Cancer was a disease with complex mechanisms, marked by the loss of normal growth regulation in cells due to genetic mutations or epigenetic dysregulation, leading to abnormal proliferation and dissemination. With hundreds of subtypes, cancer could arise in virtually any human tissue or organ. The primary cause of cancer-related mortality was metastasis, which referred to the spread of cancer cells from their original site to distant organs and accounted for approximately 90% of cancer deaths worldwide. The induction of TI involved multiple immune components including myeloid cells, natural killer cells, pattern recognition receptors, and various cytokines. Notably, the enhanced response observed during secondary stimulation remained non-specific to particular pathogens. Compared to conventional therapeutic approaches, TI demonstrated superior systemic immune activation. Simple pharmacological stimuli such as β-glucan or Bacillus Calmette-Guérin (BCG) not only triggered innate immune responses but also conferred benefits to adaptive immunity, resulting in more rapid immune activation and enhanced efficacy. TI enhanced the capacity of immune cells to recognize and eliminate cancer cells, playing a critical role in countering metastasis. In this review, we summarized existing knowledge in the field, focusing on the mechanisms underlying TI induction and its significance in combating cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be50ad019666a2caa18340fc39a316d430799286" target='_blank'>
              The significance of trained immunity in cancer
              </a>
            </td>
          <td>
            Junxing Qu, Xinya Guo, Xinru Wang, Huiwen Meng, Peizhi Li, Zhiheng Sun
          </td>
          <td>2025-12-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Immunotherapy combinations can improve patient outcomes, yet the interactions within the tumor microenvironment (TME) that drive therapeutic synergy are poorly understood. Tumor establishment drives monocyte recruitment and differentiation into tumor-associated macrophages (TAMs), which have essential roles in coordinating immune responses and are thus attractive targets for therapeutic modulation. In a murine model of combination anti-PD-1 and anti-PD-L1 checkpoint blockade, tumor control was associated with increased infiltration of CD8+ T cells and M1-like repolarization of TAMs. Live-cell imaging of the tumor microenvironment revealed stable contacts between tumor-infiltrating CD8+ T cells and TAMs, in which the extent of the contact interfaces increased with combination immunotherapy. Treatment with anti-PD-L1 was able to increase macrophage expression of pro-inflammatory factors and phagocytic activity, suggesting a role for TAMs to reactivate CD8+ T cells in the TME. However, co-treatment with anti-PD-1 was ultimately necessary for tumor control, indicating the need for combination targeting of the TME.



 Mayo Clinic David and Margaret Grohne Cancer Immunotherapy Pilot Award



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b4b5c68bd11e510478b663ba12c5b0fe316f16" target='_blank'>
              Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 2076
              </a>
            </td>
          <td>
            Tina Kwok, Jessica N Lancaster, Haidong Dong, Ildefonso Silva
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy, despite revolutionizing hematological malignancies, remains limited in solid tumors due to immunosuppressive microenvironments and systemic toxicities from combination immunotherapies. Recent engineering innovations demonstrate that physically linking anti-PD-L1 antibodies to interleukin-12 within CAR-T cells creates tumor-localized immunomodulation, concentrating therapeutic activity at PD-L1-positive sites while minimizing systemic exposure. In preclinical models, PD-L1-binding IL-12 fusion proteins achieved superior antitumor responses (100 vs. 50% complete responses) compared to non-binding controls, with significantly reduced inflammatory toxicity. Spatial proteomic analysis revealed comprehensive tumor microenvironment remodeling including enhanced CD8+ T cell infiltration and reduced immunosuppressive myeloid populations. Validation in human CAR-T cells targeting TAG72-positive ovarian cancer confirmed appropriate PD-L1 binding and enhanced cytotoxicity. This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7a6546fc7d661b815d3d60a952bbd89932e2713" target='_blank'>
              Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies
              </a>
            </td>
          <td>
            Maryam Abid, Ursula Abu Nahla, Muhammad Nabeel Saddique
          </td>
          <td>2025-11-04</td>
          <td>Annals of Medicine and Surgery</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Introduction Immunotherapy has shown clinical promise in multiple myeloma (MM), but relapse remains common, largely due to the immunosuppressive bone marrow (BM) microenvironment, characterized by T cell exhaustion and the accumulation of myeloid-derived suppressor cells (MDSCs). Recent advances highlight the therapeutic promise of 4-1BB (CD137) agonist antibodies in enhancing T cell–mediated anti-tumor responses, though their efficacy in MM remains poorly defined. Investigating 4-1BB expression dynamics in a preclinical MM model informed our rationale for targeting this pathway. Tasquinimod (TasQ), a small-molecule immunomodulatory agent, currently evaluated in a phase Ib/IIa clinical trial in MM patients (NCT04405167), offers a complementary strategy. By inhibiting the S100A9 signaling pathway, TasQ interferes with the recruitment and function of MDSCs, resulting in a less suppressive tumor microenvironment (TME) which reestablishes the anti -tumor immunity. In this study, we assessed the therapeutic potential of two distinct 4-1BB agonist antibody clones in an immunocompetent preclinical MM model. Building on these findings, we further explored the combination of the most effective 4-1BB agonist with TasQ, aiming to overcome the immunosuppressive tumor microenvironment, and strengthen anti-myeloma immune activity.
 Methods 4-1BB expression was analyzed during disease progression in 5T33MM mice using single-cell RNA sequencing of spleen and BM, 2 myeloma-infiltrating organs. These findings were validated by flow cytometry in both 5T33MM and 5TGM1 models. Therapeutic potential was assessed by treating 5TGM1 tumor-bearing mice with two 4-1BB agonist clones—LOB12.3 (IgG1κ; n=7/group) and 3H3 (IgG2a; n=5/group), using clone-specific isotype controls. Beginning on day 3 post-tumor inoculation, mice received 100µg of antibody intraperitoneally twice weekly until end stage. In a follow-up experiment, the lead 4-1BB agonist was combined with TasQ, administered at 30mg/kg in drinking water, to evaluate the impact of dual targeting the immunosuppressive TME (n=11/group). Tumor burden was assessed by determining the percentage of plasmacytosis in BM and spleen through cytospin stainings, together with M-protein measurement by serum electrophoresis. Immunomodulating effects were investigated using multi-parameter flow cytometry. Statistical significance was determined using the Mann–Whitney U test or one-way ANOVA, with p<0.05 considered significant.
 Results 4-1BB was predominantly detected on T cells and natural killer (NK) cells, with its expression further increasing as the disease progressed. Treatment of 5TGM1 mice with 4-1BB agonists significantly increased the percentage of CD4+ and CD8+ T cells in the BM and spleen. Interestingly, treatment with clone LOB12.3 resulted in a significant reduction in NK cell percentages in both the BM and spleen, while clone 3H3 selectively reduced splenic NK cells. Therapeutically, clone 3H3 significantly decreased M-protein levels and BM plasmacytosis (p<0.01), while no significant effects were observed for clone LOB12.3.
 Treatment with the IgG2a-formatted 4-1BB agonist combined with TasQ led to a significant reduction in M-protein levels and BM plasmacytosis (p<0001). Plasmacytosis was 62.50% in the isotype control group, decreased to 36.18% with 4-1BB agonist, 37.64% with TasQ, and further reduced to 14.09% in the combination therapy group, highlighting the enhanced efficacy of dual treatment. These effects were mediated by increased granzyme B–mediated T and NK-cell activation and enhanced differentiation of effector T cells (CD44⁺CD62L⁻). While this therapy did not alter the frequency of dendritic cells (DCs) in the BM, it enhanced their maturation, as evidenced by increased CD86 expression—particularly on type 1 and type 2 conventional DC subsets.
 Conclusion In conclusion, our findings demonstrate that 4-1BB activation can enhance anti-tumor immunity in MM; however, the therapeutic efficacy is dependent on the specific agonist used. Notably, the IgG2a-formatted 4-1BB agonist showed superior activity, underscoring the importance of isotype selection in achieving optimal immunotherapeutic outcomes. Moreover, co-administration with TasQ enhanced therapeutic efficacy, supporting the potential benefit of a combinatorial approach. Further investigation is warranted to elucidate the mechanisms driving these responses and to refine 4-1BB-targeted strategies for effective clinical translation.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/588054f9d7bef7f7dc4607713845e8f0a14c731a" target='_blank'>
              IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
              </a>
            </td>
          <td>
            Hatice Satilmis, Adrien Denis, Emma Verheye, E. De Bruyne, E. Menu, M. Törngren, H. Eriksson, K. Vanderkerken, K. De Veirman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="


 Long-lived plasma cells (LLPCs) sustain lifelong antibody secretion, forming the foundation of durable immune memory. However, the molecular mechanisms underpinning LLPC survival within the bone marrow (BM) remain incompletely understood. Using single-nucleus RNA-seq and ATAC-seq (10X Multiome) from matched blood and BM antibody-secreting cells (ASCs) of healthy adults, we profiled 8,059 nuclei, generating an integrated transcriptional and epigenetic map of ASCs across their developmental continuum with unparalleled resolution. In the BM LLPC cluster, Gene Set Enrichment Analysis (GSEA) validated the enrichment of the TNF/NF-κB signaling pathway and TLR cascades, emphasizing their anti-apoptotic roles. These clusters also demonstrate increased chromatin accessibility at key loci such as RELA, TLR1, TLR6, TLR10, NFKBIA, and TAB1, underscoring the central roles of TLR and TNF-α signaling pathways in activating the NF-κB pathway. Upregulated genes such as BCL2, NFKBIZ, TNFAIP3, and BIRC3 highlighted key survival mechanisms, while motif enrichment analysis revealed significant enrichment for REL and NF-κB binding motifs, supporting chromatin-level regulation of LLPC longevity. Together, these findings advance our understanding of LLPC survival and resilience and provide a framework for improving vaccine strategies and targeted immunotherapies.



 Computational and Systems Immunology (COMP)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86cf15dec942c9c651d1f78f13be792e4e03baf" target='_blank'>
              Dissecting the transcriptional and epigenetic landscape of human antibody-secreting cells in blood and bone marrow long-lived plasma cells 4589
              </a>
            </td>
          <td>
            Hira Anis, Monica Cabrera-Mora, Christopher Scharer, Ignacio Sanz, Greg Gibson, F. Eun‐Hyung Lee
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Systemic lupus erythematosus (SLE) is an autoimmune disease involving immune and non-immune cells, with complex pathogenesis and limited therapies. Dysregulated B cells, particularly double-negative 2 (DN2) B cells (CD19?, CD27?, IgD?, CD21?, CD11c?), are central to SLE by driving autoimmune processes. However, the origins and development of DN2 B cells remain poorly understood. B lymphopoiesis occurs in the bone marrow and is strongly regulated by mesenchymal stromal cells (MSCs). MSCs are non-hematopoietic immunosuppressive cells, which regulate immunity, including promoting regulatory B cells over plasma cells. In SLE, MSCs fail to suppress B cell activation into plasma blasts, but their immunomodulatory properties remain underexplored. We hypothesize that pathogenic DN2 B cells partly originate from a dysregulated bone marrow niche due to impaired stromal cell function. Single-cell transcriptomics and proteomics of healthy bone marrow identified resident DN B cells (∼30% of total B cells), with a small percentage being DN2. SLE plasma-primed MSCs while maintaining their phenotype, showed reduced PGE2 and TGF-β production and promoted naïve B cell differentiation into DN2 B cells, unlike healthy plasma-primed MSCs. These findings suggest that SLE MSCs exhibit impaired immunomodulatory capacity, contributing to the expansion of pathogenic DN2 B cells. This study provides new insights into DN2 biology and MSC dysfunction, highlighting potential therapeutic targets for SLE.



 LRA and Boston Children’s Hospital Cell Discovery Network



 Hematopoiesis and Immune System Development (HEM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5523d5b604cb369018cf0d5d4d7bd4c741b26f91" target='_blank'>
              Functional genomics deciphers pathogenic B cell dynamics in lupus bone marrow 3662
              </a>
            </td>
          <td>
            Mariasilvia Colantuoni, Nada Abdel Aziz, Marcos Chiñas, Holly Wobma, P. Nigrovic, Lauren A. Henderson, Diana Gomez Martin, María Gutiérrez-Arcelus
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment (TME), largely orchestrated by anti-inflammatory glioma-associated macrophages/microglia (GAMs). Tumor hypoxia exacerbates this immunosuppression by activating the hypoxia-inducible factor (HIF) pathway in GAMs, promoting their polarization toward an anti-inflammatory phenotype that sustains a T cell–excluded, immune “cold” TME. This hypoxia-driven reprogramming severely impairs CD8⁺ T cell infiltration and effector function through metabolic suppression, contributing to resistance against chemotherapy and immune checkpoint blockade (ICB). We demonstrate that targeting tumor hypoxia with the hypoxia-activated prodrug evofosfamide (evo; TH-302; IMGS-101) markedly improves survival in both GL261 and CT2A murine GBM models (p<0.0001). Evo treatment significantly enhances CD8⁺ T cell infiltration (p<0.01) and restores effector function, as evidenced by increased granzyme B expression (p<0.001) and decreased expression of exhaustion markers TIM-3 and LAG-3 (p<0.001). CD8⁺ T cells isolated from evo-treated tumors display robust cytotoxicity against both antigen-specific (GL261-OVA) (p<0.001) and antigen-independent (CT2A) targets (p<0.0001), underpinned by enhanced metabolic fitness, including increased ATP production via both glycolysis and oxidative phosphorylation. Evo also reconfigures the myeloid compartment by disrupting microglial clustering within hypoxic niches, promoting a phenotypic shift toward pro-inflammatory GAMs (upregulation of CD80, MHC II; p<0.001) while suppressing M2-like markers (Arginase-1, PD-L1; p<0.01). These reprogrammed GAMs support greater CD8⁺ T cell proliferation (p<0.01) and survival (p<0.001) in co-culture systems. Notably, evo-mediated hypoxia alleviation sensitizes tumors to ICB and enables durable, curative responses when combined with intracranial anti–CTLA–4—, but not anti–PD-1—in ICB-refractory CT2A tumors. Together, these findings establish hypoxia as a central regulator of immune suppression in GBM and validate hypoxia-targeting strategies as powerful adjuncts to immunotherapy. Evofosfamide emerges as a potent immunomodulatory agent capable of reprogramming the GBM TME and unlocking new avenues for therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b941e6c02c788c35cba71fb7f448d1313c0744c7" target='_blank'>
              TMIC-84. Hypoxia reduction remodels the glioblastoma immune microenvironment to enhance therapeutic sensitivity
              </a>
            </td>
          <td>
            Ivana William, Broderick Turner, Guillaume J Trusz, Spencer T Lea, Michael A Curran
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Tumor necrosis factor receptor 2-positive regulatory T (TNFR2+ Treg) cells, the most suppressive subset of Treg cells, are enriched in malignant pleural effusion (MPE), contributing to disease progression. However, the underlying mechanisms responsible for their accumulation remain unclear. Here we demonstrate that the C–X–C motif chemokine ligand 16 (CXCL16)/C–X–C chemokine receptor type 6 (CXCR6) axis plays a critical role in recruiting TNFR2+ Treg cells to MPE, with cancer-associated fibroblasts serving as the primary source of CXCL16. Mechanistically, under the hypoxic conditions prevailing in the pleural cavity, cancer-associated fibroblasts in MPE undergo glycolysis, which in turn leads to an increase in the production of endogenous lactate. This elevated lactate induces histone H3 lysine 18 lactylation (H3K18la) at the promoter regions of both the CXCL16 gene and its transcription factor forkhead box O3 (FOXO3), which may contribute to CXCL16 transcription. TNFR2+ Treg cells that express high levels of CXCR6, the only receptor for CXCL16, are subsequently recruited into MPE. The infiltration of TNFR2+ Treg cells may reinforce the immunosuppressive milieu of MPE, facilitating disease progression. Collectively, these findings uncover a novel mechanism governing immunosuppression in MPE, providing new insights into potential therapeutic strategies to disrupt this process. Malignant pleural effusion (MPE) is a severe condition often seen in advanced lung cancer, characterized by the accumulation of fluid around the lungs due to the presence of cancer cells. Researchers explored why the immune system struggles to fight MPE. They focused on a type of immune cell known as TNFR2+ Treg cells, which suppress the body’s ability to attack cancer. The study involved analyzing samples from patients and mice to understand how these cells are drawn to MPE. The researchers found that cancer-associated fibroblasts in MPE produce a protein called CXCL16, which attracts TNFR2+ Treg cells. This process is driven by lactate, which regulates genes expression in a way that increases CXCL16 production. Blocking CXCL16 reduced the recruitment of these suppressive cells and slowed disease progression. The study suggests that targeting lactate production or CXCL16 could improve treatment outcomes for MPE. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/91a71b2ab5cf300257fc0c85581cf1150ec21a51" target='_blank'>
              H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2+ Treg recruitment
              </a>
            </td>
          <td>
            L. Ye, Xuan Xiang, Zi-Hao Wang, Siyu Zhang, Q. Xue, Xiao-Shan Wei, Yao Liu, Haolei Wang, Jiaqi Ai, Bohan Yang, Long Chen, Yiran Niu, W. Peng, Qiong Zhou
          </td>
          <td>2025-11-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="


 Persistent lung inflammation characterizes cystic fibrosis (CF), mainly driven by myeloid cells (neutrophils and monocytes) that can contribute to tissue damage and disease progression. Hematopoietic stem and progenitor cells (HSPCs) are activated during inflammation to enhance myelopoiesis. While this myeloid response is critical for healthy responses during acute infections, chronic inflammatory signals can cause maladaptive epigenetic reprogramming of HSPCs, skewing hematopoiesis towards a prolonged myeloid bias that can lead to hyperinflammatory states. Although this mechanism is implicated in other chronic diseases, its role in CF is not well understood. We hypothesize that CF-associated inflammation epigenetically and functionally reprograms HSPCs, promoting a pathological immune bias that sustains chronic inflammation.



 Wild-type (WT) and CF-KO mice (n=6–8/group) were nebulized with LPS for 5 weeks and euthanized at baseline (T0), 24 hours (T1), or 6 weeks (T2) after the last LPS exposure. HSPC frequencies in the bone marrow (BM) were evaluated. Single cell RNA-seq was performed on BM Lin-Sca+Kit+ cells and ATAC-sequencing (ATAC-seq) was performed on BM Lin-Sca+Kit+ Flt3-CD48- cells sorted from n = 4 mice per group. Serum cytokine concentrations were measured at T0. To assess long-term trained immunity, BM from CD45.2 WT or CF-KO mice (T0 or T2) was transplanted into lethally irradiated CD45.1 WT recipients. Donor-derived HSCs were isolated and profiled by ATAC-seq 3 months post-transplant.



 At baseline, long-term hematopoietic stem cells (LT-HSC) in CF mice were increased in frequency with enhanced myeloid differentiation. A statistically significant increase was observed in CF LT-HSCs, specifically in the CD41+ subpopulation, which is skewed toward myeloid differentiation. Additionally, CF BM had an increased frequency of multi-potent progenitors (MPPs) with erythroid/megakaryocytic potential (MPP2) and monocyte/neutrophil potential (MPP3), but not lymphoid potential (MPP4). Granulocyte-monocyte progenitors (GMPs) were also elevated in CF. Consistent with increased myelopoiesis, CF mouse peripheral blood had higher numbers of monocytes and neutrophils than WT. By scRNA-seq of LSK, we confirmed that LT-HSC and GMP frequencies are higher in CF. CF LT-HSCs exhibited a myeloid-biased signature, characterized by increased myeloid-specific differentially expressed genes (DEGs) (e.g., Jun, Fos, Klf2, Runx1) with DEGs enriched for TNF-α signaling via NF-κB (e.g., Cebpb, Egr1, Atf3, Plaur, Tnfaip8), which was confirmed by bulk RNA-seq. TNF-α (13.66 pg/ml ± 8.43 vs 5.34 pg/ml ±1.52) and other pro-inflammatory cytokines were elevated in the serum of CF vs WT mice. There were no ATACseq differences observed at T0. Chronic LPS in CF lungs led to non-resolving inflammation, increased number of myeloid cells with a pro-inflammatory profile, lung remodeling, and decreased lung function. In contrast, WT mice lungs return to homeostasis by T2. As seen at T0, T1 and T2 CF mice retained a higher frequency of CD41+LT-HSCs and higher frequencies of GMPs. At T2, colony forming assays revealed that GMPs from CF mice had an increased tendency to differentiate into granulocytes compared to WT GMPs (n=3/genotype). Bulk RNA-seq revealed that CF HSCs kept a distinct pro-inflammatory, myeloid-skewed epigenetic signature, predominantly enriched for TNF-α/NF-κB signaling whereas WT HSC were very similar to baseline. This was associated with enhanced lung inflammation in CF mice compared with WT. Post-transplantation, WT HSCs from T2 donors resembled those from T0, showing resolution of inflammatory programming. Conversely, CF HSCs from T2 donors retained their inflammatory epigenetic profile, indicating persistent changes in long-term HSCs.



 CF-associated inflammation causes lasting epigenetic reprogramming of HSCs, promoting maladaptive myeloid skewed hematopoiesis that likely contributes to persistent inflammation in CF. The TNF-α/NF-κB signaling pathway appears central in acquiring this maladaptive response in CF. Baseline differences in HSPC composition and cytokine profiles suggest pre-existing priming of HSCs in CF mice, which may enhance their response to chronic inflammatory stimuli like LPS.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/797eb6a4ad6f65ee2bc0b85e21f728ea2fa55826" target='_blank'>
              Chronic pulmonary LPS exposure in cystic fibrosis drives maladaptive pro-inflammatory hematopoietic stem and progenitor cells
              </a>
            </td>
          <td>
            Rubia Isler Mancuso, Evrett N. Thompson, C. Braga, H. Oez, Ravindra Gudneppanavar, Ping-Xia Zhang, Thayssa Santos da Silva Neves, Will Steven Wanamaker Krause, Pamela H Huang, Thomas Murray, Marie E Egan, Emanuela M. Bruscia, Diane S. Krause
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Despite responses in other malignancies, immune checkpoint inhibitor immunotherapy does not significantly improve outcomes for most glioblastoma (GBM) patients. Our group previously showed that anti-PD-1 therapy extended survival in CD8-knockout (CD8-KO) mice, implicating that another immune population may mediate the therapeutic effect. Now, depleting the CD4 T-cell in the CD8-KO mice significantly extended survival (medOS=66) in syngeneic gliomas compared to CD8-WT mice treated with IgG (med OS=39.5, p-val=0.0256) or anti-CD4 alone (medOS=35.5, p-val=0.0008). Immune-enriched single-cell RNA sequencing from the gliomas during the therapeutic window (P45) revealed a previously underappreciated CD3⁺CD4⁻CD8⁻ double-negative T-cell (DNTs) population expanded in the tumor of the CD4-depleted CD8-KO mice. These DNTs exhibited upregulation of pro-inflammatory cytokines (Tnf, Ccl12), activation markers (Cd40lg, Il7r, Cd69, Cd226), and reduced expression of exhaustion markers (Pdcd1, Ctla4, Tox), distinguishing them transcriptionally from conventional T-cells. The DNT population lacks markers consistent with NK-cells, NK T-cells, or gamma-delta T-cells. In vitro, DNTs secrete TNF-α at baseline and in response to glioma stem cells (GSCs). DNT–GSC co-culture suppresses GSC proliferation by 20-36%. The DNTs co-cultured with M0 macrophages increased macrophage phagocytosis by 44%, as assessed by fluorescent E. coli uptake assays. Glioma-associated myeloid cells from DNT-enriched mice showed upregulated gene ontologies related to inflammation, antigen presentation, and phagocytic activation, contrasting with the immune tolerance signatures in the CD8-WT background mice. Moreover, anti-PD-1 treatment in the CD4-depleted CD8-WT background and the CD8-KO only mice blunted the survival difference, suggesting that global T-cell elimination is a prerequisite for the emergence of antitumor DNT function. In summary, our findings identify a novel immunoregulatory and antitumor role for DNTs in glioma, characterized by TNFα-driven inflammatory signaling and myeloid activation. These data uncover a previously unrecognized immune axis that may be leveraged to overcome immunotherapy resistance in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928ff08c6367893a7a75add253009e2dfc2d8104" target='_blank'>
              IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma
              </a>
            </td>
          <td>
            Malcolm F. McDonald, Yuhui Yang, Ashley Puentes, H. Najem, Khatri Latha, Eric A. Goethe, Yeunjung Ko, A. Heimberger, A. Harmanci, Ganesh Rao
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non-AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8+ T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8+ T cell-dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1+PD-1+Tim-3- stem-like memory CD8+ T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8+ T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8+ T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8+ T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c80f585d4308a75bf3227e6815a7fdd66bafcb" target='_blank'>
              Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infection.
              </a>
            </td>
          <td>
            Guangming Li, Yaoxian Lou, Jianping Ma, Liang Cheng, Haisheng Yu, Ourania Tsahouridis, Xiu-yuan He, Masaya Funaki, James Ahodantin, Wenwen Bi, Jianwen Chen, Xiaoxuan Fan, Salma Sharaf, N. Goonetilleke, R. B. Jones, Shyamasundaran Kottilil, Poonam Mathur, Lishan Su
          </td>
          <td>2025-11-05</td>
          <td>Science translational medicine</td>
          <td>1</td>
          <td>40</td>
        </tr>

        <tr id="


 Tumors attract both tumor-specific T cells and bystander T cells that do not directly fight the tumor. Understanding T-cell heterogeneity is essential for improving the efficacy of immunotherapies. Here, we demonstrate that most neoantigen-specific CD8+ T cells in the tumor are double-positive for PD-1 and IFN-γ, while those in the lymph nodes exhibit heterogeneous expression of PD-1 and IFN-γ. Using single-cell RNA sequencing (scRNA-seq), we show that the tissue microenvironment profoundly influences the transcriptional profiles of tumor-reactive T cells. In tumors, PD-1 marks highly clonally expanded tumor-reactive T cells. In contrast, neoantigen-specific CD8+ T cells in the lymph nodes include a TCF7+ stem-like subset and a transitional subset progressing toward terminal exhaustion. This study provides critical insights into the dynamic differentiation of tumor-specific T cells and highlights potential therapeutic targets for enhancing anti-tumor immunity.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77f6ce3694f3139188b09f3df0bdea17ec36389d" target='_blank'>
              Single-cell insights into CD8 T cell differentiation and exhaustion in the tumor microenvironment 3220
              </a>
            </td>
          <td>
            Kiddist Yihunie, Ying Luo, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the microenvironment (TME) underlying these resistances remain unclear. In this study, we used a cohort of melanoma patients (n = 61) treated with ICB, pre-treatment (n = 33) and post-progression (n = 28), for whole-exome sequencing, single-nucleus RNA sequencing and high-resolution spatial imaging. We developed a framework to analyze response and resistance (intrinsic and acquired) via tumor-intrinsic programs, immune features, and tumor-stromal-immune interactions. Patients with low immune infiltration exhibited enrichment of macrophages associated with hypoxia and angiogenesis phenotypes. Samples with high immune infiltrates displayed an enrichment in lymphocytes, particularly TCF7+ CD8+ T cells. Pre-treatment samples from patients experiencing durable clinical benefit are encriched in memory B cells and plasmablast-like B cells.The presence of Bcells and of follicular dendritic cells in non-lymph node biopsies support the presence of tertiary lymphoid structures within the TME. Lastly, the presence of a TIMD4-expressing macrophage subset correlates with lymphocyte infiltration, indicating its potential role in promoting anti-tumor immunity. Our work defines TME immune profile interaction with tumor-stromal cells associated with clinical outcomes in melanoma.



 NCI HTAN



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2a8d3010e6c8bda33a8b18473b82b46e0a2ceaea" target='_blank'>
              Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
              </a>
            </td>
          <td>
            Giuseppe Tarantino, Yiwen He, Priyanka Solanky, Xinyu Cui, K. Pfaff, A.R. Thorner, Timothy R. Blosser, Elliot Boblitt, Allison Frangieh, Tyler J. Aprati, Boyang Zhang, Jiajia Chen, H. Faulkner, Aleigha R Lawless, M. Manos, K. Helvie, T. Sharova, Dennie T. Frederick, Sachi Krishna, Chanell Mangum, Domenic Abbondanza, Cai McCann, Bruce Johnson, Alex K. Shalek, Eliezer M. Van Allen, Xiaowei Zhuang, Ryan J. Sullivan, Barbara Engelhardt, Sami Farhi, S. Rodig, F. S. Hodi, Genevieve M. Boland, David R. Liu
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="
 Glioblastomas (GBM) are the most common and aggressive primary adult brain tumors, and advances in immunotherapy have failed to significantly improve patient outcomes. The presence of the blood brain barrier (BBB), abundance of immunosuppressive myeloid cells, and relative paucity of cytotoxic lymphocytes are major challenges preventing immunotherapy success in GBM. We previously identified the small calcium-binding protein S100A4 as a major regulator of GBM immune suppression. Targeting S100a4 via genetic depletion in tumor or stromal cells is sufficient to reprogram the tumor immune-landscape and extend survival of GBM-bearing mice. We recently developed an S100A4 blocking monoclonal antibody to target S100A4 signaling in the tumor microenvironment; however, this antibody has limited BBB penetrance. To overcome this challenge, we generated a bispecific S100A4-Transferrin-Receptor (TFR) antibody (BsA) that utilizes TFR-mediated transcytosis to cross the BBB. We assessed efficacy of BsA treatment in the preclinical syngeneic S100ß-vErbB;p53 (SVP) GBM mouse model. Using ELISA, confocal immunofluorescent microscopy, and bulk RNA-sequencing, we report that the BsA treatment accumulates in the CNS at nearly twenty-fold the concentration of the monoclonal antibody and reprograms the tumor immune microenvironment to promote immune cell infiltration and pro-inflammatory activation. BsA monotherapy modestly extends survival in the SVP model in an immune-cell dependent manner, as treatment in SVP-tumor bearing NSG mice abolishes this survival benefit. We further assessed if BsA treatment sensitizes immune cold GBMs to immune checkpoint blockade. Combination with αPD-1 checkpoint-blockade nearly doubled median overall survival in the SVP mouse model, with increased tumor infiltrating reactive CD4 and cytotoxic CD8 T cells. Single cell RNA-sequencing revealed an enhanced interferon-γ response signature in GBM cells and macrophages from combination therapy treated-tumors, with an accompanying upregulation of MHC-I and MHC-II associated genes, respectively. These results indicate that the BsA is a promising agent to reprogram the GBM immune-landscape and reactivate anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b268ed87c481994ebeaa18e8a1d19b3140eec028" target='_blank'>
              EXTH-122. A novel S100A4/TFR bispecific antibody to reprogram the GBM tumor microenvironment and reactivate anti-tumor immunity
              </a>
            </td>
          <td>
            Thomas Wong, Xue-Mo Fan, M. Faisal, Fransisca Leonard, Nourhan Abdelfattah, Jia-Shiun Leu, Yaqoob Ali, Reece Kang, Ningyan Zhang, Kyuson Yun
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Ovarian cancer (OC) remains one of the most aggressive gynecological malignancies, with a five-year survival rate below 45% despite the recent advances in the introduction of targeted therapy. Moreover, immunotherapy, such as immune checkpoint inhibitors, does not improve the survival of OC patients. Lack of sufficient knowledge in understanding the complexity of the tumor microenvironment likely confers the treatment ineffectiveness. Recently, tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) have garnered research attention as they shape the tumor immune microenvironment, which plays a crucial role in disease progression and treatment response. This article reviews the complex roles of these innate immune cells in OC progression. TAMs represent a significant component of the immune infiltrate in OC, exhibiting considerable functional plasticity and can shift between anti-tumoral (M1) and pro-tumoral (M2) phenotypes. M2-like TAMs typically predominate in the tumor microenvironment, which aids in the development of immune suppression and disease progression. They also contribute to chemoresistance and metastasis; hence, their presence in tumors is associated with a worse prognosis. TANs, like TAMs, exhibit N1/N2 polarization and influence tumor progression through the formation of neutrophil extracellular traps. Understanding the biological interactions between various immune cells and cancer cells may offer new therapeutic opportunities. This review sheds light on the dynamic ecological transformation of the OC tumor microenvironment and highlights the potential of targeting TAM/TAN-mediated processes to improve OC treatment outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5bf69e7ede5135f1b9bda1d7b6d4024e3efe5c94" target='_blank'>
              Macrophages and neutrophils in ovarian cancer microenvironment
              </a>
            </td>
          <td>
            Kuang-Chao Cheng, Yu-Hsin Lin, Dao-Sian Wu, I. Shih, Tian-Li Wang
          </td>
          <td>2025-11-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>107</td>
        </tr>

        <tr id="
 Myeloid-rich microenvironment is a hallmark of glioblastoma (GBM), the most aggressive and lethal brain malignancies in adults, leading to profound immunosuppression and therapy resistance. Metabolic dysregulation in tumor-associated myeloid cells (TAMCs) has been recognized as a key player driving immune evasion and supporting their pro-tumorigenic roles. Our single-cell RNA sequencing analysis and multiplex immunofluorescence have demonstrated high overexpression of monocarboxylate transporter 4 (MCT4), a key lactate transporter, in TAMCs in both murine and human GBMs, which may greatly contribute to TAMC-mediated GBM immunosuppression. To enable a myeloid-specific targeting of MCT4 in GBM, we have developed MCT4 nano-therapeutics using our antibody-directed immune targeting (ADIT) nano-platform. Lipid nanoparticles were surface functionalized with anti-PD-L1 antibody and encapsulated with small interfering RNA (siRNA) that targets MCT4. Our data indicated a robust and durable MCT4 inhibition, achieving over 90% gene knockdown efficiency. In vitro, MCT4 nano-therapeutics effectively targeted and reprogrammed immunosuppressive TAMCs, and restored CD8+ T cell proliferation and activation. In vivo, MCT4 nano-therapeutics through intracranial administration significantly improved the anti-glioma effectiveness of radiotherapy in CT-2A glioma-bearing C57 mice, leading to enhanced brain tumor infiltration of effector CD8+ T cells and CD103+ dendritic cells as well as much prolonged animal survival. When further combined with anti-CTLA-4 immune checkpoint therapy, over 60% of mice were cured from CT-2A glioma, and the long-term survivor animals developed anti-glioma immunological memory. Besides intracranial injections, we have also demonstrated the effectiveness of MCT4 nano-therapeutics through a systemic intranasal delivery route. These findings altogether may highlight a great potential of targeting lactate transport for modulating myeloid-mediated GBM immunosuppression and create a new immunotherapeutic approach to improve the existing standard treatments and immunotherapies for GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3cbe44139c87ecba179bf8e865f8c5ead1c37390" target='_blank'>
              DDEL-27. Nano-therapeutic modulation of lactate transport in myeloid cells potentiates anti-tumor immunity and radiotherapy for glioblastoma
              </a>
            </td>
          <td>
            Hanchen Lin, Jiawei Huo, Xiaoyang Chen, Leah K. Billingham, H. Najem, Jingqi Sun, Caylee Silvers, Jianzhong Zhang, Rafał Chojak, Yu Han, Aurora Lopez-Rosas, Si Wang, Atique U. Ahmed, Catalina Lee-Chang, A. Heimberger, M. Lesniak, Pavithra Viswanath, J. Miska, Peng Zhang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Recent advancements in the treatment of multiple myeloma (MM), including immunomodulatory agents, monoclonal antibodies, and T cell-redirecting therapies, have significantly improved patient outcomes. However, MM remains incurable. The interaction between MM cells and non-malignant cells within the immunosuppressive tumor immune microenvironment (TiME) plays a critical role in disease progression, but it has not been fully elucidated.
 Our previous study reported that myeloid-derived suppressor cells (MDSCs), dysfunctional dendritic cells (DCs), and tumor-promoting osteoclasts (OCs) are enriched in the bone marrow of myeloma patients and play critical roles in T cell dysfunction. However, the underlying mechanisms remain incompletely understood (Front Immunol. 2022). A myeloid inhibitory receptor, LILRB4, was identified as highly expressed in a super high-risk subgroup of MM cells by single-cell RNA sequencing of patient samples. LILRB4 expression facilitated the generation of monocytic MDSCs and was associated with poor outcomes in MM patients (Haematologica 2024 & 2025). These findings suggest a potential mechanism by which LILRB4 drives an immunosuppressive microenvironment through the induction of immunosuppressive myeloid cells.
 Here, we further observed a significant reduction in erythroid-lineage commitment in MM patients with high LILRB4 expression, and we explored its molecular and cellular impact on the interaction between myeloma cells and the tumor microenvironment (TME). We report that LILRB4 is highly expressed in MM and activates the SHP2/ERK/AP-1 signaling cascade, thereby enhancing the expression of AP-1-associated chemokines and promoting the transdifferentiation of erythroid cells into immunosuppressive erythroid-derived myeloid cells (EDMCs). Through in vivo and in vitro analyses, we demonstrate that CD45⁺ erythroid progenitor cells (EPCs) in the MM microenvironment lose their erythroid differentiation potential and instead transdifferentiate into EDMCs. This reprogramming is driven by elevated levels of CCL3 secreted by LILRB4⁺ MM cells. Compared with the control group, deletion of CCL3 significantly inhibited myeloma cell growth, increased peripheral blood hemoglobin levels, reduced EDMC proportions in the bone marrow, enhanced IFN-γ secretion by CD8⁺ T cells, decreased the frequency of regulatory T cells (Tregs), and reduced the proportion of macrophages. Additionally, the ratio of monocytic MDSCs (M-MDSCs), which preferentially differentiate into tumor-associated macrophages (TAMs), to granulocytic MDSCs (G-MDSCs) was also decreased. EDMCs emerged as another major source of tumor-associated myeloid cells, further contributing to the suppressive TiME.
 These results provide a novel model of hematopoietic diversion in which myeloma “hijacks” CD45⁺ erythroid progenitor cells, redirecting them toward a myeloid fate to evade immune surveillance. EDMCs, as potent immunosuppressive players, strongly inhibit CD8⁺ T cell function and accelerate disease progression. Additionally, our findings establish a mechanistic link between LILRB4 and MM-associated anemia, a well-known poor prognostic factor.Our study therefore suggests that LILRB4 overexpression induces key molecular changes that enable macrophage inflammatory protein-1 alpha (MIP-1α/CCL3)-mediated formation of an immunosuppressive myeloid tumor microenvironment, thereby promoting MM cell growth and survival.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1316f08649414674d11974365803ce69ba88ff10" target='_blank'>
              LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells
              </a>
            </td>
          <td>
            Lanting Liu, Hao Sun, Yijie Wang, Xiyue Sun, Gang An, Lugui Qiu, Mu Hao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="


 Immunosenescence leads to impaired immunity against infections in the elderly. As a key component of adaptive immunity, T cells are crucial for immunity against infection and cancer and exhibit distinct phenotypic changes with age. Characterizing these age-related alterations in T cells is essential for developing strategies to address immune dysregulation in the elderly. In vitro activation model showed that aged mice have a higher frequency of PD1+ exhausted-like CD8 T cells at baseline and higher TCR-induced cell death upon activation. Inhibiting both apoptosis and necrosis rescues TCR activation-induced cell death. Using a murine hepatitis virus (MHV) intranasal infection model, we observed that aged mice had greater weight loss, higher mortality, and impaired CD8 T cell responses during MHV infection. Infected aged mice exhibited increased expression of inhibitory receptors on antiviral CD8 T cells and a decrease in the population of CD8 T cells producing IFN-γ. Single-cell RNA sequencing showed that aging altered the transcriptional profile of antiviral CD8 T cells and reduced T-Bet and ZEB2 expression, key factors for effector CD8 T cell differentiation. Aging also upregulated T cell exhaustion gene signature mediated by the transcription factor TOX. Overall, our findings demonstrate that aging reshapes the molecular program of antiviral CD8 T cells and compromised antiviral T cell immunity in the aged.



 Supported by NIH/ NIA AG-083398; NIAID AI-158294



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80e47c0f1fb034ad0cc56d0aad4b1018f719c06e" target='_blank'>
              Aging compromises effector differentiation and induces exhaustion-like phenotype in CD8 T cells 2511
              </a>
            </td>
          <td>
            Ziang Zhu, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e-4). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e08f1dd96dd018add58f7a79b8066098738fcfe" target='_blank'>
              Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
              </a>
            </td>
          <td>
            Denis J Ohlstrom, William C. Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez-Kozlova, R. Jayasinghe, Katherine E. Ferguson, Hope L. Mumme, Shivani Nanda, Yizhe Song, Sowmitri Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, Junia Vieira Dos Santos, Daniel W. Sherbenou, J. Keats, Alex Gout, Steven Foltz, A. Laganà, T. Kourelis, Ravi Vij, M. Dhodapkar, D. Avigan, H. Cho, L. Baughn, Ajay K Nooka, S. Lonial, Shaji K. Kumar, Mehmet K Samur, Ioannis S Vlachos, Li Ding, Sacha Gnjatic, George Mulligan, Manoj K. Bhasin
          </td>
          <td>2025-12-09</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>111</td>
        </tr>

        <tr id="Radiotherapy is a key treatment modality in many malignancies, but radiation-induced immunosuppression can undermine its outcomes and diminish the efficacy of combinatorial strategies, like radioimmunotherapy. In this issue of the JCI, Deng et al. implicate cGAS/STING signaling in the recruitment of γδ T cells that drive downstream radioresistance. Radiation-induced microparticles containing double-stranded tumor DNA led to activation of the cGAS/STING pathway in macrophages, promoting γδ T cell recruitment through CCL20 signaling. In mouse models, γδ T cell–dependent recruitment of myeloid-derived suppressor cells and T cell suppression curbed radiotherapy efficacy and drove antitumor immunity. Ablation of γδ T cells improved the efficacy of radiotherapy alone and radiotherapy combined with immune checkpoint inhibitors in mouse models, supporting further investigation of γδ T cell targeting to improve clinical outcomes with radioimmunotherapy. The findings also add complexity to the function of the cGAS/STING pathway in setting the balance between antitumor immunity and immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c3dd046d89c143823b2b4f64d8b2ae4eba149f2" target='_blank'>
              cGAS/STING-mediated γδ T cell recruitment drives radioresistance: implications for improving radioimmunotherapy outcomes
              </a>
            </td>
          <td>
            B. Braman, D. Raleigh
          </td>
          <td>2025-12-15</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b6398ddc5edaa94a066851abec2558753a9728" target='_blank'>
              NLRP1 Shapes Immune and Inflammatory Signatures in Human Melanoma but Not in Mouse Models
              </a>
            </td>
          <td>
            V. P. Targhetta, Raquel de Souza Vieira, Hedden Ranfley, C. N. de Souza Breda, N. O. Câmara
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Osteosarcoma, the most common primary malignant bone tumor, poses significant clinical challenges due to its aggressive nature, high metastatic potential, and resistance to conventional therapies. Despite improvements in surgical and chemotherapeutic approaches, survival rates for relapsed or metastatic disease remain poor. Recent advances in understanding the tumor immune microenvironment (TIME) and exosome biology have uncovered critical mechanisms driving osteosarcoma progression, immune evasion, and therapeutic resistance. Tumor-associated macrophages (TAMs), particularly the M2 phenotype, dominate the osteosarcoma immune landscape and contribute to immunosuppression through cytokine secretion and modulation of T cell function. Exosomes, as intercellular messengers, further exacerbate tumor progression by transporting oncogenic proteins, immunosuppressive factors (TGF-β), miRNAs, and drug-resistance molecules. These vesicles also influence critical signaling cascades including Wnt/β-catenin and TGF-β pathways, shaping both local and systemic tumor responses. This review delineates the roles of immune cells and tumor-derived exosomes in osteosarcoma biology and evaluates emerging immunotherapeutic strategies, including immune checkpoint inhibitors, CAR-T cells, tumor vaccines, cytokine-targeted agents, and combination therapies. We highlight ongoing clinical trials, numerical efficacy metrics, and the translational promise of exosome-based diagnostics and therapeutics. Ultimately, integrated approaches targeting both the TIME and exosome-mediated mechanisms may yield more effective and durable treatments for osteosarcoma patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be9f8ffac47c4da15c2672c4e18aa98b07a6180f" target='_blank'>
              Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy
              </a>
            </td>
          <td>
            Jingchao Wang, Kuohao Shi
          </td>
          <td>2025-11-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Multiple myeloma (MM), the second most common hematologic malignancy, presents significant clinical challenges due to its relapsing/refractory nature and incurability, primarily attributed to the high complexity of the bone marrow (BM) microenvironment. Emerging evidence suggests that metabolic reprogramming within the tumor microenvironment (TME) plays a pivotal role in tumor progression and the anti-tumor function of CD8+ T cells. However, the limited understanding of the metabolic landscape of the MM BM microenvironment has hindered the identification of potential therapeutic targets. In this study, we demonstrate that although CD8+ T cells from MM patients exhibit elevated expression of immune checkpoint molecules, they do not enter a canonical exhausted state. Instead, their dysfunction is reversibly suppressed by microenvironmental alterations. Metabolomic profiling revealed a significant remodeling of the tryptophan metabolic pathway in the MM BM microenvironment, characterized by the accumulation of nitrogen-containing metabolites and indole derivatives, which directly impair CD8+ T cell-mediated anti-tumor activity. Further investigation identified indole-related metabolites as key metabolic regulators in the MM BM niche, promoting immune evasion by functionally suppressing CD8+ T cells. These findings not only uncover a novel mechanism of immune suppression in MM but also provide potential therapeutic targets for developing metabolism-focused immunomodulatory strategies.
 In multiple myeloma (MM) patients, bone marrow CD8+ T cells exhibit elevated PD-1 expression but comparable TIM-3 levels to non-myeloma controls. Notably, no significant differences were observed in cytokine secretion capacity or exhaustion-related transcription factor expression between PD-1+/TIM-3+ and PD-1-/TIM-3- T cell subsets. Thus, while a substantial population of CD8+ T cells persists in the MM microenvironment, they do not exhibit the canonical exhausted phenotype traditionally defined in chronic viral infections or other malignancies.
 Unexpectedly, fresh myeloma BM CD8+ T cells show blunted cytokine responses, reversible by overnight culture but inhibited by autologous BM supernatant. This suppression is BM-specific, as peripheral T cells remain unaffected by plasma.
 The <3 kDa hydrophilic fraction of bone marrow (BM) supernatant significantly impaired the cytotoxic capacity of BCMA CAR T cells. Untargeted metabolomic profiling revealed that the inhibitory BM supernatant exhibited distinct metabolic alterations, primarily enriched in the following pathways：Amino acid metabolism; Energy metabolism ; Nucleotide metabolism. Notably, multiple indole derivatives were upregulated in the tryptophan metabolic pathway.
 Metabolomic analysis revealed significant upregulation of indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and kynurenine in the inhibitory bone marrow supernatant. Functional validation demonstrated that indole, indoleacrylic acid, IPA, and IAA all exhibited dose-dependent suppression of CAR T cell-mediated tumor cytotoxicity. Notably, IAA displayed potent immunosuppressive activity even at low concentrations, suggesting enhanced immunomodulatory potential. Mechanistically, both IAA and IPA significantly upregulated aryl hydrocarbon receptor (AHR) expression， indicating that indole-related metabolites may impair antitumor T cell function through AHR-mediated signaling pathways.
 Overall, we have come to the following conclusions：flow cytometric and transcriptional analyses revealed that CD8+ T cells in the multiple myeloma (MM) bone marrow microenvironment exhibit an activated phenotype rather than classical exhaustion markers, despite their functional impairment. Ultrafiltration and functional assays demonstrated that the <3 kDa hydrophilic fraction of MM bone marrow supernatant significantly inhibits CD8+ T cell effector functions. Indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) are significantly elevated in the bone marrow of a subset of multiple myeloma (MM) patients, where they potently inhibit the anti-tumor function of CD8+ T cells, likely through activation of the aryl hydrocarbon receptor (AhR) signaling pathway on T cell surfaces.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1c2fdacb0730e5456a357462f821514cc752968" target='_blank'>
              Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma
              </a>
            </td>
          <td>
            Yueyi An, Huixing Zhou, Xiaoyun Jin, Shengdian Wang, Wen Gao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Immunologically mediated clearance of senescent cells has been demonstrated in several model systems. Given increasing evidence for these cells promoting tumor pathology and immune escape, we sought to examine whether a vaccine against senescent cells can lead to tumor regression. A senolytic dendritic cell (DC) immunotherapy (“SenoVax™”) was created by pulsing DCs with lysate from in vitro generated syngeneic senescent fibroblasts. Prophylactic and therapeutic activity of SenoVax on tumor growth and metastasis was assessed in the Lewis Lung Carcinoma (LLC) model. The immunogenicity of SenoVax™ was measured using cytotoxicity, proliferation, and cytokine assays. Adoptive transfer of lymphocytes from vaccinated mice into naïve mice was performed in a prophylactic tumor challenge model. Assessment of plasma senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 was performed by ELISA. Synergy of SenoVax™ with immune checkpoint inhibitors and the universality of the vaccine’s effects against other tumors was assessed. Furthermore, induction of autoimmunity was assessed by complement activation and autoantibody formation. SenoVax™ was created by pulsing DC with cell lysate from senescent fibroblasts, producing DCs that expressed co-stimulatory molecules, stimulated T cell proliferation, and expressed the senescence antigen p16. SenoVax™ induced prophylactic and therapeutic tumor regression in LLC primary and metastatic murine tumor models. T cell proliferative and cytokine recall responses towards senescent cells but not to control stromal cell pulsed DCs were detected in vaccinated mice. Additionally, reduction in senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 were observed. Adoptive transfer experiments revealed a role for CD8+ T cells in transplanting protection. When SenoVax™ was administered in combination with anti-PD-L1 or anti-CTLA-4 antibodies, the data showed synergistic effects in reducing tumor growth. SenoVax™ also demonstrated reduction of GL281 glioma, Pan01 pancreatic cancer, and 4T1 breast cancer cell growth. No significant activation of complement or induction of autoantibodies was observed. Vaccination with DC pulsed senescent cells resulted in reduction of tumor growth in a CD8+ T cell and interferon gamma-associated manner in lung cancer as well as other tumor models. The data provide mechanistic support for advancement of senolytic immunotherapy as a novel form of cancer therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a319f213855b5647ee19bcdf7566aa5d37fe5379" target='_blank'>
              Reduction of solid tumors by senescent cell immunization
              </a>
            </td>
          <td>
            Thomas E. Ichim, Gilberto Lopes, Robert Reznik, Vladyslav Bykoriz, Christian A. Fortunati, Karenjan A. Pascual, Boris Minev, Roman A. Ramos, Anil Bajnath, Emma Lin, Joyce Hu, Francesco M. Marincola, Armin Rath, Boris N. Reznik
          </td>
          <td>2025-11-28</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3de68178f204f50d4f5e9e5e298b21f11011eca" target='_blank'>
              Multidimensional single-cell analysis reveals immune dysfunction and inflammatory response in Lymphatic malformations.
              </a>
            </td>
          <td>
            Chunxiao Chen, Wenhao Ju, Xueying Li, Kexin Yao, Jun Cao, Songqi Duan, Xueqi Lv, Tianli Zhang, Sanlin Li, Jiawen Li, Feng He, Baofa Sun, Gang Shen
          </td>
          <td>2025-11-22</td>
          <td>Protein & cell</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Dendritic cells (DCs) are essential regulators of adaptive immunity, functioning as professional antigen‐presenting cells that bridge innate sensing with the induction of adaptive immunity and immune memory. The DC population is heterogeneous, encompassing numerous phenotypic subsets depending on the tissue, pathophysiological condition and species studied, which historically complicated their classification. Advances in bulk or single‐cell transcriptomics and ontogenetic studies have clarified DC heterogeneity and highlighted type 1 conventional DCs (cDC1s) for their unique ability to induce protective CD8+ T cell responses against cancer and intracellular pathogens. Beyond immunity, DCs also maintain tolerance to self and harmless antigens. Contrary to earlier assumptions that tolerogenic DCs are simply immature, recent evidence shows that both immunogenic and tolerogenic maturation involve an extensive and convergent reprogramming of cDC1s during the activation process licensing them for shaping T cell responses, a process referred to as DC maturation. This evolving understanding is reshaping how we study DCs, including the necessity to integrate the timing of DC maturation and their microanatomical redistribution during this process. The novel insights these studies are bringing carry significant implications for vaccines or immunotherapies against intracellular pathogens or cancers, and treatments against allergy or autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f0236bce193fec556b42698afce4c36c4c5719f" target='_blank'>
              Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells
              </a>
            </td>
          <td>
            Ramazan Akyol, Marc Dalod
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e72fd69c1e9854128cc0a45768d08ad1fc1e6761" target='_blank'>
              In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma.
              </a>
            </td>
          <td>
            Morgane Krejbich, Emilie Navarro, Judith Fresquet, Marine Cotinat, Valentin Isen, Hortense Perdrieau, Virginie Forest, Aurélie Doméné, Tiphaine Delaunay, Hala Awada, Vincent Dochez, David Roulois, Nicolas Boisgerault, R. Redon, Christophe Blanquart, Isabelle Corre, Lucas Treps
          </td>
          <td>2025-11-27</td>
          <td>Journal of experimental & clinical cancer research : CR</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Neutrophils foster a pro-tumorigenic microenvironment in multiple myeloma (MM) by releasing inflammatory cytokines, immunosuppressive factors, and reactive oxygen species (ROS), contributing to immune evasion and disease progression. Elevated neutrophil-to-lymphocyte ratio serves as a poor prognostic marker, yet neutrophil-targeted therapies remain underexplored. Our prior work identified three novel drug combinations that disrupt both epigenetic regulation and cell cycle control—particularly effective in transcriptionally active, treatment-resistant MM. These combinations also upregulate Smad signaling, indicating potential to reprogram the immune microenvironment and enhance anti-myeloma immunity.
 The CDKi/HDACi combination of dinaciclib and entinostat was identified as a potent combinatorial therapy, as it showed the greatest synergy in treatment-resistant myeloma subtypes and presented higher survival in a murine Vk*MYC; Nras LSL Q61R/+; IgG1-Cre (VQ) allograft mouse model. We investigated the CDKi/HDACi combination for further preclinical development. We explored the targets, mechanism of action, and efficacy of combined CDK/HDAC inhibition in vitro (cell lines) and in vivo (NSG xenografts and Bcl-xL transgenic spontaneous tumors) and confirmed that the combination leads to MYC suppression, upregulation of tumor suppressors like p16, anddelayed tumor progression. Freshly obtained smoldering myeloma patient bone marrow biopsy cells were utilized to evaluate the efficacy of the combination compared to single-agent treatment. The CDKi/HDACi combination was effective at selectively reducing the viability of human CD138+ MM cells ex vivo.Finally, a genetic signature of combined CDK/HDAC inhibition emerged for MM cells. RNA-seq and gene set enrichment analysis revealed downregulation of DNA replication, protein folding, and, importantly,immune pathways, including those related to leukocyte migration and pro-inflammatory chemokines (e.g., CXCL1, CXCL2, IL1A, IL23A). These changes align with the suppression of inflammatory and neutrophil-recruiting signals, suggesting that CDK/HDAC inhibition may indirectly suppress neutrophil activation and trafficking in the MM microenvironment.
 To overcome translational barriers associated with dinaciclib and entinostat, we evaluated next-generation agents: KB0742, a selective and orally bioavailable CDK9 inhibitor, in combination with quisinostat or zabadinostat, two potent HDAC inhibitors with more favorable pharmacokinetic and safety profiles. We validated their synergistic action in limiting proliferation and alteration of biomarker expression. Our next steps are to use co-culture conditions of MM cells with neutrophils, to observe the effects of CDKi/HDAi combination treatment by monitoring neutrophil activation markers, including CD11b and ROS production, compared to single agents. We will further investigate pro-inflammatory cytokines and chemokines involved in neutrophil recruitment and activation (e.g., CXCL1, CXCL2, CXCL8, IL1A, IL23A). These transcriptional changes, accompanied by increased re-expression of tumor suppressors (e.g.,p16) and TGFβ/SMAD signaling components, would predict reprogramming of an anti-inflammatory microenvironment by these combination treatments in myeloma.
 These findings point to a promising but underdeveloped therapeutic avenue whereby suppressing neutrophil-driven inflammation enhances anti-myeloma immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9784fe983e1a8413d51f126d5fbd75b2e2cf4b86" target='_blank'>
              HDAC and CDK inhibitor combinations suppress neutrophil activation in myeloma
              </a>
            </td>
          <td>
            Snehal M Gaikwad, Tyler J. Peat, Wendy Du Bois, Shuling Zhang, Nana Gyabaah-Kessie, Jing Zhang, Dickran Kazandijian, Aleksandra Michalowska, Beverly Mock
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 Background: Immunotherapy has transformed cancer care, inducing durable responses in both hematologic and solid tumors. Despite these advances, many patients derive limited benefit, potentially secondary to an immunosuppressive tumor microenvironment (TME), defined by defective antigen presentation, immunosuppressive cell infiltration, and stromal barriers that restrict T-cell trafficking.
 Our group has established the use of mesenchymal stem cells (MSCs) as modifiers of the tumor microenvironment (TME) (Studeny M…Andreeff, Cancer Res 2002; JNCI 2004). We demonstrated in solid tumors that intravenously injected MSCs have the innate capacity to migrate into the TME and contribute to the generation of tumor-associated fibroblasts at the invasive edge of the tumor and their metastases. While MSCs are believed to be immunosuppressive, we hypothesized that they could be modified into immunostimulatory cells and convert a “cold” TME into a pro-inflammatoryTME. In a clinical pilot trial, we demonstrated proof-of-concept that IFNβ-secreting MSCs homed to ovarian tumors and mediated intratumoral IFNβ delivery (NCT02530047)(Andreeff M et al. Cancer Res (2018)78:75).
 Results: We developed an immunotherapeutic strategy using induced pluripotent stem cell–derived mesenchymal stem cells (iMSCs) engineered to secrete IL-7 and IL-15, two potent cytokines selected for their robust immunostimulatory properties. iMSCs, clonally derived from iPSCs, offer superior expansion and scalable production compared to BM-MSCs. These iMSCs retained classical MSC morphology and proteogenomic profiles, supporting their identity and functionality. Telomere length and CyTOF-based cell cycle analysis revealed high proliferative capacity, far superior to BM-MSCs. Stable transgene expression was validated using GFP-tracked clones throughout differentiation and expansion. These iMSCs enhanced bone marrow regeneration following radiation therapy (Okeleji, O et al ASH2025).
 Proprietary gene editing ensured efficient and consistent integration of IL7 and IL15 transgenes, providing a robust platform for cytokine delivery. IL-7/IL-15-iMSCs produced supraphysiological cytokine levels (2,000–4,000 pg/mL), representing a nearly 20-fold increase over levels seen in previously engineered T cells. This enhanced cytokine output drove proliferation of resting and CD3/CD28-activated T cells, as confirmed via CFSE assays. CyTOF profiling revealed robust downstream STAT5 phosphorylation, pS6 activation, and BCL2 upregulation, indicative of efficient IL-7/IL-15 receptor downstream signaling. Hence, immunosuppressive iMSCs were modified to be potent immunostimulatory cells. We applied this concept to high-grade serous ovarian carcinomas (HGSOC). PBMCs conditioned with IL-7/IL-15-iMSCs significantly reduced the number of both platinum-sensitive and platinum-resistant ovarian cancer cells in vitro. To evaluate therapeutic efficacy in vivo, we administered IL-7/IL-15-iMSCs i.p. into the ID8 murine ovarian cancer model in immunocompetent mice. Multiplex immunofluorescence demonstrated that iMSCs home to tumors, secrete cytokines locally, and promote intratumoral T-cell, NK-cell, and macrophage infiltration, collectively leading to prolonged survival. This outcome was associated with a shift from an immune-excluded to an inflamed, immune-infiltrated TME. The ovarian TME was enriched in CD163⁺Arg1⁺PD-L1⁺M2-like macrophages, which exhibited a phenotypic shift toward an M1-like state, marked by Arginase-1 downregulation, in the IL-7/IL-15 treatment group. Experiments investigating activity of IL-7/IL-15-iMSCs in carboplatin-resistant ID8 models are ongoing and will be reported. Results in triple-negative breast cancer will be reported separately (Singh, S et al. ASH2025).
 Conclusion: We demonstrate that IL-7/IL-15-iMSCs display potent in vitro immunostimulatory activity, inducing robust T cell proliferation and activation. IL-7/IL-15-secreting iMSCs convert an immunosuppressive TME into a “hot” milieu, defined by massive T-cell and macrophage infiltration, M1 polarization, and restoration of T-cell functionality. Gene-modified iMSC-induced reprogramming of ovarian TME resulted in reduced tumor burden and improved survival in a murine ovarian cancer model. Results support the potential of IL-7/IL-15-iMSCs as a novel immunotherapeutic platform for overcoming immune resistance in cancer, including hematological malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9ab550875609985f12d7a0a7eb4312645f47adc" target='_blank'>
              Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes
              </a>
            </td>
          <td>
            M. Muftuoglu, Sandeep Singh, Andrea D Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren B. Ostermann, Ivo Veletic, Christopher D. Pacheco, Poo Yee Mak, Edward Ayoub, Taeyun Kim, Kyle M. Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher B. Rohde, M. Andreeff
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is widely considered unresponsive to immunotherapy due to its immunosuppressive microenvironment and limited immune cell infiltration. However, recent single-cell transcriptomic studies reveal the presence of exhausted, potentially antigen-specific T cells in human GBM. We have developed a locally administered, brain-confined cytokine therapy with minimal systemic exposure using an engineered, neonatal Fc receptor (FcRn)-silenced, Compartment-Locked (CL) IL-12Fc fusion protein. This approach thus relies on presence and reactivation of tumor-resident, IL-12-responsive cells. In syngeneic, preclinical GBM models, intratumorally administered CL IL-12Fc induces robust antitumor efficacy, also under conditions of peripheral lymphopenia (induced via systemic temozolomide) or when T cell influx was pharmacologically inhibited. In 3D-perfused, patient-derived GBM explant cultures—with a largely preserved native tumor microenvironment and without addition of autologous peripheral immune cells—CL IL-12Fc triggered pro-inflammatory reprogramming. Proteomics-based secretome analysis revealed significant upregulation of interferon-gamma (IFNγ) pathway signatures. Single-cell RNA sequencing of GBM tissues prior to culture setup confirmed the presence of resident memory T cells in most patients. Notably, single cell transcriptome analysis of post-treatment explants demonstrated a robust IFNγ response in both tumor-associated macrophages, microglia and tumor cells. Our findings demonstrate that CL IL-12Fc can activate local immune responses within human GBM samples, independent of peripheral immune cell recruitment. This localized immune activation is an important prerequisite for the clinical translation of locally confined cytokine therapy. We aim to validate these findings using spatially resolved multiplex immunofluorescence histology. In summary we provide evidence that CL IL-12Fc can facilitate local immune activation without peripheral immune cell requirement.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/060cb1db812334f914a22c2a53795e6b0d1cdc11" target='_blank'>
              IMMU-51. Treatment efficacy in murine and human glioma models with brain Compartment-Locked IL-12 does not per se rely on influx of peripheral immune cells and induces distinct transcriptome and secretome changes
              </a>
            </td>
          <td>
            Sabine Spath, L. Le Large, Michal Beffinger, N. Tatari, M. Ritz, B. Taskoparan, U. Salazar, Sereina Deplazes, Felix Behr, C. Zinner, W. Vader, Carlo Bertozzi, D. van der Meer, G. Hutter, J. vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Introduction: The bone marrow (BM) microenvironment supports survival of the malignant multiple myeloma (MM) cells and is composed of cellular components that foster MM development and progression by suppression of immune responses. Despite major progresses in understanding the MM biology and pathophysiology, it is still incurable. Myeloid cells are well-described to suppress antitumor immunity (Barry et al., 2023; De Sanctis et al., 2023). However, the molecular mechanisms to achieve immunosuppressive myeloid cell states are unknown. Cytokine IL-4 is the primary driver of tumor infiltrating monocyte-derived macrophage (MO-MAC) phenotype as reported by LaMarche that deletion of IL-4Rα alone within early myeloid progenitors in BM reduced tumor burden; while deletion in downstream mature myeloid cells had no effect (LaMarche et al., 2024). Mechanistically, IL-4 derived from BM basophils and eosinophils acted on granulocyte-monocyte progenitors (GMPs) to transcriptionally program the development of immunosuppressive tumor-promoting myeloid cell.Hematopoietic Adaptor-Containing SH3 and SAM domains (HACS1) maps to a region on chromosome 21 that is frequently disrupted in hematopoietic malignancies, suggesting its involvement in these diseases (Claudio et al., 2001). Previously, we showed that Hacs1 is involved in MM development through changes of its microenvironment. It regulates IL4 signaling in B cell, T cell, macrophages and dendritic cells and affects their function (Wang et al., 2010). Hacs1-/- bone marrow derived macrophages (BMDMs) are hyper-responsive to IL-4 stimulation and display an alternative activation M2 phenotype. We found CD11b+/Gr-1+/ CD31+/Siglec F myeloid progenitors as well as immature myeloid progenitors and eosinophils were significantly increased in Hacs1-/- mouse bone marrow.
 Method: In the current study, we investigated the role of Hacs1 in MM immunosuppressive microenvironment utilizing Hacs1-/-mouse BM-myeloid derived suppressor cells (MDSCs) as well as MM tumor-bearing mice to study MM progression and therapeutic resistance.
 Results: Our results showed Hacs1-/-mouse bone marrow in MM tumor-bearing mice has upregulated PD-L1 expression in MDSCs, suppressing T cell function. Overexpression of Hacs1 or stimulation Hacs1 reduces MDSC accumulation, resulting in elevated T cell activity and reduced tumor load. Our data suggest that Hacs1 plays a key role in regulation of the immunosuppressive microenvironment in MM. Furthermore, myeloid cells from Hacs1-/-mouse BM have increased expression of MS4A3 gene, a key gene regulating cell differentiation to monocytic/granulocytic-myeloid-derived suppressor cells (M-MDSCs and G-MDSCs, respectively) (Liu et al., 2019). At the mechanistic level, MS4A3 enhances IL-3 and GM-CSF signaling in Hacs1-/-BM CD34+ cells, compared to Hacs1+/+cells.Conclusion: These data suggest that Hacs1 negatively regulate IL-4 signalling axis in bone marrow and drives pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling. Hacs1 is a key player in cellular signaling within the immune system with roles in immune regulation, cancer development, and potential serves as a MM therapeutic target.
 Keywords: Hacs1-/-, Multiple Myeloma, myeloid derived suppressor cells (MDSCs), bone marrow microenvironment, chemo resistance
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f2d0467e47b26436ae5260ef710bda44c102442" target='_blank'>
              Title: Hacs1 is a myeloma immunosuppressor driving pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling
              </a>
            </td>
          <td>
            Dingyan Wang, Xiao-Yan Wen, Jamie Li, Raymond Qu, Wiiliam JiaYi Wu, Xinmiao Andrew Yang, Derek Shiqi Xu, Jingdong Wu, Leqi Shen, Jeremy Dai, Yuan Gao, Jinyi Zhang, Anthony Gramolini Gramolini, Xiaoyuan Liu, K. Siminovitch, Keith Stewart
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Some cancers trigger a response that resembles a viral infection, called viral mimicry, which can stimulate the immune system. This process has been linked to better responses to certain drugs in solid tumors, but its role in Acute Myeloid Leukemia (AML) is not well understood. In this study, we explore whether viral mimicry in AML is associated with immune activation and its response to BCL2 inhibition
 RNA-sequencing data from 707 AML samples from the BeatAML2 dataset was analyzed. Each patient was assigned a viral mimicry score based on the expression of interferon-stimulated genes. Immune infiltration was estimated using established gene signatures for T cells, monocytes, dendritic cells, and other immune populations. The expression of immune checkpoint genes such as PD-1, PD-L1, CTLA4, and TIM-3 were also measured. Drug sensitivity was assessed using ex-vivo area under the curve (AUC) values for azacytidine, venetoclax, and ABT-737. Spearman correlation (ρ) and FDR-adjusted p-values were used for statistical analysis.
 Expression of 1,442 genes were significantly linked to viral mimicry scores (p<0.05, |ρ|>0.3). The strongest association was with IFI44L, an interferon-stimulated gene (ρ=0.91, p<0.005). Other top genes included OAS3, MX1, and RSAD2, all tied to interferon signaling. Viral mimicry was moderate to strongly correlated with immune cell markers, including monocytes (ρ=0.47), dendritic cells (ρ=0.37), cytotoxic lymphocytes (ρ=0.36), CD8+ T cells (ρ=0.31), and NK cells (ρ=0.29), all with p<0.005. These findings suggest that higher mimicry is associated with broader immune activation. Immune checkpoint gene expression increased alongside viral mimicry scores. The highest correlation was with PD-L1 (CD274) (ρ=0.46), followed by TIGIT, CTLA4, and HAVCR2, each with ρ>0.30 and p<0.005. Viral mimicry scores were not associated with ABT-737 response, and most immune checkpoints lacked predictive value. Modest correlations with azacytidine (ρ=-0.31) and venetoclax (ρ=-0.24) suggest partial enrichment for HMA and BCL2 sensitivity (both p<0.005), but not enough for clinical prediction.
 This is the first study showing that viral mimicry in AML is linked to immune activation and higher expression of immune checkpoint genes, but it does not help predict response to BCL2 inhibitors. Although the clinical impact is not yet clear, these findings highlight a unique immune-related signature that could help guide future studies of immunotherapy or hypomethylating agents in AML. Further clinical validation is needed.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f628c14fb62d4b292b806619aec4afa5af2e330" target='_blank'>
              Viral mimicry in AML is linked to immune activation but not BCL2 inhibitor sensitivity
              </a>
            </td>
          <td>
            Mobina Shrestha
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Neutrophils are granulocytic myeloid cells that have critical effector functions during infectious disease but are typically thought to be short-lived, terminally differentiated phagocytic cells. We directly compared lung neutrophil activation following infection with different groups of pathogens including bacteria (Staphylococcus aureus), fungi (Aspergillus fumigatus), and helminths (Nippostrongylus brasiliensis) at 2 days after infection. Our results showed considerable heterogeneity depending on the type of infectious agent. Bulk RNAseq, EdU incorporation, and flow cytometric staining for necrosis/apoptosis identified distinct activation states with rapid cell death predominant in neutrophils after S. aureus and A. fumigatus infection, while neutrophils from helminth infected mice exhibited increased cell cycling and expression of signaling pathways associated with proliferation, type 2 responses, and wound healing. Spectral flow cytometry, intravascular staining, and scRNAseq revealed a distinct c-kit+ proliferating subset of lung neutrophils that expanded shortly after helminth infection and was released from the endothelial niche to co-localize with invading parasites in the airways. These findings challenge current models of neutrophil function during infectious disease, suggesting that neutrophils uniquely assume a persistent and proliferative phenotype that may contribute to tissue repair and resistance in the context of the type 2 pulmonary inflammatory response.



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc63af91fce596ab00aa753f7624aba3a3f97766" target='_blank'>
              Helminth infection favors persistent and proliferating alternatively activated neutrophils in the lung 2684
              </a>
            </td>
          <td>
            Suheyla Batirbek, Fei Chen, V. Espinosa, Lianhua Jin, Wenhui Wu, Keyi Wang, Katherine E. Lothstein, Dane Parker, Mark C. Siracusa, A. Rivera, W. Gause
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6008f52253955f9261442a5b18d9c18c5700cd27" target='_blank'>
              mTORC2 inhibition reduces tumor burden via STAT1 activation and enhanced response to anti-PD-L1 therapy.
              </a>
            </td>
          <td>
            Anna Gschwendtner, Birgit Schütz, Madalina A. Mirea, Oliver Eckel, Mikolaj Z Kepa, S. Fritsch, Raimund Oberle, T. Weichhart, Markus Hengstschläger, M. Mikula
          </td>
          <td>2025-12-22</td>
          <td>Cell death & disease</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="


 Waldenström Macroglobulinemia (WM) is an incurable lymphoid malignancy characterized by a spectrum of differentiation states from clonal B lymphocytes (Ly) to IgM-expressing plasma cells (Pc). Activation of mitochondrial apoptosis by Bcl-2 antagonists is already under clinical investigation for treatment-naïve (TN) and relapsed/refractory (R/R) patients. However, the biological mechanisms whereby WM cells evade mitochondrial apoptosis remain undefined. In this work, we leveraged functional and single-cell transcriptomic approaches to unravel fundamental principles of apoptosis evasion in WM.
 We collected viable WM cells from the bone marrow of 27 WM patients (25 MYD88L265P and 2 MYD88WT; 25 patients were TN, 2 were R/R). Samples were subjected to intracellular BH3 profiling (iBH3), a functional assay that derives the apoptotic priming and the anti-apoptotic dependencies based on the pattern of cytochrome c release in response to pro-apoptotic stimuli. Surface staining with anti-CD19 and anti-CD138 antibodies was included to discriminate Ly and Pc in each sample. We found that the apoptotic profile differed considerably between malignant Ly (CD19+CD138-) and Pc (CD19+CD138+). WM Pc displayed lower apoptotic priming (P=0.002) and lower Bcl-2 dependency (P=0.03) than WM Ly. In contrast, non-Bcl-2 anti-apoptotic dependencies, particularly Mcl-1 dependency, were higher in Pc than Ly (Mcl-1 dependency: 93.0 and 42.8%, respectively, P<0.001).
 Despite being predominantly Bcl-2 dependent, Ly showed remarkable heterogeneity across samples. Integrating Ly apoptotic profiles with patient clinical data, we found a positive correlation between the amount of serum monoclonal component (MC) and co-dependency upon Mcl-1 specifically detected in Ly (Pearson r=0.68, P<0.001). We also observed an increasing gradient of Mcl-1 dependency (P<0.001) when comparing Ly from patients affected by chronic lymphocytic leukemia (a prototypical Bcl-2 dependent malignancy, N=17), hyposecretive (MC<30 g/L, N=20), and hypersecretive WM (MC<30 g/L, N=7).
 To assess whether Ly and Pc express different sets of pro- and anti-apoptotic genes, we performed single-cell RNA sequencing coupled with BCR sequencing on 8 WM bone marrow samples, 3 of which were hypersecretive. As expected, BCL2 was upregulated in WM Ly compared to residual normal memory B-cells. With respect to normal Pc, WM Pc expressed a higher level of the MCL1/PMAIP1 couple and a lower level of the pro-apoptotic BCL2L11 (encoding Bim). Focusing on tumor cells only, we identified 9 clusters with different transcriptional profiles. Five of them (Clusters 1-5) covered the Ly population, two harbored features of intermediate lymphoplasmacytic states, one corresponded to canonical JCHAINhighPRDM1high Pc, and an additional minor cluster was composed of atypical JCHAINhighPRDM1neg Pc. Consistent with iBH3 results, there was a clear-cut progressive increase of MCL1 expression during the differentiation of WM Ly towards canonical WM Pc. In contrast, BCL2, as well as BIRC3 and BIRC6, remained high up until the intermediate clusters and then dropped down at the Pc end of the differentiation trajectory. Interestingly, PMAIP1 followed a wave-like pattern with very high expression in intermediate states and low levels on the two ends of the differentiation process. BCL2A1, an anti-apoptotic gene often involved in therapy resistance, was highly expressed in a fraction of WM Ly belonging to Cluster 5. More importantly, within the WM Ly population, the highest expression of MCL1, at levels comparable to those observed in intermediate states,was detected in Cluster 4. This Ly cluster was particularly enriched in hypersecretive patients and may underpin the functional Mcl-1 dependency associated with this clinical phenotype.
 Lastly, we searched for targetable signaling pathways transcriptionally upregulated in clusters with high MCL1expression. While B-cell receptor signaling and NF-kB activity were comparable across clusters, IRE1/XBP1 pathway and, to a lesser extent, STAT3 activity were increased in JCHAINhighPRDM1high Pc and may represent actionable targets to suppress Mcl-1 addicted cells.
 In sum, cell differentiation stage coordinates the expression of Bcl-2 family genes and modulates anti-apoptotic dependencies in WM. Such transcriptional and functional intratumor heterogeneity may underlie the relatively low rate of deep responses to Bcl-2 antagonism in WM and suggest novel combination strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a9fe24492d9101d3917015b59b6d5449cccef431" target='_blank'>
              Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia
              </a>
            </td>
          <td>
            Cristina Frusteri, A. Real, F. Nadeu, Laura Fumagalli, Valentina Manconi, Ali Jafari Kia, Eleonora Terrabuio, A. Montresor, Maria Pia Manto, Eleonora Gugole, Angela Mercuri, L. Bonaldi, Gabriela Constantin, M. Krampera, C. Visco, M. Scupoli, Carlo Laudanna, Isacco Ferrarini
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified four bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across four activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 hours. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune Checkpoint Expression in Mucosal-Associated Invariant T (MAIT) Cells is Stimulus-Dependent.
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of leukocyte biology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Invariant Natural Killer T (iNKT) cells are a rare, non-conventional T cell subset that recognize lipid antigens presented by the MHC class I-like molecule CD1d. Upon activation, iNKTs rapidly produce a wide range of cytokines, enabling them to serve as first responders and modulators of both innate and adaptive immunity. Their roles in inflammation, infection, tumor surveillance, and tissue homeostasis are well documented, but how iNKTs behave in the context of early hematologic transformation remains unclear. Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a common, age-associated premalignant condition characterized by somatic mutations in hematopoietic stem/progenitor cells, most frequently in genes involved in epigenetic regulation such as TET2. CHIP not only predisposes to myeloid malignancies but also promotes systemic inflammation, a hallmark of early disease evolution. While TET2 loss has been shown to promote myeloid skewing and inflammatory signaling, its impact on iNKT biology remains unexplored.
 We hypothesized that TET2-deficient clonal hematopoiesis alters peripheral iNKT cell homeostasis and function through inflammation and disruption of lipid antigen presentation. To model CHIP, we used a non-irradiated bone marrow chimera system in which wild-type recipients were transplanted with Tet2-deficient (Tet2KO) bone marrow cells. This setup preserves a functional thymus, allowing us to study peripheral effects of clonal hematopoiesis on immune cells in the absence of irradiation-induced artifacts.
 Tet2KO murine chimeras exhibited a significant and progressive loss of peripheral non-mutated iNKT cells, correlating inversely with the extent of Tet2-deficient hematopoiesis. Thymic iNKT development remained intact, suggesting that peripheral environmental factors, rather than developmental defects, are responsible for the observed phenotype. Single-cell RNA sequencing revealed that Tet2-exposed iNKT cells displayed transcriptional signatures consistent with chronic activation, enhanced TCR signaling, and skewing toward the iNKT17 lineage, while iNKT1-defining transcriptional programs were suppressed. Flow cytometry confirmed a marked reduction in iNKT1 cells and a reciprocal expansion of iNKT17 cells in the spleens of Tet2KO chimeras. The cytokine known to promote iNKT17 differentiation, IL-6, was significantly elevated in the plasma of Tet2KO mice. Transcriptomic data revealed robust enrichment of IL-6–STAT3 target genes in iNKTs exposed to the Tet2-deficient microenvironment, further supporting a mechanistic link. In parallel, ATAC-seq profiling of iNKTs revealed increased chromatin accessibility at NFκB-associated transcription factor motifs and inflammatory response elements, indicating sustained activation.Given that iNKT activation depends on recognition of lipid antigens presented by CD1d, we next examined whether Tet2 loss alters this axis. Tet2KO hematopoietic cells exhibited significantly increased CD1d surface expression on multiple immune cell populations. To assess whether Tet2 deficiency perturbs the composition of lipid antigens available for CD1d presentation, we performed liquid chromatography–mass spectrometry LC-MS lipidomic profiling on Tet2-deficient and WT K562 cells. Notably, Tet2 loss resulted in significant alterations in endogenous glycolipid composition, including the enrichment of several lipid species known to be presented by CD1d to iNKT cells. These findings suggest that Tet2 regulates not only immune signaling but also the antigenic landscape that shapes iNKT activation and differentiation.
 Our study reveals a novel mechanism by which TET2 mutations in hematopoietic cells reprogram the immune microenvironment and impair the function of iNKT cells. We demonstrate that TET2 loss promotes a dual-hit effect: it generates a pro-inflammatory environment that skews iNKT differentiation toward an iNKT17 fate, and it alters both CD1d expression and lipid antigen composition, potentially reshaping the antigenic context that governs iNKT activation. These findings uncover a previously unrecognized role for TET2 in regulating lipid antigen presentation and iNKT homeostasis. By linking epigenetic dysregulation to innate-like T cell dysfunction, our work provides a mechanistic framework for understanding immune evasion in early clonal hematopoiesis and offers novel immunometabolic targets for therapeutic intervention in CHIP and preleukemic states.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b939cfce91858c120d06f5230155f1bc2759e0a9" target='_blank'>
              Perturbation of iNKT differentiation during clonal hematopoiesis from rewiring of inflammation and lipid presentation
              </a>
            </td>
          <td>
            Francesca Luca, Alana M. Franceski, Paran Goel, Brittany Crown, A. Connelly, Caroline C. Ennis, Daniel W. Phillips, Sajesan Aryal, V. Kuznetsova, A. Costa, Molly Boettiger, Angelo D’Alessandro, R. Welner
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 The infant immune system undergoes pre- and postnatal development that must rapidly and nonspecifically respond to signals of danger and tissue damage. There is evidence from animal models that fetal naïve T cells share characteristics with typical innate immune populations, which may enhance their reactivity outside of a well-controlled and antigen-specific response. We hypothesized that naïve CD8+ T cells among premature and full-term infants overlap phenotypically with adult naïve CD8+ T cells but harbor functions that are permissive to TCR-independent reactivity. We used high-parameter flow cytometry and multimodal single cell sequencing to profile CD8+ T cells from infant cord blood as well as healthy adult PBMCs. Multiple naïve CD8+ T cell subpopulations were consistently detectable in cord blood and waned variably in adult donors. KLRG1+CD161+IL18R1+ cells were most abundant in premature subjects, responded to IL-12/IL-18 stimulation, and produced TNF and a gene expression program related to antiviral immunity. Innate cytokine (IL-8) producing cells were most abundant in full-term infants. Cells with innate cytokine functions expressed TCR sequences that were widely shared among subjects (“public” clones). We report that infants harbor specific CD8+ T cell populations with innate-like characteristics that vary by gestational age. These findings can clarify age-specific mechanisms of perinatal inflammation and identify cellular drivers of immunopathology in early life.



 Supported by: URMC MSTP (NIH MSTP grant: 5T32GM007356), URMC Dept. of Pediatrics Small Grants Program.



 Hematopoiesis and Immune System Development (HEM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3fd8713e68f8cedc1eaab218540768f350b0496" target='_blank'>
              Infant αβ CD8+ T cells are enriched for innate-like populations 4435
              </a>
            </td>
          <td>
            Adam B. Geber, Darline Castro-Meléndez, Nathan Laniewski, David J. Topham, H. Huyck, Gloria Pryhuber, Kristin marie Scheible
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="
 The tumor microenvironment of glioblastoma is dominated by immunosuppressive microglia/macrophages that dampen anti-tumor immunity, comprising a major barrier to effective immunotherapy. Developing strategies to reprogram these macrophages is essential to overcome treatment resistance. Bacterial extracellular vesicles (bEVs) are secreted nano-sized (~25–100 nm) particles that modulate myeloid cell activity in a species-dependent manner. We developed a scalable strategy to purify bEVs from the human commensal Escherichia coli Nissle strain consisting of: tangential-flow filtration, Benzonase depletion of free nucleic acids, and size-exclusion chromatography, yielding ~3.5 mg of bEV-associated protein per liter of culture. E. coli Nissle bEVs activated NF-κB and IRF pathways in THP-1 dual-reporter monocyte-derived cells in a dose-dependent manner, with an ED50 approximately seven-fold lower than that of purified LPS or heat-killed bacteria, indicating a distinctly higher potency. We further depleted free LPS that may co-isolate with bEVs, and noted a ~3000-fold reduction in LPS content, with less than 10% protein loss. LPS-depleted bEV bioactivity surpassed LPS amount-matched crude bEVs, supporting that bEV, not residual copurifying LPS, drove the observed in vitro bioactivity. bEVs activated peripheral-blood mononuclear cell-derived CD11b⁺CD68⁺ macrophage-like cells at concentrations as low as 1 ng/mL, while lymphocyte populations experienced minimal effects, in line with bEVs acting primarily on myeloid cells. We next treated M-CSF, IFNγ, and IL-4 polarized human monocyte-derived macrophages with bEVs. In IL-4 polarized (M2-like) macrophages, bEVs induced a more pronounced M1-like reprogramming compared to IFN-γ treatment, increasing CD38, CD80, and CD86 while decreasing CD47 and CD206. This reprogramming persisted even at sub-ED50 concentrations, as low as 0.6 ng/mL. Collectively, this workflow consistently yielded bioactive bEVs that robustly reprogram macrophages. Future work will test the ability of bEVs to reprogram GBM-associated microglia/macrophages, with the ultimate goal of combination with immunotherapies to overcome treatment resistance in the immunosuppressive GBM microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/314efedf3ab7696248eb4216de5020641b87b2b2" target='_blank'>
              IMMU-16. Development of high-purity bacterial extracellular vesicles for suppressive myeloid cell reprogramming in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Irem Karaman, Justin Ruiz, O. T. Pumar, Asmita Pathak, Jonathan Mitchell, B. León, Selma Maacha, Wael El-Rifai, Defne Bayik, Dionysios C. Watson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 KLRG1+ long-lived effector cells (LLECs), are CD8 T cells that persist in the blood and spleen for months and contribute robust protective immunity against systemic infection. We asked whether LLEC (or their progeny) ever leave the blood stream to combat tissue-restricted infections like influenza, and whether they could generate resident memory T cells (TRM). We found that effector cells derived from LLECs rapidly enter nonlymphoid tissues and reduce pathogen burden but show dependence on antigen presentation by vascular endothelial cells. Flow cytometry and single-cell RNA sequencing revealed that secondary memory cells arising from any memory precursor develop a similar resident memory phenotype and transcriptional signature. These data lead us to conclude that despite other limits on their differentiation, LLECs retain the ability to enter non-lymphoid tissues and establish residency. In specific pathogen free mice exposed to a single acute infection, LLECs tend to fade over time. However, in mice which are first exposed to natural commensals and pathogens through cohousing with pet store mice, LLECs dominate the memory CD8 T cell pool. We find that increased production of short-lived effector cells followed by a diminished contraction phase improves formation of LLEC. Current work tests whether noncanonical cytokines or conversion from other memory subsets supports LLEC in cohoused mice, potentially revealing new strategies for memory T cell persistence.



 This work was supported by NIH/NIAID: R01AI155468 and F32AI178962



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/69a8b8ead575177338c13fe60014873a7b4e5ed2" target='_blank'>
              Formation, flexibility, and function of long-lived effector cells 3815
              </a>
            </td>
          <td>
            Sara Hamilton, Erin D. Lucas, M. Huggins, Changwei Peng, Christine O’Connor, Abigail R. Gress, Claire E. Thefaine, Emma M Dehm, Yoshiaki Kubota
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet resistance and immune-related adverse events (irAEs) remain significant challenges. γδ T cells and B cells are recognized as critical players in the tumor microenvironment (TME), but their roles in shaping T cell phenotypes and contributing to ICI resistance are not fully understood. Using syngeneic tumor models in autoimmune-prone NOD mice, which enable simultaneous profiling of tumor immunity and autoimmunity, we investigated mechanisms underlying ICI sensitivity and resistance. In the resistant tumor model, CD8+ T cells exhibit a naïve phenotype, with elevated TCF-1 expression and reduced activation markers such as PD-1 and CTLA-4. In contrast, activated CD8+ T cells dominate the sensitive tumor model, highlighting T cell phenotypes as key drivers of ICI responses. Further analyses implicated γδ T cells and B cells in these divergent responses. Depleting γδ T cells in the resistant model significantly improved tumor control, underscoring their role in mediating resistance. Conversely, CD8+ T cell activation was enhanced in B cell-deficient mice, suggesting B cells may restrict antitumor immunity. Together, these findings provide critical insights into the interplay between T cells, γδ T cells, and B cells within the TME and highlight potential therapeutic strategies to overcome ICI resistance without inducing irAEs.



 National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number: T32AI138945



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a88c64fd65f389029580f6961ad4a61916ee0e46" target='_blank'>
              The Interplay Between γδ T cells and B cells Contributes to Immune Checkpoint Inhibitor Resistance 3426
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Persistent antigen exposure, a hallmark of chronic infections and tumors, drives the formation of a distinct population of CD8+ T cells, known as exhausted CD8+ T (TEX) cells, with increased expression of immune checkpoint molecules and reduced effector function. Immune checkpoint inhibition (ICI) therapy has emerged as a powerful tool to reinvigorate the function of TEX cells. However, despite the immunostimulatory effects of radiotherapy (RT), combining RT with ICI has yielded modest clinical benefits in cancer patients. While the success of ICI therapy largely depends on the presence of progenitor TEX cells, the impact of high-dose ionizing radiation (IR) on the TEX population, particularly enriched within the treatment field, remains understudied. Here, we show that chronically infected mice with LCMV-Clone 13 subjected to sublethal whole-body irradiation (WBI) exhibited a lasting numerical decline and impaired antigen-specific function in their TEX cells. Using single-cell RNA sequencing and multiparameter flow cytometry, we observed that WBI gradually altered the subset composition of surviving TEX cells, highlighted by the loss of progenitor and effector-like TEX cells while terminally-exhausted TEX cells were enriched. Lastly, WBI rendered ICI therapy less effective in rescuing TEX cells and decreasing viral burden. These findings provide important insights into how high-dose IR alters the fate of TEX cells, potentially impairing their responsiveness to ICI therapy.



 Supported by NIH Grants GM134880, AI114543



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ef55b305a83cb203c9064f70e6ab8c59e03b2320" target='_blank'>
              Ionizing radiation impairs the efficacy of immune checkpoint inhibition by driving terminal exhaustion of progenitor exhausted CD8+ T cells 4054
              </a>
            </td>
          <td>
            Mohammad Heidarian, S. Kannan, Xin Zhao, M. Mix, Hai-Hui (Howard) Xue, John T. Harty, V. Badovinac
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="


 Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting can be detrimental, as recent evidence shows that inflammatory macrophages are essential to support CAR T-cell activity. We therefore identified CD123 as selectively expressed on immunosuppressive TAMs, making it a promising target to remodel the TME. Meanwhile, B7-H3 is a tumor-associated antigen that is broadly expressed in pHGGs, making it an ideal target for CAR T-cell therapy. We now hypothesize that dual targeting of CD123+ TAMs and B7-H3+ tumor cells would synergistically deplete suppressive myeloid populations, restore T-cell function, and enhance anti-tumor efficacy.



 To evaluate the therapeutic potential of CD123 and B7-H3 dual CAR T-cell therapy in modulating the TME, preserving supportive myeloid subsets, and enhancing anti-tumor efficacy in pHGG.



 Using immunocompetent pHGG models, we tested CD123 and B7-H3 CAR T-cells through in vitro cytotoxicity, antigen stimulation, and co-cultures with bone marrow–derived M1 or M2 macrophages. In vivo, CD123 CAR T-cells were administered intratumorally as monotherapy or in combination with B7-H3 CAR T-cells. Endpoints included TAM depletion, phenotypic and transcriptomic TME remodeling, tumor progression, and survival.



 CD123 CAR T-cells exhibited minimal cytotoxicity against B7-H3+ glioma cells but selectively depleted M2-like TAMs in vitro and in vivo. M2 macrophages suppressed B7-H3 CAR T-cell persistence in vitro; this suppression was reversed by co-treatment with CD123 CAR T-cells. Dual CAR T-cell therapy significantly enhanced anti-tumor activity, reduced myeloid and microglial infiltration, and extended survival in vivo.



 Targeted depletion of CD123+ TAMs enhances B7-H3 CAR T-cell efficacy by mitigating immunosuppressive signaling while preserving beneficial myeloid support. This dual-targeting strategy offers a mechanistically guided approach to overcoming TME-driven resistance in DIPG and other pHGG.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43e9945f878d4e3f16528ee181777513363175aa" target='_blank'>
              EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Paulina Velsquez, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Decades of experimental work have helped define the heterogeneity of the various cell types that compose the immune system. The different cell types arise from distinct hematopoietic stem and progenitor cells in a coordinated fashion during ontogeny, providing a set of diverse cells that contribute to host defense. Cells can also differentiate into different subsets in response to the cytokine and tissue environment, creating a level of cellular heterogeneity that helps direct the nature and magnitude of the immune response. Here we are discussing a variation whereby cellular heterogeneity arises due to the expression of X‐linked immune genes that escape X chromosome inactivation, giving an advantage to a subset of cells more prone to respond to stimulation by external (pathogens) but also internal signals (i.e., mechanosensing). Interestingly, these inflammatory subsets are much more likely to be differentially enriched in patients with autoimmunity or inflammatory diseases which are well known to be predominant in females. We are using plasmacytoid dendritic cells (pDCs) as a model cell type, as these cells are a rare but critical subset of innate immune cells, with a rapid and massive capacity to produce type I IFNs (IFN‐I) upon sensing of nucleic acids from pathogens, but also from the self, and these cells have been linked to the pathogenesis of many autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98b5143104584df960a1c460b9d9fe7799416cad" target='_blank'>
              Escape From X Chromosome Inactivation as a Driver of Plasmacytoid DC Heterogeneity in Health and Disease
              </a>
            </td>
          <td>
            Franck J. Barrat, J. Guéry
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="
 Introduction:
 Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate immune cells against tumor cells but can cause immune related adverse events such as myocarditis, a serious side effect with up to 40% case fatality rate. We hypothesize that cardiac fibroblasts and cytotoxic T-Cells work in tandem to direct inflammation in the setting of ICI treatment, resulting in myocarditis.


 Methods:
 To study the role of CFBs in ICIM, we first examined fibroblast behavior
 in vivo
 through picrosirius red staining for cardiac fibrosis. We then cultured C57BL/6 murine CFBs and treated them with cardiac serum acquired from a genetic mouse model of ICIM and analyzed
 Cxcl9
 expression by qPCR. Additionally, we stimulated CFBs with media or IFNγ for 24 hours (uCFBs and sCFBs respectively) before co-culturing them with CD8 CXCR3hi T-Cells for 6 hours, after which we analyzed
 Cxcl9
 and
 Cxcl10
 CFB expression by qPCR (Fig 1C) and T-Cell cytotoxicity by flow cytometry (Fig 1D/E). We next examined CD8 T-Cells harvested from C57BL/6 mice treated with combination immunotherapy to induce ICIM via single-cell sequencing to investigate potential axes of T-Cell/CFB crosstalk
 in vivo
 .


 Results:
 Our picrosirius red staining revealed a significant increase in cardiac interstitial and perivascular fibrosis, suggesting that CFBs are inflammatorily active and fibrotic in the context of ICIM (Fig 1A). We demonstrated that treating CFBs with ICIM cardiac serum results in a significant upregulation of CXCL9 by qPCR (Fig 1B). Utilizing our co-culture system, we demonstrated that the presence of CD8 CXCR3hi cytotoxic T-cells significantly increases CXCL9/10 expression compared to both control and IFNγ stimulation, underscoring the importance of T-cell presence in CFB activation (Fig 1C). We also used flow cytometry to confirm the cytotoxic quality of the T-Cells used in our co-culture system (Fig 1D/E). Using single-cell sequencing, we identified a cluster of CXCR3hiVLA4hi CD8 T-Cells from ICI-treated myocarditis mice (Fig 1F.) which are highly cytotoxic compared to other clusters (Fig 1G.), demonstrating that VLA-4:VCAM-1 signaling between T-cells and CFBs may act as a critical driver of cytotoxicity in the heart.


 Conclusions:
 Our findings position cardiac fibroblasts as potentially critical drivers of T-Cell migration and increased cytotoxicity in the context of ICIM, rendering this crosstalk an important direction of study in future of understanding and treating ICIM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f55ccb863bc3d94fa9ccdf7c648353cb039d3ca" target='_blank'>
              Abstract 4369397:
 Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis
              </a>
            </td>
          <td>
            Noah Wagner, Maria Rosaria Vitale, Yin Sun, Maria Zambrano, Abraham L. Bayer, Pilar Alcaide, Javid Moslehi, Han Zhu
          </td>
          <td>2025-11-04</td>
          <td>Circulation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 During a recall immune response, memory B cells differentiate into plasma cells (PCs), which are indispensable for antibody production and humoral immunity. Furthermore, memory B cells proliferate sooner and require less stimulation to differentiate into PCs relative to naïve B cells and can thus be considered ‘poised’. The exact mechanisms explaining this discrepancy remain incompletely understood. Our lab has previously observed that mouse Marginal Zone (MZ) B cells are analogously ‘poised’ to become PCs relative to Follicular (FO) B cells. Transcriptomic analyses have shown that MZ B cells are enriched for hallmark mTORC1 signaling, unfolded protein response (UPR) pathway, and Myc target gene signatures compared to FO B cells, which are all required for PC differentiation. We hypothesized that these same gene signatures would be enriched in human memory B cells. From a cohort of healthy human donors, RNA-sequencing was performed on splenocytes. Indeed, we observe these same hallmark gene signatures enriched in memory B cells along with others involved in the synthesis of ribosomal proteins and translation. These results suggest that human memory B cells are better equipped to produce massive amounts of proteins that involve mTORC1 and Myc activity along with the UPR pathway, all of which are needed for antibody production by PCs. The better we understand PC differentiation mechanisms, the higher potential they can be manipulated for clinically relevant purposes.



 5RO1AI175185-02 - Biochemical Mechanisms for Sustained Humoral Immunity



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dd3d5c1fdc51b8e4993b6ad53828921baab12d6d" target='_blank'>
              Are human memory B cells ‘poised’ to become plasma cells? 4156
              </a>
            </td>
          <td>
            Isaiah Rozich, Brian T. Gaudette, Jennifer Londregan, David Allman
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Activation of the stimulator of interferon genes (STING) modulates cellular responses in a cell-context-dependent manner. Intrinsic IFN-stimulated gene (ISG) expression enhances cellular responses to STING activation. We previously demonstrated that chronic myelomonocytic leukemia (CMML) is characterized by cell-intrinsic ISG upregulation. While STING-activation can mediate hematopoietic stem-cell (HSC) self-renewal or exhaustion and CD14+-monocyte depletion, the distinct effects of acute, short-term and long-term STING activation in distinct clonal hematopoietic populations remains unclear.
 Therefore, we sought to evaluate the effects of STING activation dynamics in normal and CMML HSC and monocyte populations. To do so we first treated BM mononuclear cells (MNCs) from patients (pts) with CMML (n=11) or healthy donors (HDs, n=6) in co-culture with mesenchymal stromal cells with a STING agonist (dazostinag). Given that monocytic lineage is characterized by high expression of cysteine-cysteine chemokine receptor 2 (CCR2), MNCs were also treated with TAK-500, an IgG1 anti-CCR2 antibody linked to a STING agonist payload, to evaluate the specific effects of STING activation in monocyte populations. Dazostinag or TAK-500 depleted total and CCR2+ MNCs from CMML pts but not from HDs Accordingly, STING activation with dazostinag or TAK-500 induced a dose-dependent depletion of monocytic cell lines (MOLM13, THP1) through IRF3 phosphorylation and caspase 3 cleavage. To evaluate if acute STING activation impairs CMML's HSPCs repopulation potential we performed colony-formation studies in BM CD34+ cells from CMML pts (n=8) and observed that TAK-500 and dazostinag impaired myeloid, but not erythroid, colony-formation.
 We previously reported that Vav-KDM6B/Tet2f/f/Vav-Cre (KDM6B/Tet2)mice recapitulate features of CMML. Single-cell RNA-sequencing (scRNA-seq) of MNCs from these mice and control (Vav-cre) mice confirmed myeloid bias and expansion of CCR2+ monocytes that upregulate IFN response genes and inflammatory signals in KDM6B/Tet2 mice. BM CCR2+ monocyte expansion in KDM6B/Tet2 mice was confirmed by flow cytometry. Therefore, to evaluate the effects of acute STING activation in vivo, we treated KDM6B/Tet2 mice with a single dose of TAK-500. TAK-500 enhanced CCR2+ BM cell apoptosis and reduced LSK colony formation capacity. In vivo depletion of MOLM-13 and human CD45+ cells was also observed after acute TAK-500 treatment in xenograft models and in a CMML patient-derived xenograft model, respectively.
 To dissect the effects of short-term STING activation, we then treated KDM6B/Tet2 mice with vehicle or TAK-500 weekly for 3 consecutive weeks. Therapy was associated with peripheral blood monocyte depletion, BM CCR2+ cell depletion, and apoptosis. TAK-500 also induced LSK expansion and depletion of granulomonocytic, common-myeloid, and megakaryocytic/erythroid progenitors. LSK expansion with reduced colony-forming capacity and CD14+ monocyte differentiation was sustained in colony-formation assays. Bulk RNA-sequencing of sorted LSKs demonstrated downregulation of genes involved in RNA metabolism and translation, G1/S transition and neutrophil degranulation, suggesting reduced cell activity and differentiation. scRNA-seq of BM MNCs after 3 weeks of therapy confirmed depletion of CCR2+ cells, myelomonocytic precursors and monocyte populations with TAK-500 but not with vehicle. STING activation induced type I IFN gene expression (e.g Irf7) in monocytes and splenic extramedullary hematopoiesis. Analysis of cell-cell communication networks revealed increased number of interactions involved in cell migration, inflammation and immune interactions between monocyte and other cell types.
 To compare the effects of short vs long-term STING activation, we treated control and KDM6B/Tet2 mice with TAK-500 over a period of 14 weeks. In contrast to short-term STING activation, long-term TAK-500 exposure was not associated with CCR2+ cell depletion, changes in LSK or progenitor populations or transformation in KDM6B/Tet2 mice. scRNA-seq of MNCs revealed decreased expression of inflammatory genes on monocyte and progenitor populations compared to short-term exposure which suggests cell-adaptive responses to overcome inflammatory and cell death programs associated with acute STING activation.Together, these data highlight the complex effects of STING activation dynamics in distinct hematopoietic populations and their role in CMML pathophysiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d404567ac411e598fe7813e54939096a5ebec9" target='_blank'>
              Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
              </a>
            </td>
          <td>
            Yue Wei, Xiaoping Su, Ziyi Li, S. Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alexander Parent, N. Lineberry, Siddha Kasar, G. Garcia-Manero, G. Montalban-Bravo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>141</td>
        </tr>

        <tr id="


 CD8 T cells are a critical component of the immune response to infections as well as in prevention and restriction of cancer growth. Across multiple solid cancer types, tumor infiltration of CD8 T cells is associated with improved patient survival. CD8 T cell cytotoxicity and cytokine production have been characterized as the primary mechanisms by which these cells execute their immune function. However, basal cell motility, defined as random walk and exploratory spread, is an essential and underappreciated aspect of the CD8 T cell-mediated antitumor response. Cell motility enables effector CD8 T cells to search for and reach their cell targets within a solid tumor microenvironment. Here, we investigate the impact of IL-21 on effector CD8 T cell motility. We show that compared to effector CD8 T cells expanded in the presence of IL-2 alone, those expanded in IL-2 and IL-21 exhibit increased cell motility in vitro and in vivo. We also show that IL-21 enhances mitochondrial respiration and mitochondrial calcium in effector CD8 T cells. Our data suggests that increased mitochondrial calcium and mitochondrial ATP promote CD8 T cell motility through IL-21-mediated STAT3 activity. Therefore, IL-21 plays an important role in effector CD8 T cell mitochondrial fitness, cytoskeleton stiffness, and cell motility, which can be leveraged in the design of adoptive T cell therapies for the treatment of solid tumors.



 Supported by NIH R01 CA260909; T32AI007405.



 Cytokines and Chemokines and Their Receptors (CCR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c85e17d7c962d1daada79818491cc536bfb732e9" target='_blank'>
              Enhancement of effector CD8 T cell motility by IL-21 through STAT3 4131
              </a>
            </td>
          <td>
            Maureen Hoen Rauhut, Fahiima Abdullahi, Felipe Valença-Pereira, Mercedes Rincon
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 The treatment landscape of diffuse large B-cell lymphoma (DLBCL) has progressed with the emergence of immune-cell therapies (ICTs), such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. However, many patients still remain incurable despite these innovative options. Treatment resistance in DLBCL is associated with the immunosuppressive tumor microenvironment (TME), and myeloid-derived suppressor cells (MDSCs) play a crucial role in contributing to it. Furthermore, an increase in MDSCs has been linked to disease progression, poor prognosis, and reduced effectiveness of ICTs. Therefore, understanding how DLBCL cells promote MDSC development is essential for overcoming treatment resistance to ICTs. To address this issue, in this study, we investigated how DLBCL cells induce monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs) using an indirect co-culture system and traced the molecular changes involved. Four human DLBCL-derived cell lines (HDBCLs), including two double-expressor HDBCLs (KPUM-UH1 and KPUM-MS3) (Sasaki N, Exp Hematol 2011) and two activated B-cell-like HDBCLs (HBL1 and DLBCL2), were used. PBMCs from healthy donors were indirectly co-cultured with HDBCLs for 96 hours, and flow cytometry was used to analyze PBMCs for the induction of M-MDSCs displaying the CD14+/HLA-DR-/low phenotype. Total RNA was extracted from the CD33+ myeloid fraction of PBMCs after co-culture, and gene expression profiles (GEP) were analyzed using microarray analysis. Consequently, we first demonstrated that all four HDBCLs tested were effective in inducing CD14+/HLA-DR-/low myeloid cells from normal PBMCs within 96 hours of co-culture. The induced CD14+/HLA-DR-/low myeloid cells were also shown to be potent in inhibiting T cell proliferation, confirming these cells as M-MDSCs both phenotypically and functionally. The ability to induce M-MDSCs was highest in DLBCL2, followed by HBL1, while KPUM-UH1 and KPUM-MS3 showed modest M-MDSC-inducing capabilities. Based on the finding that M-MDSCs were induced through indirect co-culture with HDBCLs, we screened soluble factors in the conditioned medium (CM) of HDBCLs secreted by these cells using cytokine arrays, and found that all four HDBCLs secreted MIF. Additionally, the results showed that DLBCL2 cells produced high levels of interleukin-10 (IL-10), while HBL1 cells secreted IL-10 at low levels, and KPUM-UH1 and KPUM-MS3 cells did not produce detectable IL-10. We then examined the functional roles of MIF and IL-10 in the induction of M-MDSCs by HDBCLs. Interestingly, the MIF inhibitor 4-IPP greatly reduced M-MDSC induction by all four HDBCLs, and exposure to recombinant (r) MIF alone had minimal ability to induce M-MDSCs from normal PBMCs, indicating that MIF plays an essential but preparatory role in M-MDSC induction. Conversely, blocking IL-10 with a neutralizing antibody significantly decreased M-MDSC induction from PBMCs by IL-10-secreting HDBCLs, and adding rIL-10 increased the M-MDSC-inducing effect of IL-10-non-secreting HDBCLs, indicating that IL-10 plays a more facilitative role in inducing M-MDSCs. To understand the molecular regulation in PBMCs during the induction of M-MDSC by the co-existence with HDBCLs, we examined gene expression changes in CD33+ myeloid cells at 24, 48, and 96 hours after co-culturing with HDBCLs. We also examined the molecular dynamics in co-culture with non-IL-10-secreting cell lines that occurred after 96 hours of rIL-10 treatment. Results from gene set enrichment analysis revealed that gene sets associated with inflammatory response and tumor necrosis factor-alpha (TNF-α) signaling, as well as inflammatory molecules such as IL-1α, were upregulated 24 hours after co-culture. However, these upregulated gene sets became less expressed after 48 hours and eventually were downregulated after 96 hours. Additionally, the downregulation of inflammatory response and TNF-α signaling was further amplified by rIL-10. In conclusion, our study demonstrated that the multistep process of M-MDSC induction from PBMCs, triggered by HDBCLs, begins with an initial transient hyper-inflammatory phase induced by MIF and transitions into a post-inflammatory immunosuppressive phase accelerated by IL-10. Our findings suggest that targeting phase-specific cytokines and related molecules could reduce the induction, maturation, and proliferation of M-MDSCs, ultimately enhancing therapeutic outcomes, especially in ICTs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ebe1659b4ff0741b0dd9144d5311758dfae1768" target='_blank'>
              Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells
              </a>
            </td>
          <td>
            Yu Inoue, Y. Shimura, Yui Niiyama-Uchibori, Shotaro Chinen, Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Immune Aplastic Anemia (AA) is an autoimmune disease where hematopoietic stem and progenitor cells (HSPC) are destroyed by cytotoxic CD8+ T cells, resulting in peripheral cytopenias, i.e. anemia, thrombocytopenia and neutropenia. Most compelling evidence that HSPC destruction is immune-mediated is that two-thirds of severe AA patients demonstrate hematologic improvement in response to immunosuppressive therapy consisting of anti-thymocyte globulin and cyclosporin A. Interferon γ (IFNγ) and tumor necrosis factor α (TNFα) have both been implicated as critical effector molecules involved in the destruction of bone marrow HSPCs in AA. Furthermore, mRNA expression of the inflammatory chemokine receptor CXCR3 and the chemokine CCL20, a ligand of CCR6, has been shown to be elevated in peripheral blood and bone marrow mononuclear cells, suggesting a role for T helper/cytotoxic (Th/c) 1 and Th/c17 cells in the pathobiology of AA.



 To further elucidate the pathobiology of AA, we conducted a comprehensive multiproteomic analysis of adult AA patients eligible for bone marrow transplant ([BMT]; n=20; samples pre-BMT) and matched healthy controls (n=20). We performed plasma proteomic analyses using Olink and conducted high-dimensional immunophenotyping by flow cytometry using peripheral blood mononuclear cells (PBMCs).



 Using Olink proteomic analysis, we observed that, relative to healthy controls, plasma from AA patients exhibited significantly higher levels of several hematopoietic growth factors, including thrombopoietin (TPO), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and Fms-like tyrosine kinase 3 ligand (FLT3LG), indicating that an AA disease signature is reflected in circulation. Furthermore, we observed that AA patients had significant (Bonferroni corrected) elevations in interleukin 15 (IL15), a cytokine that plays a crucial role in T cell activation and effector functions. Thus, we looked at other T cell-associated molecules and observed trends towards elevations in several other cytokines in plasma of AA patients, including IFNγ, IL17A, IL17F, and interleukin 2 receptor α (IL2Rα). Interestingly, there was also a trend towards an increase in plasma CCL20 in AA patients, as previously reported.
 Using high-dimensional flow cytometry immunophenotyping on PBMCs, we observed an increase in the percentage of circulating T cells, both CD4+ and CD8+ T cells, in PBMCs from AA patients. These T cells exhibited an activated phenotype with increased surface expression of the costimulatory receptor 4-1BB. Profiling of both CD4+ and CD8+ T cell subsets revealed a T helper 17 (Th17) and T cytotoxic 1 (Tc1) cell enrichment with increased proportions in overall Th17 (both Th1.17 and Th17.22 cells) and Tc1 cells (both Tc1 and Tc1.17 cells).
 While antigen presentation plays a critical role in initiating immune responses in autoimmune diseases, little is known about the role of antigen presenting cells (APCs) in AA pathobiology. Here, we showed that, while the percentage of professional APCs, i.e., B cells, monocytes and dendritic cells, was reduced in blood of AA patients, these cells presented an activated phenotype characterized by significant upregulation of the costimulatory receptor 4-1BB at their surface. In addition, B cells from AA patients exhibited higher surface expression of the inflammatory chemokine receptor CCR6 and the antigen presentation molecule HLA-DR, while monocytes expressed higher level of CCR7, a chemokine receptor essential for cell migration to lymph nodes.Conclusion: In this study, we confirmed that AA is characterized by significant increases in several hematopoietic growth factors in the periphery, which may reflect compensatory mechanisms that counterbalance the lack of blood cell production in the bone marrow. Furthermore, we demonstrated that AA is an autoimmune disease characterized by an inflammatory phenotype biased towards a Th/c1.17 immune response and increased circulating Th1 and Th17 cytokines (e.g. IFNγ and IL17A/F). Finally, we showed that multiple APCs may participate in antigen presentation in AA, as both B cells and monocytes/DCs exhibit an activated phenotype with increased expression of chemokine receptors and major histocompatibility complex class II molecules. Overall, our data suggest that broad APC activation and pathogenic Th/c1.17 immune responses contribute to AA pathobiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc62d3214c4189d70d8471303aff50affc5b9a9f" target='_blank'>
              Comprehensive multiproteomic analysis reveals an inflammatory phenotype in immune aplastic anemia characterized by broad activation of antigen presenting cells and t helper/cytotoxic 1.17 immune responses
              </a>
            </td>
          <td>
            audrey le floch-ramondou, Julie Horowitz, Kirsten Nagashima, Maria Matthaiakaki Panagiotaki, Erica Chio, Shane McCarthy, Kerry Casey, S. Hamon, Thomas Norton, L. Perlee, Andrea T Hooper, J. Orengo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 We are witnessing a significant increase in complex T cell-mediated immune disorders, such as food allergies and autoimmune disease. This trend suggests that the activation threshold for T cells may be altered, and understanding how to modulate this threshold has profound implications for disease treatment. In this study, we demonstrate that the effector program of CD8? T cells (including naïve, circulating memory, and tissue-resident cells) induced by TCR and cytokine stimulation is regulated by the class II histone deacetylase, HDAC5. HDAC5 exhibits little to no deacetylase activity against histone tails, but can function in the cytoplasm as a scaffolding protein or to directly deacetylate protein targets. Using small interfering RNA (siRNA) in cell lines of primary human CD8+ cytotoxic intraepithelial lymphocytes (IE-CTLs), we show that the loss of HDAC5 decreases their activation. Furthermore, inhibiting HDAC5 activity with the HDAC4/5 inhibitor LMK235 reduces the activation potential of ex vivo isolated human intestinal IE-CTLs following stimulation, suggesting that HDAC5 enzymatic activity is required for this effect. Finally, our data indicate that HDAC5 inhibition broadly impacts CD8? T cell activation, including in circulating memory and naïve subsets. This work identifies HDAC5 as a critical enzyme regulating the activation of CD8? T cells and highlights the potential of targeting HDAC5 to modulate CD8? T cell activation thresholds in inflammatory disorders.



 Supported by NIH BIBIB 2 T32 EB 9412; NSF Graduate Research Fellowship Program; University of Chicago Celiac Disease Research Center.



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3f63a425ec70d967412fb047c150bfd3ab601d0" target='_blank'>
              HDAC5 regulates the activation of cytotoxic CD8+ T cells 4190
              </a>
            </td>
          <td>
            Megan Borregard, C. Ciszewski, Yandong Zhang, Hening Lin, B. Jabri
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="


 T cell-engaging bispecific antibodies (TCBs) depleting B cell subsets are promising therapeutics for cancer and autoimmune diseases, with several approved or in development. However, an unavoidable consequence is immunosuppression in already vulnerable patients. Depleting B cells compromises the ability to fight infections and vaccine efficacy. These risks vary with underlying disease, effects on off-target cell populations and the TCB target. Differentiating drug candidates’ secondary TCB effects is key in drug development, but preclinical models may not fully capture complex B cell biology. We employed a multimodal systems immunology approach of two human in-vitro systems: immune organoids capturing productive germinal center responses, and an immunocompetent bone marrow model with B precursor- and differentiated plasma cells. We integrated data from high-dimensional flow cytometry, single cell RNA- and CITE-sequencing, to assess the consequences of TCB-mediated immune responses across different tissues. This allowed us to capture a differential off-tumor B cell subset toxicity of TCBs directed against two therapeutically validated TCB targets, in line with the reported clinical infection risk and B cell depletion that diverge between both. Overall, this translational work shows the value of human in-vitro approaches as a preclinical evaluation for immunosuppression, by accurately capturing complex human immune biology and therapeutic activity of candidate molecules.



 Translational and Interventional Immunology (TI)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ab71e60522c5a275a95f316de0a2c67184842200" target='_blank'>
              Translating immunosuppressive risks of T-cell bispecifics using human in vitro models and systems immunology 9247
              </a>
            </td>
          <td>
            Lea Schroer, Jenna M. Kastenschmidt, Michael Bscheider, Nick Corr, Susanne Fischer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB). Several alterations in the BM microenvironment have been linked to AML onset and progression, some of which affect the immune system and promote tumor evasion. Genetic alterations also contribute to these processes, including overexpression of the MN1 gene, which is addressed in this study. MN1 overexpression is associated with a more aggressive leukemic phenotype and therapeutic resistance. Among the pathological findings in the leukemic BM microenvironment, the relative increase in AML-associated macrophages (AAMs) appears to support AML progression. AAMs display a phenotype similar to that of healthy M2-like macrophages and are thus linked to anti-inflammatory and immunosuppressive activity. In this context, therapeutic approaches aimed at reprogramming AAMs toward a more inflammatory and antitumoral profile, resembling M1-like macrophages, have been investigated. This study aimed to evaluate the immunomodulatory effects of BPI-2358, a tubulin polymerization inhibitor and JNK pathway activator, on AAMs in AML models driven by MN1 overexpression. Human PB-derived M2 macrophages were treated with BPI-2358 (0.125–0.5 µM) for 48 hours. Immunophenotyping (CD80, CD86, CD206, CD163) and cytokine analysis (TNF-α, IL-1β, TGF-β) revealed a shift toward a pro-inflammatory profile. Our findings showed that BPI-2358 treatment had a significant impact on marker expression, leading to an upregulation of CD86 and a downregulation of CD163 in human samples. Additionally, we detected elevated levels of pro-inflammatory cytokines, including IL-1β and TNF-α, along with a reduction in TGF-β secretion. Similarly, murine BM-derived M2 macrophages treated under the same conditions showed increased expression of M1-related genes (Cd80, Tnf-α, Nos2) and downregulation of Arg1, a classical M2 marker, by qRT-PCR. A phagocytosis assay was performed using M2-polarized murine macrophages treated with BPI-2358 (0.5 μM) and MN1-GFP⁺ murine AML cells. Treated macrophages exhibited an increased phagocytic capacity compared to untreated controls. A cell proliferation assay was performed by co-culturing BM-derived M2 murine macrophages, pre-treated with BPI-2358 (0.5 μM), with MN1-GFP⁺ murine AML cells at a 1:1 ratio. Cell growth was monitored over a 10-day period by performing regular cell counts. Notably, a significant decrease in MN1 cell proliferation was observed on days 3 and 4 in co-cultures with BPI-2358-treated macrophages, indicating that the treatment impaired leukemic cell expansion. Moreover, exposure to an AML-conditioned microenvironment induced a tolerogenic macrophage profile in vitro, which was partially reversed by treatment, highlighting the functional plasticity of these cells. Transcriptomic analysis by RNA-seq revealed differential gene expression and pathway enrichment consistent with macrophage reprogramming. Transcriptomic analysis showed that BPI-2358 upregulated 4,829 genes, including those involved in tissue damage response, tissue remodelling, and the pro-inflammatory cytokine Il1b. The treatment also significantly suppressed the IL-6/JAK/STAT3 pathway, a key driver of the immunosuppressive M2 phenotype and tumor immune evasion. Ex vivo cytotoxicity was assessed in a panel of primary AML samples (n=25) treated with BPI-2358 (0.125–0.5 µM) for 72 hours. Flow cytometry was used to evaluate viability of leukemic blasts (CD34⁺ or CD117⁺ for CD34⁻ AMLs) and macrophages (CD34⁻ or CD117⁻ HLA-DR⁺ CD14⁺) using Annexin V/DAPI staining and TMRE for mitochondrial membrane potential. Finally, the in vivo efficacy of BPI-2358 was assessed in an MN1-driven AML mouse model (MN1-GFP⁺). Mice received BPI-2358 (7.5 mg/kg IP, daily), and flow cytometry analysis of the BM showed a reduction in leukemic engraftment. The treatment did not impact the animals' body weight, suggesting minimal systemic toxicity. A significant decrease in the frequency of circulating MN1⁺ cells was observed, along with a marked reduction in MN1⁺ cell infiltration in the spleen. This was further supported by a significant decrease in spleen weight in the BPI-2358-treated group. These findings reinforce the potential of macrophage reprogramming as a complementary strategy in AML treatment, especially in molecularly high-risk subtypes such as those associated with MN1 overexpression.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7341436505bbad9e3856fea1f022bb194207dcdb" target='_blank'>
              BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo
              </a>
            </td>
          <td>
            L. Pinheiro, I. Weinhäuser, D. Pereira-Martins, Katherine Hampton, Annalisa Altera, D. Fowler-Shorten, Matthew Markham, A. Polski-Delve, Tabitha Bartlett, C. Hellmich, Luíse A A Simões, Cleide Lúcia Araujo, Rita De Cássia Cavaglieri Medeiros, L. Quek, G. Huls, J. Schuringa, S. Rushworth, E. Rego
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="
 Brain metastases (BM) from lung adenocarcinoma represent a formidable clinical challenge due to limited therapeutic efficacy. To gain insight into complex tumor microenvironment (TME) of BM, we analyzed single-cell RNA-sequencing data comprising 66,769 cells from primary tumors (PTs; 44,355 cells) and matched BM lesions (22,414 cells). Our analysis revealed a profound shift in cellular composition during metastasis: while T cells predominated PT (44.12%), tumor cells became the most abundant population in BM (55.17%), with corresponding reductions in T cells (27.57%) and macrophages (19.3%). Cell–cell communication analysis identified fibroblasts as central mediators in both PT and BM, with a transition from collagen signaling in PT to thrombospondin signaling in BM, facilitating interactions with tumor cells, B cells, and oligodendrocytes. Ingenuity Pathway Analysis revealed enrichment of collagen-related genes in fibroblasts (MFAP4, COL15A1, FBLN1, FBLN2) and Th1/Th2 pathway genes in T cells (IKZF1, SH2D1A, RASGRP1, SKAP1). Subclustering uncovered seven distinct fibroblasts subpopulations and a notable shift from PT-enriched C0 to BM-enriched C1, suggesting dynamic phenotypic adaptation. Pseudotime trajectory analysis further clarified fibroblasts differentiation states. T-cell subclustering revealed a significant increase in immunosuppressive regulatory T cells (84.1%) and proliferating CD4+ T cells (10.5%) in BM, highlighting mechanisms of immune evasion. COL15A1 expression correlated with poor patient survival and emerged as a promising therapeutic candidate, showing increased sensitivity to Dabrafenib, Trametinib, Piperlongumine, Cabozantinib, Staurosporine, and Vemurafenib. Additional gene drug associations were observed, with FBLN1, RASGRP1, MFAP4, SH2D1A, and IKZF1 linked to potential sensitivity to Erlotinib, Afatinib, Fluorouracil, and Brefeldin A. These findings provide a high-resolution map of the BM TME and highlight COL15A1 and related pathways as potential targets for precision therapy in patients with BM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc3a5b204d80d9cd5d66d31480f9cf9dd3274795" target='_blank'>
              TMIC-44. Fibroblast reprogramming and immune evasion define the tumor niche in brain metastases
              </a>
            </td>
          <td>
            Sanskriti Dey, J. Chuang, Chih-Yang Wang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b11f53599c3647080eae65b0a4800ec464539ab" target='_blank'>
              Single-Cell and TCR Profiling across Tissues Reveals GZMKâºCD8âº T Cells as Drivers of Fibrosis in IPF
              </a>
            </td>
          <td>
            B. Yue, S. Jing, Q. Li, G. Xie, , T. Yan, G. Zhu, B. Huang, J. Zhao, X. Yang, J. Huang, P. Yin, Q. Yao, H. Yang, , J. Yang, M. Huang
          </td>
          <td>2025-12-22</td>
          <td>None</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exhausted T cells, marked by sustained expression of inhibitory receptors such as PD-1 and impaired effector function. These exhausted T cells represent a major barrier to durable anti-tumor immunity and effective immunotherapeutic intervention. To address this, we explored PD1-IL2v, an engineered immunocytokine designed to selectively stimulate PD-1⁺ cells with IL-2 signaling while minimizing activation of regulatory T cells. Using both the immunogenic GL261 and the immune checkpoint-resistant SB28 murine models of GBM, we administered PD1-IL2v either systemically or directly into the tumor. Flow cytometry was employed to assess changes in tumor-infiltrating lymphocytes, with particular focus on exhaustion and effector phenotypes. Notably, local administration of PD1-IL2v, but not systemic delivery, effectively reactivated CD8⁺ T cells within the tumor microenvironment. PD1-IL2v treated mice exhibited enhanced cytokine production, increased proliferation, and restoration of cytotoxic activity in T cells. Phenotypic profiling of tumor infiltrating lymphocytes (TILs) revealed an expansion of a stem-like subset of exhausted T cells (PD-1⁺TCF1⁺), alongside the emergence of a novel, differentiated population with superior effector functions, termed “better-effector” T cells. Therapeutic intervention with PD1-IL2v led to complete tumor rejection in a subset of animals, and increased infiltration of functional T cells into the tumor core. Our findings underscore T cell exhaustion as an untapped reservoir of tumor-reactive T cells that can be therapeutically reinvigorated using PD1-IL2v. This approach not only restores anti-tumor immunity but also induces superior effector populations capable of driving tumor regression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d2a360e4ecb23a3988292b555a7155b5788a697" target='_blank'>
              IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
              </a>
            </td>
          <td>
            U. Salazar, B. Taskoparan, Sereina Deplazes, V. Nicolini, Laura Codarri-Deak, H. Okada, C. Klein, Johannes vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Objectives: Vaccination by a nonmucosal route to elicit CD8+ T cell-mediated mucosal immunity against respiratory infections presents a great challenge for the development of an effective vaccine or immunization strategy. This study aimed to explore a new strategy to address the challenge. Methods: To test this strategy, s.c. vaccinated mice were administered i.p. with tanshinone I (TSN1), a main bioactive compound found in the root of Salvia miltiorrhiza, and CD8+ T cell responses were analyzed using flow cytometry. The differentiating effects of TSN1 on CD8+ T cells from naïve mice were also evaluated in an in vitro setting. Results: Nonmucosal vaccination and administration of TSN1 induce pulmonary-resident vaccine-specific memory CD8+ T cells through increased lung-specific recruitment and retention. The improved memory response appears to result from the impact of TSN1 introduced during the primary immunization phase. Given a specific range of varying concentrations of this natural compound, it exhibits a differential effect on the memory differentiation of CD8+ T cells in the process of being activated. Effector memory T cells expand robustly relative to central memory T cells, and both memory subsets have additionally increased expression of CD44 and CD69. With more potent cytolytic activity, CD8+ Trm expressing CD69 particularly predominate the population lacking the CD69 expression in the lungs of TSN1-treated mice. Conclusions: Our study suggests that TSN1 as an important natural compound may hold great promise for novel approaches to the design and development of a more practical and efficient vaccination strategy to generate effective respiratory mucosal immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d479bdad9d5bb68029b830878c39fe1902b2c55" target='_blank'>
              Tanshinone I Enhances the Pulmonary Immune Response of CD8+ T Cells by Promoting Memory Differentiation
              </a>
            </td>
          <td>
            Manqiu Wang, Honglei Wang, Yaling Wang, Changxing Gao, Leqi Fan, Jing Li, Qing Zhu
          </td>
          <td>2025-11-01</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Background Cellular immunotherapy has revolutionized cancer treatment. Yet its efficacy in acute myeloid leukemia (AML) remains limited due to an immunosuppressive tumor microenvironment (TME) often characterized by deficient immune-stimulatory cytokines and elevated immunosuppressive metabolites. Adenosine (Ado), a key inhibitor is degraded by the non-redundant enzyme adenosine deaminase (ADA), which converts Ado into the immune-stimulatory inosine (Ino). IL-12 is a potent cytokine that strongly boosts immune cells, but its systemic toxicity limits clinical use. To address this, we engineered tumor-homing, non-pathogenic Escherichia coli (E. coli) to co-display surface-tethered IL-12 and ADA, enabling localized cytokine delivery and metabolic reprogramming. We hypothesized that this dual strategy efficiently reprograms the immunosuppressive niche in AML, thereby unlocking robust local NK (and T cell) anti-leukemic immunity.
 Method Non-pathogenic E. coli K12 DH5α were engineered to surface-display murine and human IL-12, ADA, or IL-12+ADA fusion using optimized outer membrane scaffolds with FLAG tags using an approach in our recently published paper (Yang et al, Nature Biotechnology 2024). Expression was induced with rhamnose and confirmed by flow cytometry. IL-12 bioactivity was validated via HEK-Blue reporter assay. ADA kinetics and activity were assessed via LC-MS and colorimetric assays. NK cells were co-cultured for 24h with E. coli displaying ADA, IL-12, ADA+IL-12, or scaffold control followed by multicolor flow cytometry to assess Ado-signaling (A2AR, CD73, CD39, CD26), surface markers (i.e., CD25, NKG2D, NKp30), and AML-directed cytotoxicity (Zombie-NIR, IFNg, TNFα) against the AML targets NOMO1 and OCI-AML3. To model TME metabolism, cells were treated with 1mM Ado, Ino or PBS. In-vivo efficacy was tested in a immunocompetent B16-F10 melanoma model and BALB/c mice bearing GFP⁺/NanoLuc⁺ WEHI-3 AML cells. Leukemic burden (bioluminescence imaging, blood), weight, and survival were monitored. Bacterial distribution was assessed by CFU assays in relevant organs.
 Results Engineered E. coli co-displaying IL-12 and ADA showed robust FLAG-tagged surface expression (>80%) with significant IL-12 bioactivity (OD650, 0.9 vs. 0.2, p<.001). Murine ADA displayed by YiaT181 showed highest enzymatic activity (Km=0.05, Vmax=53µmol/min), fully converting Ado to Ino within 4h. NK cells cocultured with IL-12 displaying E. coli showed strong upregulation of key activation markers compared to scaffold control (CD25, 56 vs. 25% and NKp30, 68 vs. 35%, p<.001), leading to a ≥3.4-fold greater AML-directed cytotoxicity and IFNγ production. Importantly, rhIL-12 (50ng/ml) increased expression of the Ado-generating metabolic checkpoint CD73 (2 to 9%, p=.003) and Ado receptor A2AR on NK cells (31 to 51%, p=.001), indicating increased Ado susceptibility. Ado exposure reduced AML-directed killing by ~50% (p<.001) and NK cell activation (NKp30 expression was 33 vs. 18%, p=.003). ADA-expressing E. coli restored NK cell immunity and AML lysis in-vitro (55 vs. 15%, p<.001). Co-display of IL-12 and murine ADA maintained full NK effector function under Ado-rich conditions and enhanced AML-targeted lysis (15 vs. 56%, p<0.01). In-vivo, i.v. delivery of E. coli expressing ADA, IL-12, or ADA+IL12 fusion was well-tolerated and demonstrated potent antileukemic activity in immunocompetent WEHI-3 AML models. Substantial tumor control led to prolonged survival in the IL-12+ADA group (2 of 3 alive at d29, median survival not reached) vs a median of 10 days in control mice. Robust tumor control was reached in the IL-12 (26d) and ADA (17d) group. Post-mortem analysis of mice revealed unprecedented tumor-guided bacterial migration to the bone marrow, a phenomenon not previously reported. ADA-engineered bacteria accumulated up to 4x105 CFU and IL-12 displaying bacteria up to 3x104 CFU in the bone marrow. Intratumoral delivery of IL12+ADA-engineered E. coli induced complete tumor regression and 100% survival in a B16-F10 melanoma model, with tumor rechallenge confirming durable antitumor immunity, suggesting immune memory and long-term immune protection.
 Conclusion Engineered nonpathogenic E. coli co-displaying IL-12 and ADA effectively reprogram the AML TME, enhance NK cell activation, and drive sustained anti-tumor responses. This live microbial platform offers a safe, localized, and versatile immunotherapy strategy applicable to both hematologic and solid tumors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04c11cfcf5a3539fa2c39d0839134cb7fc2116bd" target='_blank'>
              Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
              </a>
            </td>
          <td>
            Stephanie Sendker, Shaobo Yang, Anna Clara Bader, Alice Chen, Eden Bobilev, Ashley Hu, Xingyu Deng, Fuguo Liu, Veronica Hui, Maily Nguyen, Andreia Maia, Sara Piccinelli, Kerim Berkay Aslan, Fabian Göllner, A. Ali, Rémy Duléry, Hetal Nath, Daniel Chen, Mounica Vallurupalli, Andrew Lu, Stephanie Chamberlain, Tereza Kochs, Nathalie Javidi-Sharifi, Michal Sheffer, Roman Shapiro, Andrew Lane, Robert J. Soiffer, Mubin Tarannum, Jerome Ritz, R. Romee
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 A durable T cell immunity against cancer is dependent on a continually refilling of effector CD8+ T cells. Thymic output has been correlated with favorable prognosis in cancer patients of advanced ages, suggesting thymus is an important source for refilling T cells that are capable of controlling cancer progression in the periphery. However, it remains unclear how PD-1 signals regulate the cytotoxic potential of CD8+ T cells in thymus before they egress to the periphery to establish durable anti-tumor immunity. Here we report PD-1 signaling prelimits thymic single positive (SP) CD8+ T cells to acquire cytotoxic potential by downregulating Gzmb and Nkg7, which are required for CD8+ T cell-mediated cytotoxicity. Unexpectedly, we found the absence of Pdcd1 also led to upregulation of Tox and Tim3 in thymic SP CD8+ T cells, thereby pre-programming these cells for exhaustion within the tumor. Thus, the absence of PD-1 signals in CD8+ T cells only partially delayed tumor growth in peripheral tissues. To improve therapeutic effects of PD-1 inhibition, we observed that tumor growth in CD8-specific Pdcd1 conditional knockout mice was further suppressed by treatment with a PD-L1 antibody that blocks PD-L1 and CD80 interaction. Our results imply that PD-1 inhibition promotes the expansion of effector cytotoxic CD8+ T cells but also retains T cell exhaustion potential, which can be mitigated by PD-L1 blockade that allows more CD80 to provide costimulatory signals to T cells via CD28.



 NCI R01CA256927 NCI R01CA261932 NCI P30CA15083



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb1a412c0952a008bc31b083b4dec69b7fbe6657" target='_blank'>
              PD-1 prelimits both cytotoxic and exhaustion potential in thymic CD8+ T cells and affects sustaining peripheral tumor immunity 2875
              </a>
            </td>
          <td>
            Zhiming Mao, Jacob B Hirdler, Cindy Liu, M. Maynes, Joanina K. Gicobi, Michelle A Hsu, Emilia R Dellacecca, Wenjing Zhang, Fabrice Lucien-Matteoni, Haidong Dong
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Despite significant advancements in targeted therapies and immunotherapies, a substantial proportion of non-small cell lung cancer (NSCLC) patients remain unresponsive to treatment. One contributing factor is tumor-induced immunosuppression, which impairs effective T cell responses. Natural killer (NK) cells, while playing a pivotal role in antitumor immunity, have been shown to negatively regulate adaptive immune responses in various contexts. In this study, we characterized the phenotype of NK cells within the NSCLC microenvironment and investigated their potential contribution to immune suppression. CD3- CD56+ NK cells were isolated from tumor resection specimens and profiled using single-cell RNA sequencing and CITE-seq. Identified NK cell clusters were subsequently quantified in tumor-infiltrating lymphocyte (TIL) cultures exhibiting different expansion rates. Our analyses identified a tumor-specific NK cell subset associated with reduced recurrence-free survival (RFS). This subset was preferentially enriched in TIL cultures with low expansion rates compared to those with high expansion rates, suggesting a potential role in limiting T cell proliferation. Future investigations will focus on confirming the regulatory role of this NK cell subset and elucidating the mechanisms underlying its suppressive function.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96876b361473daba1aa036fd63568ae3002f5c55" target='_blank'>
              Immunoregulatory NK cells in non small cell lung cancer (NSCLC) 3221
              </a>
            </td>
          <td>
            Jules Sotty, D. Chung, Nicolas Jacquelot, Jehan Vakharia, Azin Sayad, Ben X Wang, P. Ohashi
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Acute graft-versus-host disease (aGVHD) is one of the most severe complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily caused by donor-derived alloreactive T cells that attack recipient tissues, leading to systemic inflammation and multi-organ damage. While the effector role of donor T cells is well recognized, their developmental origin, activation dynamics, and persistence remain poorly understood. The thymus is the central organ for T-cell development and immune tolerance, yet its role in aGVHD pathogenesis remains underexplored.
 In preliminary experiments using a murine aGVHD model, we observed marked thymic atrophy, along with a significant reduction in total thymocyte numbers. Flow cytometric analysis revealed a near-complete absence of CD4⁺CD8⁺ double-positive (DP) thymocytes, with only a small population of single-positive (SP) CD4⁺ and CD8⁺ cells remaining. These findings suggest that thymic architecture and function are severely compromised during aGVHD, potentially interfering with both positive and negative selection processes. This impairment may lead to the premature release of incompletely developed T cells into the peripheral circulation.
 Unexpectedly, we identified a substantial accumulation of DP T cells in peripheral target organs, including the colon, liver, and skin, in aGVHD mice. These cells were virtually absent in bone marrow–transplanted, T cell–depleted (BM-TCD) controls. Given that DP cells are typically restricted to the thymus and are rarely found in the periphery under normal conditions, their presence in peripheral tissues suggests a pathological process of premature egress from the thymus due to structural and functional failure. This observation raised the hypothesis that these peripheral DP cells may be developmentally abnormal and functionally involved in mediating tissue injury.
 To investigate the biological properties of these DP cells, we performed both single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic profiling of three representative tissues in aGVHD mice: the colon (a representative target organ), the thymus (the central lymphoid organ), and the spleen (a peripheral lymphoid organ). The aGVHD model was established using GFP-labeled C57BL/6 donor cells transplanted into lethally irradiated BALB/c recipients. The BM-TCD group served as the negative control.
 scRNA-seq analysis revealed that peripheral DP cells in the aGVHD colon expressed high levels of cell cycle–related genes such as Birc5, Cdca8, Pclaf, and Mki67, indicating strong proliferative potential. In contrast, expression of lineage-defining transcription factors and effector molecules typically associated with SP T cells, including Cd83, Tnfsf8, and Gata3, was minimal. These data suggest that the peripheral DP cells are in a non-canonical, undifferentiated state distinct from conventional effector T cells. Spatial transcriptomic data confirmed that these DP cells were enriched in subepithelial regions of the colon, which colocalized with areas of epithelial disruption and immune infiltration, implicating them in direct tissue damage.
 We further compared DP cells from the thymus of BM-TCD mice with splenic DP cells from aGVHD mice. Thymic DP cells exhibited high expression of normal developmental markers including Rag1, Rag2, Rorc, Ccr9, and Sox4, consistent with ongoing T-cell maturation within a healthy thymic environment. In contrast, splenic DP cells from aGVHD mice expressed elevated levels of activation and cytotoxicity-associated genes such as Gzmb, Il2rb, and Cd38, suggesting that they had transitioned into an activated and potentially pathogenic state. This phenotypic shift supports the concept that the inflammatory milieu of aGVHD promotes extrathymic activation and reprogramming of aberrantly exported DP cells.
 Our findings reveal that thymic dysfunction in aGVHD permits the release of immature DP T cells into the periphery, where they acquire pathogenic features and accumulate in target tissues. This thymus–periphery axis may be a key driver of ongoing inflammation and damage in aGVHD. Therapeutic strategies that restore thymic function or eliminate pathogenic DP cells may provide novel avenues to alleviate disease severity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4d45448d48e53c36fcb43dee5871db163da2fc50" target='_blank'>
              Thymic dysfunction promotes the emergence of pathogenic peripheral CD4⁺CD8⁺ T cells and induces tissue injury in acute gvhd
              </a>
            </td>
          <td>
            Meng Zhang, Hengwei Wu, Xinyi Lai, Xiangjun Zeng, Mengmeng Huang, Yingru Jiang, Yanjuan Liu, Yanmin Zhao, Fang Ye, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract infections in infants, older adults, and immunocompromised individuals. Despite decades of research, effective therapies are limited, largely due to an incomplete understanding of how infected cells and immune responses interact to shape disease outcomes. Recent evidence indicates that RSV activates multiple regulated cell death (RCD) programs-including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy-associated cell death which interact through shared molecular mediators to form a multimodal cell death (MMCD) network. This integrated system regulates the balance between viral clearance and immunopathological injury. Central mediators such as caspase-8, RIPK3, and NLRP3 act as molecular hubs coordinating these death programs and amplifying inflammatory responses. Understanding how MMCD shapes RSV immunopathogenesis provides a unified framework linking cell death to immune dysfunction. This review summarizes recent progress in elucidating the MMCD network, highlights its role in death-inflammation feedback loops, and discusses potential strategies for therapeutic modulation. Conceptualizing RSV disease through the lens of MMCD may guide the development of precision interventions that restore immune homeostasis while preserving antiviral defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48caf42a43b176c4dbbd30d2ec467dfbc9dd6c6" target='_blank'>
              Multimodal cell death drives the immunopathogenesis of RSV infection
              </a>
            </td>
          <td>
            Tianxiang Yang, Zhizhong Mi, Zhaolong Li
          </td>
          <td>2025-12-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Post-Acute Sequelae of COVID-19 (PASC) are rapidly evolving into a major public health concern. However, the link between acute infection and chronic disease remains unclear. With insights from 3 PASC patient cohorts, we established a clinically relevant mouse model and identified an aberrant immune-epithelial progenitor niche unique to the fibroproliferation in respiratory PASC. Using spatial transcriptomics and imaging, we found that lung-resident CD8+ T-cell (TRM)-derived IFN-γ and TNF stimulated local macrophages to chronically release IL-1β, promoting the accumulation of dysplastic epithelial progenitors to drive fibrosis. Neutralization of IFN-γ and TNF, or IL-1β activity improved alveolar regeneration and pulmonary function, presenting a therapeutic strategy to rescue post-viral disease in the aftermath of infection. We believe that the accumulation of CD8+ TRMs occurs due to an evolutionary need of the epithelium to maintain memory of injury and ensure rapid protection at these vulnerable sites in case of subsequent viral exposures. Dysregulation of this immune-epithelial crosstalk however, results in pathological remodelling of the lungs as observed in PASC. Thus, we are exploring the role of epithelium and the molecular basis of this crosstalk to identify key mediators to ultimately uncouple the protective and pathological functions of CD8+ TRMs post-infection to promote functional lung recovery without compromising immunity to future infections.



 Harish Narasimhan: F31HL170746 and T32AI007496 Jie Sun: AI147394, AG069264, AI112844, HL170961, AI176171 and AI154598



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/543188223d45038e3c98aeb834d328a6cf25d7e3" target='_blank'>
              An aberrant immune-epithelial progenitor niche drives post-viral sequelae 3466
              </a>
            </td>
          <td>
            H. Narasimhan, Jie Sun
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Immune checkpoint inhibition (ICI) has dramatically advanced cancer treatment but is associated with adverse outcomes including ICI-induced myocarditis. Recent work demonstrated that T cells restricted to cardiac antigens are indispensable, yet how these cells provoke fatal cardiac damage remains poorly defined. To interrogate the mechanisms underlying myocarditis, we derived a transgenic mouse line with cardiomyocyte-restricted ovalbumin expression. Transfer of naïve OTI T cells into transgenic recipients did not induce pathology, but the addition of ICI led to myocarditis. Critically, PD-1 blockade alone proved sufficient. Our findings suggest that PD-1 blockade facilitates de novo CD8 T cell priming, independent of conventional microbial stimuli. Current work aims to determine if ICI obviates the need for classical 2nd and 3rd priming signals. Additionally, we characterized diseased hearts following CD8 T cell priming and subsequent cardiac infiltration. T cells constitute half of the infiltrating immune cells, while inflammatory monocytes/macrophages and DCs dominate the non-lymphocyte population. Elevations in innate cytokines IL-1β and IL-6 were also identified. We then targeted T cell-mediated innate inflammation to ameliorate disease. Thus, these studies use a novel mouse model to 1) underscore the role for CD8 T cells, 2) reveal a noncanonical activation pathway of CD8 T cells during PD-1 blockade, and 3) posit a role for innate inflammation as a driver of pathology.



 Supported by AHA predoctoral fellowship (24PRE1198808); NIH/NIAID AI123176; NIH/NHLBI HL156852



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3a81d81333df1541d1c40b6e6fdc183b42d1e5e" target='_blank'>
              Immune checkpoint blockade induces de novo CD8 T cell priming and innate inflammation leading to myocarditis 3714
              </a>
            </td>
          <td>
            Kathrynne A. Warrick, Jeffery D. Molkentin, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Emerging evidence has suggested that primary infection and/or insult can “train” or “prime” long-term alterations in the transcriptional and epigenetic profiles of innate immune cells, particularly macrophages. Currently, it is unknown whether those “infection-experienced” macrophages can facilitate adaptive immune memory responses after infection resolution. Here, we show that influenza virus infection induces lasting transcriptional and epigenetic changes in lung alveolar macrophages (AMs) compartment following the resolution of primary infection. Further analysis showed that the IL-1b was persistently upregulated in the “infection-experienced” AMs at the memory phase compared to those of AMs from the naïve mice, and the “primed” AMs represent the major source of IL-1b in the infection-experienced lungs. Strikingly, blocking IL-1β or ablating it in myeloid cells during the memory phase led to decreased number of antigen-specific CD8 resident memory T cells (Trm) specifically in the airway but not the lung parenchyma. Consistently, IL-1b blockade caused diminished Trm-mediated protective immunity during heterologous influenza virus re-challenge. Our data suggest that infection-primed innate immune compartment facilitates protective local adaptive immune memory in the respiratory mucosa after the resolution of primary infection. Our findings may inform future vaccine design aiming to induce strong mucosal CD8 T cell immunity against respiratory viral infections.



 Immune Response Regulation: Cellular Mechanisms (IRC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c545200b85997582aa0e6b4cd460d5da7beff03a" target='_blank'>
              Infection-experienced alveolar macrophages sustain airway T cell memory 3555
              </a>
            </td>
          <td>
            I. Cheon, Y. Son, J. Im, Jie Sun
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="


 Tumor-immune infiltration is an important predictor of immunotherapy response in undifferentiated pleomorphic sarcoma (UPS). However, most patients respond poorly to immunotherapy due to a lack of tumor infiltrating T cells and an enrichment of tumor-promoting macrophages. Increasing tumor-immune infiltration is therefore critical to improve survival and treatment response in UPS patients. Our goal is to determine why some tumors recruit more immune cells than others. We are investigating how Vgll3, a frequently overexpressed gene in UPS, regulates tumor immune infiltration. In a mouse model of UPS, recent work showed increased immune infiltration into Vgll3-overexpressing tumors (Vgll3+) and a robust response to chemotherapy compared to immune-excluded sarcomas. We are now defining the cellular and molecular mechanisms by which Vgll3 drives immune infiltration to identify pathways that could potentially be targeted therapeutically in genetically distinct, immune-excluded tumors. We observed stronger type I IFN production by Vgll3+ sarcoma cells than sarcoma cells with normal levels of Vgll3, and that Vgll3+ tumors are enriched in a subset of immunostimulatory IFN-responsive classical monocytes. Our studies will reveal new insights into the mechanisms of sarcoma-immune cell infiltration, highlight differential responses of immune subsets to tumor-derived factors, and uncover therapeutic targets to enhance treatment response and survival outcome in UPS patients.



 Supported by funds from the Board of Governors Regenerative Medicine Institute at Cedars-Sinai (to HSG).



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20e44e54d02e13d3da3880c3c66228daf1821c74" target='_blank'>
              Role of Vgll3-driven Type I IFN in Shaping the Sarcoma Immune Landscape 9365
              </a>
            </td>
          <td>
            Basia Gala, E. Ko, Karina Nance, Helen S. Goodridge, Jlenia Guarnerio
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="


 Cancer immunotherapies have shown significant promise in multiple myeloma (MM). However, their long-term efficacy is limited by immune evasion, and MM remains incurable. A key evasion strategy involves upregulating inhibitory phagocytosis checkpoints (IPCs), which prevent antigen-presenting cells (APCs) from phagocytosing cancer cells. This pathway is critical for the immune effects of standard anti-MM agents, including bortezomib (BTZ), an inducer of immunogenic cell death (ICD), and the monoclonal antibody daratumumab (DARA). Yet, the mechanisms regulating IPCs in MM remain poorly understood.
 To address this gap, we screened IPC axes in MM cells and APCs using bone marrow (BM) aspirates from MM patients (n=39) and healthy donors (n=5) via multiparametric flow cytometry. Immunophenotyping included 9 parameters for MM cells and 16 for APCs, covering IPC and lineage markers. We identified the B2 microglobulin (B2M) / leukocyte immunoglobulin-like receptor B1 (LILRB1) axis as the dominantly expressed IPC in MM. B2M, expressed on MM cells, binds LILRB1 on APCs. Notably, B2M is a known adverse prognostic factor in MM.
 Computational analysis of flow-cytometry data using a semi-automated pipeline allowed us to define 8 distinct myeloid cell clusters, with consistently high LILRB1 abundance, especially in conventional type 1 dendritic cells (DCs). Single-cell RNA-seq data from 90 MM BM samples confirmed LILRB1 expression in DCs, monocytes (Mo) and macrophages (MΦ). qRT-PCR of BM Mo-derived DCs found that LILRB1 mRNA levels increased from healthy donor to smoldering MM to overt MM, suggesting a link to disease progression.
 To functionally assess the B2M/LILRB1 axis, we knocked out B2M in MM cell lines (n=3) and re-expressed a chimeric B2M mutant (B2MMUT) lacking functional LILRB1-binding site by introducing 16 missense mutations. B2M functions as an MHC-I subunit, so this mutant allowed us to isolate its checkpoint role without the confounding effects from complete B2M loss. Yeast 2-hybrid assays confirmed a direct interaction between B2M and LILRB1, but not for B2MMUT. Phagocytosis assays found that B2MKO and B2MMUT cells were more susceptible (more than 2-fold) than WT to phagocytosis by DCs and MΦ after BTZ or DARA treatment (p<0.01). LILRB1 knockdown (KD) in APCs, using an antisense oligonucleotide, similarly enhanced the phagocytic potential after BTZ treatment (p<0.05).
 Since MM cells actively secrete B2M (s-B2M), we analyzed the media from MM cell lines with different B2M statuses: B2M WT, B2MKO, and B2MMUT. We found s-B2M in the media from B2M WT cells, but no B2M in the KO cells and s-B2MMUT in the B2MMUT. Exposure of DCs to the conditioned media of WT s-B2M, but not s-B2MMUT, reduced phagocytosis after BTZ or DARA (p<0.05) of B2MKO cells, suggesting that s-B2M impairs APC function in a LILRB1-dependent manner. Treatment of APCs with His-tagged recombinant B2M (rB2M) confirmed activation of downstream LILRB1 signaling, assessed by modulation of p-SHP1.
 Interestingly, APCs internalized rB2M in a LILRB1-dependent manner, as both LILRB1 KD and treatment with rB2MMUT resulted in reduced internalization. Correlative light and electron microscopy (CLEM) and TEM revealed that internalized rB2M localized to perinuclear vesicles near the microtubule-organizing center (MTOC). Confocal imaging found that rB2M uptake increased microtubule stability, as assessed by a higher acetylated-to-tyrosinated tubulin ratio. Functionally, this correlated with impaired APC maturation following lipopolysaccharide stimulation (assessed by phalloidin staining) and a reduced ability to activate T cells after ICD, as measured shown by reduced T cell-mediated MM cell lysis.
 To evaluate the in vivo relevance, we generated a murine MM cell line (5TGM1) expressing a chimeric B2M (B2Mmut), which cannot bind the murine LILRB1 ortholog. Mice injected with B2Mmut cells exhibited reduced tumor engraftment and growth compared to those injected with WT cells, accompanied by increased infiltration of CD3⁺ and CD8⁺ T cells.Ongoing studies are assessing the effect of the B2M/LILRB1 axis on BTZ or DARA efficacy in vivo and will be presented at the meeting.
 This work provides fundamental insight into the immune role of B2M in MM, revealing the B2M/LILRB1 axis as a novel immune checkpoint in MM driven by impaired APC function. Targeting this axis represents a new therapeutic vulnerability to restore immune competence and improve MM outcomes.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92134e520cb60136119f8590dc507a1192c1b610" target='_blank'>
              The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
              </a>
            </td>
          <td>
            M. Turi, Pietro Folino, Francesca Barello, Tallya Maciel, Selma Cifric, Paola Rampa, Mehmet K Samur, Giovanni de Nola, Rita Starace, Vanessa Favasuli, Alessandro Salatino, Sofia Pasparaki, Carlo Campa, Delaney Vinaixa, Cole Clericuzio, Priya Thurman, Megan E Johnstone, F. Bonello, Abigail Lytton-Jean, Cirino Botta, Eugenio Morelli, Nikhil C Munshi, Kenneth Anderson, Annamaria Gullà
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 CD8+ T cells have the unique capacity to efficiently detect and eliminate intracellular pathogen-infected cells and tumors. One important functional feature of memory CD8+ T (Tm) cells that we and other characterized in prior works, is their ability to provide early protection during reactivation prior to clonal expansion, by enabling the rapid activation and mobilization of innate immune defenses. However, the molecular transcriptional and epigenetic mechanisms underlying CD8+ Tm cell rapid cognate antigen (Ag) dependent reactivation in vivo are poorly understood. Through single cell transcriptomic and chromatin accessibility analyses of Tm cells early post cognate Ag reactivation, we discovered that a small set of transcription factors (TF) are differentially regulated and have enriched binding sites in newly accessible promoters. We hypothesize that these TF drive the early protective effector program that mediate CD8+ Tm cell-dependent host protection. We are using high dimensional flow cytometry and multiplex assays to explore the kinetic of expression of cognate Ag-dependent TF expression, how they regulate each other and how they control distinct effector functions of the Tm cells. We are also testing the roles of these TF using in vitro and in vivo gain and loss of function approaches. We will present data offering new insights into the transcriptional regulation required for an effective CD8+ Tm cell response.



 Supported by NIH R01 AI103338



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb5ea1846a9c481b19e3f99101f2b081fd4d0b9c" target='_blank'>
              Molecular mechanisms of early memory CD8+ T cell reactivation in vaccinated hosts 4399
              </a>
            </td>
          <td>
            Richard Garcia Betancourt, Marie Boutet, G. Lauvau
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 Aging profoundly impacts the immune system, yet the underlying mechanisms driving age-related immunopathologies remain poorly understood. Previous studies have demonstrated that CD8 T cells undergo significant remodeling with age, where memory CD8 T cells largely replace the naïve cells and form two distinct subsets defined by PD1 expression. However, the data connecting these cells to physiological outcomes remained scarce. In this study, we report striking functional differences between young and aged PD1- memory CD8 T cells. We found that aged PD1- memory CD8 T cells lose antigen specificity upon activation and engage in MHC I-independent killing. Despite lacking canonical surface markers of activated or effector T cells, aged PD1- memory CD8 T cells exhibit a transcriptional profile and surface markers resembling pathogenic CXCR6+ CD8 T cells, known mediators of liver damage in the NASH model. In aged mice, these pathogenic cells accumulate systemically and drive widespread tissue damage. Mechanistically, this process is mediated by Fas-FasL interactions and regulated by IL-15 in an antigen-independent manner. This novel cellular mechanism offers a potential explanation for the extensive tissue damage observed in elderly individuals during inflammatory conditions and underscores the therapeutic potential of targeting CD8 T cells to mitigate age-associated diseases.



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7ea1e9bf0ad0a553f67bfe65bf772b9feed2510" target='_blank'>
              Non-specific cytotoxicity of aged memory CD8 T cells drives excessive tissue damage 3669
              </a>
            </td>
          <td>
            I. Shchukina, Patrick Rodrigues, Veronika Vachova, Jan Kossl, Maxim N. Artyomov
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Chronic inflammatory stress is a key characteristic of bone marrow failure syndromes (BMFS) and myelodysplastic syndromes (MDS), but we do not fully understand how hematopoietic stem cells (HSCs) respond to and are affected by this ongoing stress. HSCs can show immunological memory after short-term exposure to inflammation. This leads to lasting changes in their transcription, metabolism, and function. However, the molecular basis of this memory and its role in MDS pathogenesis remain poorly defined. Here, we identify mitochondrial antiviral signaling protein (MAVS) as a critical mediator of dsRNA-induced HSC immune memory and inflammation-driven hematopoietic dysfunction.
 Using repeated polyinosinic-polycytidylic acid (polyIC) exposure as a dsRNA mimetic, we show that HSCs undergo persistent transcriptional and epigenetic remodeling marked by increased expression and accessibility of immune and mitochondrial genes. ATAC-seq of polyIC-treated LSK cells revealed long-lasting chromatin changes with open region for CTCF, IRF1, and PU.1 binding motifs, closed regions for RUNX1, ERG, ETS binding motifs. RNA-seq identified sustained upregulation of innate immune effectors (CD74, S100a8/9) and mitochondrial regulators. We performed single-cell RNA-seq analysis of the LSK-SLAM pool. We identified 6 clusters, comprised of 3 clusters expressing HSC markers, one expressing multipotent progenitor markers, and 2 expressing cell cycle genes with megakaryocyte priming, consistent with LSK-SLAM heterogeneity. Interestingly, polyIC challenges expanded one HSC cluster marked by expression of immune genes (CD81, CD24a, Nr4a1, Cebpb), AP1 complex genes (Fos, Jun, Junb), as well as metabolic genes (OXPHOS, TCA, mTOR), at the expanse of other HSC-enriched clusters. This inflammatory signature is similar to what is found following LPS or mycobacterial challenges and consistent with immune memory. Immune memory involves metabolic reprograming. Mitochondria serve as platform of innate immune signaling, activating the inflammasome and the dsRNA sensing adaptor mitochondrial antiviral signaling protein (MAVS) to trigger immune responses. Confocal microscopy demonstrated persistent MAVS aggregation on mitochondria and elevated mitochondrial content in polyIC-challenged murine HSCs, months after transient polyIC challenge. Remarkably, MAVS-deficiency prevented expansion of HSC clones with immune memory in response to polyIC challenges. MAVS–/– mice resisted polyIC-induced HSC functional decline, and retained superior HSC engraftment capacity in serial competitive repopulation assay. Finally, MAVS-deficiency prevented the sustained activation of caspase-1 in HSCs that persisted in WT HSC months after polyIC challenge, linking MAVS to the inflammasome in polyIC-induced HSC dysfunction. Hence, HSC immune memory is mediated by MAVS.
 To probe MAVS's pathogenic potential, we utilized an inducible model of active TGF-β1 overexpression (TgCre+) that phenocopies key features of high-risk MDS upon inflammatory stimulation. PolyIC-treated TgCre+;MAVS+/+ mice developed cytopenias, myeloid dysplasia, increased HSC frequencies, elevated mitochondrial membrane potential, and persistent MAVS aggregation with increased caspase-1 activity. MAVS deletion (TgCre+;MAVS–/–) reversed cytopenias, normalized stem/progenitor ratios, and prevented dysplastic features, establishing MAVS as a central node connecting inflammation, mitochondrial stress, and ineffective hematopoiesis. These observations were extended to human MDS. CD34+CD38- cells from high-risk MDS patients showed elevated phospho-SMAD2, mitochondrial aggregation, sustained MAVS clustering, and caspase-1 activation, similar to murine data.
 Together, these findings indicate that repeated exposure to dsRNA elicits MAVS-dependent immune memory in HSCs, and causes HSC functional decline with expansion of a subset of inflammatory HSCs. MAVS-deficiency not only preserves HSC integrity following inflammatory stress but also reverses MDS-like features in vivo. Our findings establish MAVS as a critical molecular link between inflammation and hematopoietic failure and suggest mitochondrial associated immune signaling may be a promising therapeutic target in inflammation-driven MDS and related disorders.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3c6b5f7f34187a78587b80d05002010f5646c168" target='_blank'>
              Mavs mediates inflammatory memory in hematopoietic stem cells and promotes ineffective hematopoiesis
              </a>
            </td>
          <td>
            Waseem Nasr, V. Pham, Juying Xu, Micheal Jordan, Amit K. Verma, Gang Huang, M. Filippi
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 Suppressive immune cells and their associated cytokines and chemokines promote vascular endothelial proliferation and malformation, hindering immune cell penetration into the tumor core. In a phase II trial combining bevacizumab with atezolizumab in metastatic NSCLC patients (with a disease control rate of 87.5%) whose disease progressed after atezolizumab monotherapy, we analyzed blood biomarker changes collected at baseline, one week post-therapy, and at disease progression. Myeloid cells, including neutrophils, PMN-MDSCs, and M-MDSCs, were significantly correlated with responses to therapy. Durable responders exhibited high CXCL5 levels (p = 0.005) in blood. Additionally, lower neutrophil-to-lymphocyte ratios (p = 0.022), PMN-MDSCs (p = 0.036), and PD1+CD8+ T cells (p > 0.001) were associated with improved overall survival. Lower levels of suppressive proteins, including TCTP (p = 0.013), IL-6 (p < 0.001), IL-18 (p = 0.03), VEGF-A (p < 0.001), TIE-2 (p = 0.06), PD-L2 (p = 0.041), and CD147 (p = 0.008), were associated with better survival outcomes, highlighting their roles in therapy resistance. In vivo, vascular malformation and immune cell exclusion were prominent, with differential immune cell distribution between the tumor core and edge depending on hypoxia and vascular abnormalities. Combination therapy reduced suppressive and exhausted immune cells. These findings underscore the role of myeloid cells and factors such as IL-6, TCTP, and VEGF-A in resistance to therapy.



 This research was supported by NRF (National Research Foundation of Korea) funded by the Korean Government (RS-2022-NR075028)



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b83f651a43406b89a53faee6059bef8047e5b3f" target='_blank'>
              Immune exclusion driven by myeloid cells contributes to resistance to checkpoint inhibitor and anti-angiogenic therapy in NSCLC 4771
              </a>
            </td>
          <td>
            J. Koh, Young Kyoung Lee, Mi Soon Kim, B. Ku, Sehhoon Park, Myung-Ju Ahn
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains a paradigm of immunotherapy resistance, characterized by minimal effector T cell infiltration and failure to respond to immune checkpoint blockade (ICB) therapies such as anti-PD-1. In contrast, autoimmune states such as experimental autoimmune encephalomyelitis (EAE)—a murine model of multiple sclerosis—elicit robust, antigen-specific T cell responses within the central nervous system. We hypothesized that proinflammatory mechanisms sustaining autoimmunity in EAE could be co-opted to overcome immune tolerance in GBM. Single-cell RNA sequencing was used to profile T cell phenotypes from EAE and syngeneic GBM (CT-2A) models. EAE was induced in tumor-bearing mice, and tumor-specific EAE variants were generated using tumor cell lysate immunization. Cytokine expression was profiled via Luminex and white matter changes were visualized with diffusion tensor imaging and T2 mapping. Functional studies included adoptive transfer of CD3+ T cells or regulatory T cells, and hydrogel-based delivery of IL-6, IL-23, and anti-TGF-β to tumor-draining lymph nodes (TDLNs). T cell bioenergetics were assessed via Seahorse metabolic profiling and flow cytometry. EAE induction in GBM-bearing mice significantly improved survival and increased intratumoral Th1 and Th17 T cell infiltration. Tumor lysate immunization reproduced these effects and sensitized tumors to anti-PD-1 therapy. IL-6, IL-23, and IL-1β were identified as shared inflammatory mediators in both EAE and tumor-immunized states. Targeted lymphoid conditioning via hydrogels loaded with recombinant IL-6, IL-23, and anti-TGF-β reprogrammed TDLNs, enhanced T cell activation and oxidative phosphorylation, and extended survival (P<0.0001). Therefore, autoimmune inflammatory circuits can be repurposed to recondition the immunosuppressive GBM TME. Lymphoid niche modulation using a combination of IL-6, IL-23, and TGF-β blockade offers a novel strategy to sensitize GBM to currently available immunotherapeutic strategies such as anti-PD-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec557fff3154e9f6980a04bed886b991ce663c85" target='_blank'>
              IMMU-13. Leveraging the immune milieu of experimental autoimmune encephalomyelitis to perpetuate an anti-tumor T cell response in glioblastoma
              </a>
            </td>
          <td>
            John Choi, Lily H Kim, John Klich, Andrew Tran, Peggy Ho, Rohit Verma, Kwang Bog Cho, Si Yeon Lee, Gordon Li, Lawrence Steinman, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Glioblastoma (GBM), the most common and malignant primary brain tumor, exhibits profound immune suppression, hindering immunotherapy efficacy. GBM-derived extracellular vesicles (EVs) play a major role through the immunosuppressive polarization of myeloid cells. Inhibition of EV-myeloid cell interactions thus represents a novel target to mitigate GBM-mediated immune suppression. However, there are multiple mechanisms of EV-target interaction, and downstream pathways of GBM-EV signaling are poorly understood. We explored two pharmacological agents targeting different mechanisms of EV uptake: Methyl-B-cyclodextrin (MBCD), which disrupts lipid rafts, and cytochalasin D, which inhibits actin polymerization. Our results showed immunosuppressive myeloid cell (CD11b+/ CD15-/ HLA-DRlow/ CD14high) populations increased upon GBM-EV treatment. Following cytochalasin D treatment, fewer immunosuppressive myeloid cells were observed (7.40%±1.01 vs. untreated 9.66%±2.86), with rescuing T cell proliferation. Conversely, MBCD treatment increased immunosuppressive myeloid cell levels (10.42%±2.38 vs. untreated 8.87%±3.97) without impacting T cell proliferation. This study demonstrates the feasibility of pharmacologically targeting EV-myeloid cell interactions to rescue tumor mediated immune suppression by inhibiting actin-dependent endocytosis with cytochalasin D. The converse results using MBCD treatment indicate differential importance of different EV uptake pathways in monocyte regulation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c83aad2ce4bc7312164a625b88f12016523ef26e" target='_blank'>
              Selective Targeting of EV Uptake Pathways in Glioblastoma to Combat Tumor-Induced Immune Suppression 4324
              </a>
            </td>
          <td>
            Minori Aoki, Mohammad Asad, Julio Inocencio, Stefan Mitrasinovic, C. Crisman, Ian Parney, Patrick Lasala, Vijay Agarwal, Emad Eskandar, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is the deadliest primary brain tumor, characterized by immunosuppression, low infiltration of lymphocytes, and lack of response to immune checkpoint blockade (ICB) therapies. In other solid tumors, the presence of functional B cells is predictive of response to ICB. However, in GBM, although B cells are antigen-experienced, they do not differentiate to functional plasma cells. B cell activation is opposed by inhibitory signaling, especially mediated through the key inhibitory receptor CD22, which must be halted for differentiation to proceed. We hypothesized that GBM-infiltrating B cells are functionally arrested via CD22 and the immunosuppressive GBM microenvironment, which is characterized by high numbers of tumor-associated myeloid cells (TAMs). Using patient GBM samples and GBM single-cell RNA sequencing data, we showed that TAMs such as microglia strongly express the CD22 ligand α2,6 sialic acid and the α2,6 sialic acid-synthesizing enzyme ST6GAL1. We created an in vitro model of TAMs by treating murine bone-marrow-derived myeloid cells (BMDMs) with supernatant from the murine glioma cell line CT2A. Tumor cell supernatant doubled the expression of α2,6 sialic acid on the TAMs compared to BMDMs, driven by increased expression of St6gal1, showing that secreted factors from tumor cells may remodel TAMs toward a more immunosuppressive state. To elucidate the direct impact of myeloid cells on B cells, we cocultured B cells with TAMs or the microglial cell line BV2. B cells cocultured with TAMs and BV2 cells showed increased phosphorylation of repressive signaling molecules downstream of CD22, including p-SHP-2 and p-SHIP1. This study suggests that myeloid cells are reprogrammed in the context of the tumor microenvironment to become more suppressive to B cells. In future work, we aim to develop a therapeutic targeting α2,6 sialic acid on TAMs in vivo to restore B cell function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c16dc7ca0407ae61b2e9c308129f9a72d793423" target='_blank'>
              TMIC-72. Glioma-associated myeloid cells promote B cell inhibition
              </a>
            </td>
          <td>
            Alina R Murphy, Si Wang, G. Vázquez-Cervantes, Hanxiao Wan, Joshua Katz, Rebecca Du, Jiawei Huo, Tzu-yi Chia, Leah K. Billingham, Suzi Delay, M. Lesniak, Peng Zhang, J. Miska, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Respiratory syncytial virus (RSV) infection causes significant morbidity in elderly adults. To determine how advanced age impacts myeloid cell (MC) antiviral responses, we developed a 3D human lung model (HLM) to recapitulate the small airway. The HLM is composed of layered primary differentiated small airway epithelial cells at air-liquid interface, fibroblasts embedded in collagen, and endothelial cells. Introduced blood MC (monocytes and dendritic cells) from 36-40yo (Adult) or 69-88yo (Elderly) donors migrated throughout the HLM. Recovered MC were assessed using flow cytometry, microscopy, and transcriptional profiling. MC acquired phenotypes and morphology of tissue-resident cells, indicating adaptation to the airway environment and differentiation into tissue-resident macrophages. However, prior to infection, sorted Elderly MCs showed reduced expression of genes promoting macrophage differentiation and function, e.g. PPARG, MARCO, INHBA, yet showed higher basal expression of pro-inflammatory genes, e.g. IL18, CDKN1A, TLR9, compared to sorted Adult MCs. After RSV challenge, HLM built with Elderly MC harbored significantly more RSV RNA, consistent with poor induction of genes in IFN signaling, viral sensing, and macrophage activation pathways. Thus, diminished expression of canonical macrophage genes, increased baseline inflammation, and reduced ability to build up antiviral IFN responses contribute to the impaired viral clearance in HLM bearing Elderly MC.



 Funded by NIH R01 EB025596



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23985d18f4cdd665e0b30abb7a4851c7e3a9795d" target='_blank'>
              Age shapes the myeloid cell antiviral response to RSV infection in a human airway tissue model 4051
              </a>
            </td>
          <td>
            S. Kovats, Mandi M. Roe, Taylor Do, Magdalena Chlebicz, Sean Turner, Laura Mejia, Antonius Oomens, H. Gappa-Fahlenkamp
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="


 Background: Autologous stem cell transplantation (ASCT) remains the standard of care consolidation in eligible patients with multiple myeloma. Typically, this is followed by lenalidomide maintenance therapy until progression or intolerance. This combinatorial approach results in improved progression-free survival compared to drug-based consolidation. However, the majority of patients ultimately relapse, consistent with myeloma progression and immune escape. Increasing evidence suggests that myeloma may invoke a suppressive tumor microenvironment (TME), principally in the bone marrow (BM), which may impair endogenous T cells and/or therapeutic T cell engagers or chimeric antigen receptor T cells targeting tumor antigen. Immunosuppressive myeloid cells are known to be abundant in the TME, and we and others have previously implicated macrophages in this process.
 To examine potential cellular sources of immunosuppression in the TME, we used flow cytometry to analyze myeloid cells in the BM from patients undergoing ASCT for myeloma. BM mononuclear cells were isolated from aspirates drawn at approximately 2-6 weeks prior to ASCT (n=13), 90 days post-transplant, and at relapse or 1-year post transplant. Post-transplant samples were categorized as relapsed (n=12) or controlled for >1 year (n=8). BM from patients with progressive myeloma was characterized by a population of CD64+CD172+ macrophages that express CD169, putatively marking BM residency, and exhibiting a highly immunosuppressive phenotype evidenced by expression of CD163, CD155, PD-L1, and CSF-1R. Notably, the frequency of CD169+CD163+ macrophages (within CD64+ cells) but not the CD64+CD172+ macrophage population as a whole were expanded in patients at the time of relapse (mean frequency pre-ASCT: 3.46%, D+90: 2.96%, controlled: 4.02%, relapse: 13.83%; P<0.05 relapse vs. controlled; P<0.01 relapse vs. pre-ASCT or D+90), and correlated with multiple myeloma burden in the BM (r2 = 0.477, P=0.0103).
 Using a preclinical system of ASCT in mice bearing VK*MYC myeloma, we identified a similar macrophage subset in the BM, characterized as CD11b+Ly6GnegCD11c+CD64+ with high expression of CSF-1R, PD-L1, and F4/80. We sought to target these putatively immunosuppressive macrophages, using antibody-based CSF-1R inhibition, to determine whether we could augment lenalidomide maintenance after ASCT. We used a suboptimal T cell dose wherein endogenous anti-myeloma immunity is limited and assessed each therapy alone and in combination. We used cereblon (CRBN)-transgenic mice that are genetically modified to allow engagement of thalidomide and its derivatives (including lenalidomide), resulting in degradation of the IMiD targets, Aiolos and Ikaros. As expected, CSF-1R inhibition efficiently ablated the CX3RC1+Ly6Clo monocyte population in the blood and BM (mean frequency in lineage negative in blood: 2.9% vs. 18.1% in isotype-treated; in BM: 0.4% vs. 5.8% in isotype-treated; p<0.001 for both sites). While single agent CSF-1R inhibition or lenalidomide had no significant effect on disease progression, the combination of the two agents had a synergistic effect in attenuating myeloma relapse after ASCT. At 108 days follow-up, median overall survival for mice receiving CSF-1R inhibition and lenalidomide was not reached, while median survival was 65 days for either isotype- or lenalidomide-treated mice, and 77 days for mice receiving only CSF-1R inhibition (P<0.05). Myeloma M band progression was also significantly reduced with combination therapy (p<0.001).
 Conclusion: The ability of CSF-1R inhibition to deplete CSF-1R+ macrophages and prevent tissue fibrosis has previously been demonstrated in preclinical models of chronic graft-versus-host disease (GVHD). Subsequent clinical trials have proven axatilimab, a human anti-CSF-1R antibody, to be well tolerated and effective for the treatment of chronic GVHD, leading to FDA approval. Given lenalidomide is already a standard maintenance therapy, combination therapy with axatilimab represents a readily testable clinical strategy for augmenting progression-free survival in patients with multiple myeloma after ASCT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93ee7098bb14373b537fde66a2a31ad8ddc75d5f" target='_blank'>
              CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation
              </a>
            </td>
          <td>
            Simone A. Minnie, Rachael Adams, Kathleen S. Ensbey, Christine R. Schmidt, Melissa Comstock, Justina Lyons, Samuel R. W. Legg, Tomoko Sekiguchi, Nicole S. Nemychenkov, Julie R. Boiko, M. Koyama, Andrew Spencer, Damian Green, Geoff Hill
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 This work aims to understand how myeloid cell development and function are dysregulated in Down syndrome (DS). Introduction: Individuals with DS experience severe immune dysregulation, including altered myeloid cell function and hyperactive interferon (IFN) signaling. However, it’s unclear which phenotypes are cell-intrinsic effects of trisomy 21 (T21) or how IFN signaling impacts myeloid cell function in DS.



 Induced pluripotent stem cells (iPSCs) generated from individuals with and without DS were used to create hematopoietic stem and progenitor cells (HSPCs). These HSPCs underwent myelopoiesis, and cell subsets were characterized by flow cytometry. Myeloid functions, such as phagocytosis and NET formation, were measured after stimulation in the presence or absence of IFNs.



 T21 samples showed lower ratio of mature to progenitor immune cells during myelopoiesis and impaired production of total myeloid cells and monocytes. IPSC-derived and primary T21 monocytes showed impaired phagocytosis of S. Aureus at baseline and after IFN treatment. Meanwhile, unstimulated and PMA-stimulated T21 neutrophils showed elevated and earlier NET formation.



 T21 results in cell-intrinsic alterations in monocyte production and defects in phagocytosis of bacteria, both in the presence and absence of interferons. Elevated and earlier NET production suggest that T21 neutrophils are primed for NET formation.



 NIH grant R01AI150305, NIH grant R24OD035579, Linda Crnic Institute for Down Syndrome, Global Down Syndrome Foundation, and the Anna and John J Sie Foundation.



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/66da24ad513bbfe58177e311cbeb37debf473082" target='_blank'>
              Multimodal analysis of dysregulated myeloid cell function in Down syndrome 9171
              </a>
            </td>
          <td>
            Brian F. Niemeyer, Eleanor C. Britton, Madeline Hipp, Pamela Navarrete, A. Rachubinski, Joaquin M. Espinosa
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Background: Despite recent advancements in the treatment of chronic lymphocytic leukemia (CLL), Richter's transformation (RT) into diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge with poor outcomes (Coombs et al., 2023). While CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) has shown efficacy in de novo DLBCL, its effectiveness in RT is less well defined (Kittai et al., 2024). Factors such as prior treatment, T cell exhaustion, and distinct immune microenvironments may contribute to limited efficacy in DLBCL (Fraietta et al., 2018; Jain et al., 2023). We evaluated clinical outcomes and immune correlates of CD19 CAR-T in patients with RT at our institution.
 Methods: We retrospectively analyzed 15 patients with RT-DLBCL treated with CD19 CAR-T between 2017 and 2024. A comparator cohort of 19 patients with de novo DLBCL treated with CD19 CAR-T was also analyzed. Pre-infusion peripheral blood mononuclear cells (PBMCs) were analyzed using multiparametric flow cytometric profiling. RNA expression from tumor biopsies was analyzed using NanoString transcriptomic profiling with the IO360 panel, which includes 770 genes found in the tumor microenvironment.
 Results: Fifteen patients with RT-DLBCL were included, 47% male with a median age at infusion of 69 years (range 47-77). The median interval from CLL to RT diagnosis was 41 months (range: 7-210), and from RT diagnosis to CAR-T was 20 months (range: 2-50). CAR-T products used were tisagenlecleucel (tisa-cel, 53%), lisocabtagene maraleucel (liso-cel, 27%), and axicabtagene ciloleucel (Axi-cel, 20%). One patient had received an allogeneic CAR-T product 7 months prior to Tisa-cel. Three patients received hematopoietic stem cell transplant before CAR-T (2 autologous, 1 allogeneic). Leading up to CAR-T, 93% had received RT-directed therapy (median 4 lines) and 66% had received prior CLL therapy. Cytokine release syndrome (CRS) occurred in 67% (7% grade ≥3) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 40% (13% grade ≥3). Overall response rates (ORR) were 80% at day 30 and 47% at 3 months. The median follow-up was 9 months.
 In the comparator de novo DLBCL cohort, median age at CAR-T was 68 (25–76), with 68% male. Most (74%) had received 1–2 prior lines of therapy before CAR-T. The majority (18/19) received axi-cel, and one patient received tisa-cel. Three patients received an autologous stem cell transplant before CAR-T. CRS of any grade occurred in 79% (11% grade ≥3), and ICANS in 74% (42% grade ≥3). The ORR was 88% at day 30 and 82% at 3 months. The median follow-up period was 26 months (range: 1-67).
 Flow cytometry revealed significantly higher frequencies of exhausted T cells in RT patients compared to de novo DLBCL (p=0.0329). RT patients had significantly higher frequencies of TCF1⁺ PD1⁺ (p=0.0217) and TCF1⁺ TIGIT⁺ (p=0.0158) CD8+ T cells, indicating a predominance of dysfunctional precursor-exhausted populations in circulation prior to CAR-T infusion. Moreover, there was an increase in central memory (CM, CD45RO⁺ CCR7⁺) CD8+ T cells in RT samples compared to de novo DLBCL (p=0.0436). Notably, these CM cells exhibited a significantly more exhausted phenotype in RT patients than in de novo cases (PD-1+ p=0.0266, TIGIT+ p=0.0490). Supporting the exhaustion phenotype found by flow cytometry, Nanostring analysis confirmed a significant increase in ENTPD1 expression, a gene that encodes the ectonucleotidase CD39, in tumors from RT patients compared to de novo DLBCL (p=0.02), as well as an increase in DUSP2 expression (p<0.0001), a phosphatase associated with exhaustion on tumor-infiltrating T cells and poor outcomes (Lu 2020; Dong 2018).
 Conclusions: CD19 CAR-T therapy shows promising initial responses in RT, though durability remains limited. Compared to de novo DLBCL, RT patients exhibit higher pre-treatment T cell exhaustion and more immunosuppressive tumor gene expression profiles, which may underlie poorer CAR-T durability. Ongoing transcriptomic analyses will further elucidate tumor-intrinsic and microenvironmental mechanisms of CAR-T resistance in RT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8898e13acca4c0791f3ab6eeb2b41de76671fe10" target='_blank'>
              Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation
              </a>
            </td>
          <td>
            M. B. Hammami, C. Savid-Frontera, Sean Haney, Douglas Marachion, Sean Yoder, Mohammad Hussaini, Michael D. Jain, Frederick L Locke
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 The immunosuppressive tumor microenvironment is a major challenge in GBM. We are developing oncolytic Zika virus (ZIKV) as a treatment that targets treatment-resistant glioma stem cells and ignites CD8+ T-cell dependent anti-tumor immune response. We previously demonstrated that ZIKV infection significantly improves survival in multiple mouse models of GBM (Nair et al, JCI insight, 2021). However, myeloid driven immunosuppression remains a critical barrier. While Siglec-15 has recently been described as a myeloid immune checkpoint in other cancers (Wang et al, Nat Med, 2019), it is relatively unexplored in GBM. An antibody against Siglec-15 is in a phase II clinical trial for metastatic solid tumors (NCT04699123), but not tumors of the central nervous system. In human GBM specimens, we observed that Siglec-15 is highly expressed on myeloid (16-23%) and tumor cells (18-19%). Here, we use therapeutic and genetic approaches to target Siglec-15, as well as immunotherapy-resistant mouse models of GBM. In CT2A-bearing mice, long-term survival (90 days) increased from 40% (only ZIKV) to 60% (anti-Siglec-15+ZIKV). Adding antibody against PD-1 further improves the long-term survival (83%). In the immunotherapy-resistant SB28 model, triple therapy (anti-Siglec-15+ZIKV+anti-PD-1) led to 76% long-term survivors and greater CD8+ T-cell activation (1.7-fold). Upon re-challenge of cured mice, we detected an increase in CD8+ brain resident memory T-cells (11-fold) and CD8+ effector memory T-cells (11-fold), and 80% of mice survived. These findings with antibody against Siglec-15 were further confirmed using Siglec-15 knockout mice. Mechanistically, using bone marrow derived myeloid cells and T-cell proliferation assays, we determined that depletion of Siglec-15 improves phagocytosis of tumor cells (CT2A; 25.2% and SB28; 6.9%) and significantly improves T-cell activation (81%) and T-cell proliferation (86.8%), and these findings may explain why we observed improved outcomes. These results suggest the potential of this triple therapy in overcoming the problem of the immunosuppressive tumor microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a95001b5599103be9128f5ed56fc151095bff75" target='_blank'>
              TMIC-21. Dual blockade of Siglec-15 and PD-1, combined with oncolytic Zika virus therapy, confers protection against immune-resistant gliomas
              </a>
            </td>
          <td>
            Ashwani Kesarwani, Sonam Verma, Amber Neil Griffith, Tong Hu, Fei Shu, Amanda Andrade de Costa, Y. Li, Mridu Kanga, Brett H Herzog, D. DeNardo, Mai Dang, Jingqin Luo, Pei-Yong Shi, Xuping Xie, Jun Wang, Lieping Chen, Albert Kim, Peggy L. Kendall, Michael S Diamond, Milan G Chheda
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="
 Glioblastoma multiforme (GBM) is a highly aggressive brain tumor marked by resistance to standard therapies, largely due to a profoundly immunosuppressive tumor microenvironment (TME). The nuclear orphan receptors NR4A1 and NR4A2 are overexpressed in GBM and act as key drivers of immune dysfunction and epithelial–mesenchymal transition (EMT). Novel dual NR4A1/2 inverse agonists, termed CDIMs, have been shown to inhibit PD-L1 and TWIST1 while reactivating S1PR1, restoring T cell trafficking to the tumor. Three CDIM compounds (DIM-3,5-Cl₂, DIM-3-Cl-5-CF₃, and DIM-4-OH-3,5-(tBu)₂) were administered at low (8-10 mg/kg) and high (20-25 mg/kg) dose for 12 consecutive days in healthy immunocompetent mice to evaluate tolerability and effects on immune cell distribution. Splenocytes, bone marrow, and peripheral blood mononuclear cells (PBMCs) were then isolated and analyzed via FACS. Notably, DIM-3,5-Cl₂ and DIM-3-Cl-5-CF₃ reduced CD4⁺ and CD8⁺ T cells in the bone marrow, with a corresponding increase in PBMCs, supporting reversal of T cell sequestration. To assess therapeutic relevance, the same regimen was applied in a syngeneic orthotopic CT2A glioma model. DIM-3,5-Cl₂ maintained elevated CD4⁺ and CD8⁺ T cells in PBMCs, further supporting its role in restoring systemic T cell circulation and availability for tumor infiltration. In contrast, DIM-3-Cl-5-CF₃ and DIM-4-OH-3,5-(tBu)₂ induced pronounced immune remodeling, including reduced CD19⁺ B cells and expansion of CD11b⁺ and triple-negative (CD11b⁻CD4⁻CD8⁻) populations, thus reshaping adaptive immunity. Ongoing studies will evaluate survival benefit, systemic cytokine responses, and local immune changes within the tumor microenvironment. Brains from treated animals will be analyzed by immunohistochemistry to assess changes in key immune markers to clarify the impact of CDIMs on intratumoral immune composition. Overall, the presented findings position DIM-3,5-Cl₂ as a promising candidate for reversing immune suppression in GBM and enhancing response to immune checkpoint therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4ee11f3a994d6e3a11769fbefb1d349f6c5b72d" target='_blank'>
              TMIC-108. Therapeutic immune reprogramming in Glioblastoma using novel dual NR4A1/2 inverse agonists
              </a>
            </td>
          <td>
            Ana Gutierrez, Andrei Mikheev, Chu-Hsia Chen, Zheng Yin, Svetlana Mikheev, Stephen Safe, Robert C. Rostomily
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="major obstacle is the immunosuppressive liver microenvironment, characterized by the presence of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and a high proportion of tumor-associated macrophages (TAMs). Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors such as nivolumab and pembrolizumab have shown limited clinical efficacy in HCC, with only a subset of patients responding to treatment. Conversely, CAR-T cell therapies targeting tumor antigens such as glypican-3 (GPC3) and alpha-fetoprotein (AFP) have shown promise but face limitations due to the difficulty of generating effective T cell responses within the immunosuppressive liver milieu (11). Organoids provide an excellent platform for investigating T cell interactions in hepatobiliary cancers. These 3D models enable the study of immune responses in an environment that closely resembles the in vivo tumor microenvironment (12). Researchers have successfully">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a1b0e2f8ddf3d5e1eaebd7db8f530b03067bdcc" target='_blank'>
              Organoid models for T cell-based immunotherapy in hepatobiliary cancers
              </a>
            </td>
          <td>
            Liwei Du, Jiaxun Dong, Shunda Du
          </td>
          <td>2025-11-25</td>
          <td>Hepatobiliary Surgery and Nutrition</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Objective: Diffuse Large B-cell Lymphoma (DLBCL) is a hematologic malignancy characterized by the clonal expansion of myeloid progenitor cells and a highly immunosuppressive tumor microenvironment (TME). Among the key contributors to this immunosuppression are tumor-associated macrophages (TAMs), particularly those polarized toward an M2-like phenotype. These M2 macrophages support leukemia progression by suppressing anti-tumor immunity, promoting angiogenesis, and enhancing resistance to chemotherapy. Heme oxygenase-1 (HO-1), a stress-inducible enzyme known for its antioxidant and anti-inflammatory functions, has been reported to be upregulated in various cancers, including DLBCL. However, the immunological consequences of HO-1 overexpression in DLBCL, especially its impact on TAM polarization and immune evasion, remain poorly understood. This study aimed to investigate the molecular mechanism by which HO-1 modulates macrophage polarization and shapes the immune microenvironment in DLBCL. The ultimate goal is to provide a theoretical basis for targeting HO-1 or TAM phenotypes as a therapeutic strategy to improve clinical outcomes in DLBCL.
 Methods: A combined bioinformatic and experimental approach was employed. Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) DLBCL cohort and multiple GEO datasets were analyzed. Patients were divided into HO-1^high and HO-1^low groups based on expression levels. Immune cell infiltration was estimated using CIBERSORT and xCell algorithms. Differentially expressed genes (DEGs) between the two groups were identified using DESeq2 and further analyzed through GO and KEGG enrichment to explore biological pathways associated with HO-1. Weighted gene co-expression network analysis (WGCNA) was applied to identify gene modules related to HO-1 and immune infiltration. Protein-protein interaction (PPI) networks were constructed using STRING, and key hub genes were identified using Cytoscape's CytoHubba plugin.
 For in vitro validation, DLBCL cell lines were transduced with HO-1-overexpressing or control lentiviral vectors. Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated and induced to differentiate into M0 macrophages with M-CSF. Co-culture assays were performed using transwell systems, exposing macrophages to HO-1-overexpressing DLBCL cells. Macrophage polarization was assessed by qPCR for M1 (TNF-α, IL-12) and M2 (CD163, IL1RN, ARG1) markers, ELISA for cytokine secretion, and flow cytometry for CD86/CD206 surface markers.
 Results: Patients in the HO-1^high group displayed significantly higher levels of M2 macrophage infiltration and reduced NK cell activation, suggesting a link between HO-1 expression and immunosuppression in DLBCL. DEG analysis revealed enrichment in immune regulatory and vesicle transport pathways. WGCNA and PPI analyses identified HO-1 as closely associated with M2 markers such as CD163 and IL1RN.
 In vitro co-culture experiments confirmed that HO-1-overexpressing DLBCL cells promoted M2 polarization of macrophages. Macrophages exposed to HO-1^high DLBCL cells exhibited increased CD206, CD163, and IL1RN expression, and decreased IL-12 and TNF-α. Flow cytometry analysis corroborated these findings, showing an elevated proportion of CD206⁺ macrophages.
 Through qPCR and WB detection, it was found that the expression levels of IL-4 and IL-10 in DLBCL cells in the HO-1 upregulated group increased, and the levels of IL-4 and IL-10 in the supernatant also increased accordingly. Overexpression of HO-1 upregulated the production of interleukin-4 and interleukin-10 in leukemia cells. IL-4 alone could induce similar M2 polarization in macrophages. Neutralizing IL-4 could partially reverse the M2 polarization induced by HO-1, indicating that IL-4 at least partially mediates the immunomodulatory effect of HO-1.
 Conclusion: This study demonstrates that HO-1 is a critical driver of TAM polarization and immune microenvironment remodeling in DLBCL. Through upregulation of IL-4, HO-1 enhances M2 macrophage polarization, contributing to immune evasion and potentially to treatment resistance. These findings highlight HO-1 as both a biomarker and a promising therapeutic target. Inhibiting HO-1 or reprogramming TAMs from an M2 to an M1 phenotype may improve anti-leukemic immune responses and enhance the efficacy of current DLBCL therapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fd5c0c36b45197dd9125d511c8e92c3765a6546c" target='_blank'>
              Heme oxygenase-1 facilitates immune evasion in diffuse large B-cell lymphoma by reprogramming tumor-associated macrophage polarization
              </a>
            </td>
          <td>
            Wenbin Lei, Jishi Wang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Increased activation of the NLRP3 inflammasome in immune cells, including macrophages, has been implicated in the pathogenesis of multiple chronic inflammatory diseases. Targeted depletion of macrophages has been explored as a cross-disease therapeutic strategy, but without subtype-specific markers, this strategy risks elimination of macrophages with homeostatic functions. In this study, Liu et al. identified a subpopulation of pathogenic macrophages, referred to as Toe-Macs, which are characterized by overexpression of the DNA demethylase TET3 in metabolic dysfunction–associated steatohepatitis (MASH), non–small cell lung cancer (NSCLC), and endometriosis. When induced into the disease microenvironment, Toe-Macs produced proinflammatory cytokines and chemokines. Selective elimination of Toe-Macs attenuated disease progression without any discernible side effects in mouse models of MASH and NSCLC. These findings highlight the role of Toe-Macs in the pathogenesis of chronic inflammatory diseases and provide a rationale for exploring TET3 as a therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/104b6ef43608f9bf119926e9935cb7aaf2a5e734" target='_blank'>
              TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases
              </a>
            </td>
          <td>
            Shojiro Haji, Yoshihiro Ogawa
          </td>
          <td>2025-11-03</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Group 3 medulloblastoma (G3MB) is the most aggressive medulloblastoma subtype. Although CAR T-cell therapy is promising, it has shown limited efficacy in G3MB due to poor T-cell persistence, largely driven by the immunosuppressive tumor microenvironment (TME) and an intact blood–brain barrier (BBB). M2-like tumor-associated macrophages (TAMs) are major contributors to this immunosuppression, whereas inflammatory TAMs can support CAR T-cell function. We identified Resiquimod, a Toll-like receptor (TLR) 7/8 agonist, as a potent immunomodulator capable of reprogramming TAMs toward a pro-inflammatory phenotype. In parallel, low-intensity focused ultrasound (LIFU) provides a noninvasive method to transiently disrupt the BBB, potentially enhancing both immunomodulatory effects and CAR T-cell infiltration.



 To improve the efficacy of B7-H3-directed CAR T-cell therapy in G3MB by optimizing CAR design, reprogramming the TME using POx-encapsulated Resiquimod (POx-R), and enhancing tumor accessibility with LIFU.



 We engineered B7-H3 CARs with CD28, 4-1BB, or dual costimulatory domains and tested their efficacy in vitro and in vivo. POx-R was administered systemically to enable brain penetration and TAM repolarization. LIFU was applied with microbubbles to transiently open the BBB and facilitate delivery of CAR T-cells. Immune profiling included flow cytometry and RNA sequencing.



 In vitro, CAR T-cells with dual CD28 and 4-1BB costimulatory domains demonstrated superior cytotoxicity and persistence. In vivo, systemically administered POx-R effectively crossed the BBB and induced pro-inflammatory TAM repolarization, as evidenced by upregulation of M1 markers and inflammatory cytokines detected by bulk RNA sequencing and flow cytometry. Preliminary data also indicate enhanced CAR T-cell infiltration and TME remodeling when combined with LIFU-mediated BBB disruption. Ongoing studies aim to elucidate the underlying mechanisms and optimize treatment scheduling to maximize therapeutic synergy.



 This multimodal strategy of integrating CAR engineering, myeloid reprogramming, and BBB modulation offers a promising path to overcome the key barriers limiting CAR T-cell therapy in G3MB.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/504746b3e43fabadaa7dc965df28e142fde180fd" target='_blank'>
              EXTH-71. Optimizing CAR T-Cell therapy in group 3 medulloblastoma through tumor microenvironment modulation and blood-brain barrier disruption
              </a>
            </td>
          <td>
            Serge Yaacoub, Stefanyda Maslova, Ying-ting Hsu, Zhongzhen Yi, Kaleem L Coleman, Martine F. Roussel, T. Gershon, Marina Sokolsky-Papkov, Cheng-Chia Wu, Natasha Sheybani, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fe1fd70d582b73456d2a4754cfa0b98111080ee7" target='_blank'>
              pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection.
              </a>
            </td>
          <td>
            Elena Hernández-García, Miguel Galán, Sofía C Khouili, Elena Moya-Ruiz, Ana Redondo-Urzainqui, F. J. Cueto, Saraí Martínez-Cano, Manuel Rodrigo-Tapias, E. Tomasello, Santos Mañes, Marc Dalod, D. Sancho, S. Iborra
          </td>
          <td>2025-11-25</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="


 Lupus is a complex autoimmune disease that involves dysregulation of the B cell compartment. Potential mechanisms for this dysregulation include abnormalities in immune dampening pathways, such as the programmed cell death 1 receptor (PD-1). Though PD-1 functions as a negative regulator in T cells, its role in B cells is not clear. We used comprehensive flow and mass cytometry to examine the expression of PD-1 on peripheral blood B cells from lupus and healthy controls in two large patient cohorts. PD-1 was increased on antigen experienced B cells including double negative, memory, and CD11c+ age-associated B cells. Heterogeneity in patient PD-1+ B cells was uncovered, including an enriched PD-1+CD11c+CXCR3+ B cell subset which we speculate may be pathogenic due to their potential to migrate to sites of inflammation, and a diminished PD-1+PD-L1+ B cell subset which we expect is an immunosuppressive phenotype. PD-1 expression was higher in patients with elevated anti-dsDNA, high disease activity and increased with in vitro stimulation (anti-BCR and TLR9). Surprisingly, PD-1+ B cells proliferated more than PD-1- B cells, and PD-1 blockade with an anti-PD-1 antibody further increased proliferation. Our results suggest that PD-1 function in B cells is different than its inhibitory signaling role in T cells. Further, the expansion of PD-1 expressing B cells in lupus, especially in patients with high disease activity, highlights a new potential pathogenic B cell population.



 Supported by T32ES007026; Public Health Sciences Pilot Award; NIH Accelerating Medicines Partnership (RA/SLE Network)



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5935df81b4ecf4492f3d3f23ff65634bbec5dc4d" target='_blank'>
              PD-1 expressing B cells are expanded in lupus 4452
              </a>
            </td>
          <td>
            Melanie Perkins, Nida Meednu, Daria Krenitsky, Alice Horisberger, A. Griffith, Joshua Keegan, Fan Zhang, James A. Lederer, Deepak A. Rao, Lisa A. DeLouise, J. Anolik
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="


 Inducing robust mucosal memory T cells in the lung is critical for developing vaccines against respiratory pathogens like Influenza A virus (IAV). Lung tissue-resident memory (TRM) cells serve as the first defense against IAV but undergo rapid attrition, challenging T cell-based mucosal vaccine strategies for durable immunity. This study examined the impact of combination adjuvants targeting distinct innate receptors on CD8 T cell differentiation and TRM persistence. Intranasal delivery of Adjuplex (ADJ) combined with either TLR4 agonist GLA or STING agonist CDN induced strong expansion of mucosally-imprinted CD8 T cells in lungs and airways. ADJ+GLA predominantly generated Type III T cells, while ADJ+CDN favored Type I T cells. ADJ+GLA vaccination led to the persistence of greater number of lung TRMs, correlated with sustained IL-7R expression and lower viral titers (180d p.v.). Also, ADJ+GLA but not IAV induced stem-like, functionally plastic Type III TRMs provided durable immunity to IAV. In Tbx21 conditional KO mice, ADJ+GLA increased IL-17A+, RORγt+, ICOS+, and CD127+ CD8 T cells, suggesting the roles of RORγT and T-bet in vaccine-induced TRM development. Ongoing studies aim to elucidate the precise role of T-bet and RORγT in durable TRM formation. In summary, innate receptor engagement shapes T cell differentiation and lung TRM durability. Our findings highlight Type III programming as a promising avenue for mucosal vaccine design against respiratory viral pathogens.



 This work was supported by Public Health Service Grants UO1AI12499 and R21AI173757 from the National Institutes of Health and the John E. Butler Professorship to MS.



 Vaccines and Immunotherapy (VAC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38455ec87f8c161d0e6405c997dadf4ef1b047d7" target='_blank'>
              Innate immune receptor engagement governs functional differentiation of effectors and persistence of tissue-resident memory T cells 4002
              </a>
            </td>
          <td>
            Hongtae Park, Brock Kingstad-Bakke, Thomas Cleven, Hailey E. Bussan, Cynthia Pryde-Aguilar, Myunghwan Jung, M. Suresh
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 While cancer cells adapt to the tumor environment by maintaining a low level of differentiation despite high proliferation, T lymphocytes undergo terminal differentiation. One of the unique adaptive mechanisms in tumors is the epithelial-to-mesenchymal transition (EMT). We identified that the EMT gene Snail1 may also be expressed by effector CD8+ T cells, and IL-2 maintains its expression via STAT5 and GSK-3. Snail1 enhances T cell persistence and stabilizes their effector phase by enhancing the β-catenin pathway. Snail1 expression in CD8+ T cells is associated with increased anti-tumor immunity in animal models and correlates with the efficacy of immune checkpoint blockade in cancer patients. Treatment with H9T, an engineered IL-2 partial agonist, enhances Snail1-dependent T cell immunity in vivo. Snail1-expressing CAR-T cells show superior persistence and anti-tumor activity in preclinical models. Thus, Snail1 is a potential target for cancer immunotherapy.



 CA248430



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f1370d3c977d23566a0d5046e052590b0d847ffb" target='_blank'>
              Snail1 retains CD8+T cell effector function in tumor immunity 2104
              </a>
            </td>
          <td>
            Ilona Kryczek, Karolina Okła, Yoshitaka Adachi, Tison Kole, Michael Pitter, Yijian Yan, Weichao Wang, Jiali Yu, Shuang Wei, Sara Grove, Linda Vatan, Fei Mo, Nicholas P Restifo, Rosanne Spolski, K. C. Garcia, Leonard Warren
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="


 Our adoptive cellular therapy (ACT) enhances dendritic cell (DC) and T cell infiltration into tumors, improving survival in murine brain tumor models. However, tumors employ mechanisms to restrict immune surveillance and efficacy of immunotherapy. We hypothesize that tumor-induced DC dysfunction facilitates immune evasion during ACT. This study investigates the mechanisms of DC dysfunction in ACT-escaped gliomas.



 T cell phenotypes were characterized using flowcytometry, and DC function was assessed through T cell activation assays. Gene set enrichment analysis (GSEA) was performed on transcriptomic data to identify enriched pathways. The impact of hypoxia and factors secreted from tumor-T cell interactions on DC tolerance was evaluated using RT-qPCR. In vivo correlations between hypoxia and DC tolerance were analyzed using GeoMx spatial transcriptomics.



 ACT-escaped tumors retained adoptively transferred cytotoxic but non-exhausted T cells that failed to recognize antigen-shifted tumors. DCs from both untreated primary and ACT-escaped tumors showed impaired T cell activation and reduced expression of antigen-presentation genes. DCs from ACT-escaped tumors exhibited increased expression of tolerance-associated genes, with significant enrichment in hypoxia pathway genes. Hypoxia induced the expression of DC tolerance genes in a HIF1α-dependent manner, impairing T cell activation. Spatial transcriptomics confirmed a strong correlation between HIF1α and ARG1 in tumor-bearing brains. Increased immune infiltration in ACT-treated gliomas exacerbated hypoxia, as shown by HIF1α and CD45 co-expression, further driving DC dysfunction. Inflammatory factors secreted during tumor-T cell interactions activated hypoxia pathways and induced DC tolerance genes.



 Hypoxia-driven DC tolerance is a key driver of immune escape under ACT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6e9caf76d495a58d49e11136e34904db71176f32" target='_blank'>
              TMIC-38. Dendritic cell dysfunction driven by hypoxia pathway activated DC tolerance as an immune evasion mechanism in adoptive cellular therapy
              </a>
            </td>
          <td>
            D. Jin, A. Reid, John Figg, C. Francis, L. Font, C. Love, Kaytora Long-James, David Hilferty, Sofia Stansbury, Norman Morikawa, Mathew Sebastian, Steeve Boulant, D. Mitchell, C. Flores
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 CD8+ T cells play a pivotal role in protective immune responses against intracellular pathogens and tumors. Most CD8+ T cells activated during a primary immune response will contract and die, however, a small percentage persist to form long-lived memory populations (CD8+ Tmem). CD8+ Tmem rapidly deploy their effector functions (i.e., cytotoxicity, cytokine secretion) to respond to subsequent antigen challenges. While these canonical roles are critical, previous studies have suggested that CD8+ T cells can confer protection in the absence of their cytotoxic machinery. The underlying mechanisms for such non-canonical roles remain ill-defined. Our studies have discovered that CD8+ Tmem engage myeloid cells, namely dendritic cells (DCs), in a cognate fashion to drive robust innate inflammatory responses indicative of both NF-kB and IRF activation. These responses appear to be driven by TNFSF ligand-receptor interactions between CD8+ Tmem and DCs, respectively. The ability to induce innate inflammation is directly correlated with the expression of certain TNFSF ligands, and lack of inhibitory molecules, on CD8+ Tmem. These data suggest an evolutionary adaptation wherein CD8+ Tmem facilitate protective responses not only through direct effector functions, but also by inducing broad innate inflammation. Thus, we propose memory CD8+ T cells as surrogate microbes that can initiate proinflammatory and anti-viral responses through previously unexplored mechanisms.



 Cincinnati Children’s Research Foundation



 Immune Response Regulation: Cellular Mechanisms (IRC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf8f9321a00c72bc1594dfeaba5a6a038af8275a" target='_blank'>
              Memory CD8+ T cell-induced activation of the innate immune system drives inflammation and anti-viral immunity 3109
              </a>
            </td>
          <td>
            Charles N. Vallez, Satomi Ando, Koichi Araki, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Background: Recently, emerging evidence indicated that inflammation-induced epigenetic remodeling in tissue stem cells enhances either degenerative or regenerative responses of epithelial cells to subsequent inflammatory stimuli, a concept recently termed “inflammatory memory” (Zhao D: Blood 2025). We have previously demonstrated that GVHD induces epigenetic remodeling in intestinal stem cells (ISCs) in an IFN-γ-dependent manner, leading to enhanced antigen presentation, particularly via MHC class II (MHC-II), and increased susceptibility to apoptosis in intestinal epithelial cells (IECs) upon subsequent inflammatory stimulation (Miyajima T: 66th ASH annual meeting). In the current study, we investigated the mechanisms by which GVHD induces inflammatory memory in intestinal stem cells (ISCs) and evaluated strategies to suppress this process, using a mouse allogeneic hematopoietic cell transplantation (HCT) model, high-dose IFN-γ administration in naive mice, and an intestinal organoid culture system.
 Methods: Lethally irradiated BDF1 (H-2b/d) recipient mice were transplanted from allogeneic B6 (H-2b/b) or syngeneic BDF1 donors. Intestinal organoids were generated from the small intestines on day 21 post-transplant, cultured for 6 days, and subjected to RNA sequencing (RNA-seq), ATAC sequencing (ATAC-seq), and chromatin immunoprecipitation with quantitative PCR (ChIP-qPCR). We performed QIAGEN Ingenuity Pathway Analysis (IPA) of differentially expressed genes obtained from our RNA-seq data. Additionally, small intestines isolated on day 21 post-transplant were subjected to immunofluorescence staining for histopathological assessment.
 Results: IPA of RNA-seq data from intestinal organoids generated 21 days after mouse allogeneic or syngeneic HCT, focusing on epigenetic modifiers, identified histone acetyltransferase E1A-binding protein (p300) and its paralogue, CREB-binding protein (CBP), as candidate upstream regulators of GVHD-induced transcriptional modifications in IECs. Moreover, ATAC-seq of intestinal organoids revealed enrichment of ATF-3-binding motifs, a transcription factor that interacts with p300 and CBP, in chromatin regions that became significantly more accessible in GVHD compared to syngeneic controls. Consistent with the role of p300/CBP in promoting transcription through histone 3 lysine 27 acetylation (H3K27ac), immunofluorescence staining of the small intestine showed an increased number of H3K27ac+ IECs in GVHD mice. ChIP-qPCR analysis demonstrated that H3K27ac was enriched at the promoters of MHC-II genes (e.g., H2-Aa and H2-Eb1) in IECs from GVHD mice. High-dose IFN-γ also promoted H3K27ac enrichment at the promoters of IFN-γ-responsive genes in IECs, leading to enhanced antigen presentation and increased susceptibility to apoptosis upon subsequent exposure to low-dose IFN-γ. To assess whether p300/CBP is essential for inflammation-induced epigenetic modification, we knocked down (KD) Ep300 (encoding p300) and Cbp in intestinal organoids generated from naïve mice using lentiviral transduction of short hairpin RNA (shRNA). Ep300- or Cbp-KD organoids were treated with a high concentration of IFN-γ to induce epigenetic remodeling and subsequently rechallenged with a low level of IFN-γ. Compared with organoids transduced with nontargeting control shRNA, Ep300- or Cbp-KD organoids exhibited significantly attenuated enhancements of MHC-II upregulation and apoptosis induction following low-dose IFN-γ rechallenge, with Cbp-KD organoids exhibiting particularly strong suppression of inflammatory memory. This was further supported by experiments demonstrating that treatment of IFN-γ-stimulated intestinal organoids with inobrodib, a p300/CBP inhibitor, abrogated IEC hyperresponsiveness to IFN-γ rechallenge, whereas p300-specific inhibitors C646 and curcumin only partially suppressed this response.
 Conclusions: We found that GVHD induces epigenetic remodeling in ISCs through a p300/CBP-dependent manner, in which IFN-γ activates p300/CBP, leading to H3K27ac enrichment at target genes involved in IFN-γ responses. Given the emerging efficacy of p300/CBP inhibitors in various hematological malignancies (Nicosia L: Cancer Cell 2023, Welsh SJ: Blood Cancer Discov 2024), these agents represent promising therapeutic candidates for GVHD by suppressing inflammatory memory in ISCs, while potentially preserving GVL effects and additionally exerting direct anti-tumor activity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/882ab44caa862512ed803885d99907ad37117460" target='_blank'>
              Histone acetyltransferase p300/CBP as a therapeutic target to ameliorate gvhd-induced inflammatory memory
              </a>
            </td>
          <td>
            Toru Miyajima, D. Hashimoto, Asako Moriki, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Yumika Saito, Wenyu Li, Zixuan Zhang, S. Harada, H. Senjo, Yuki Yokoi, Y. Hasegawa, H. Ohigashi, Takahide Ara, Kiminori Nakamura, Koji Taniguchi, Takanori Teshima
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="


 Introduction:Cd39 expression in TIB-49 cells enhances the stemness and aggressiveness of AML blasts in vivo (PMID: 39157874, EHA2024-1113) via the Cd39-P2rx7-Wnt signaling axis. However, the impact of Cd39 overexpression in leukemic blasts within the bone marrow (BM) microenvironment still needs to be elucidated.
 Methods: Wild-type (WT) C57BL/6 mice were bred and maintained at Shandong Cancer Hospital and Institute. The syngeneic murine AML cell line TIB-49 from American Type Culture Collection was transduced with a lentiviral vector to overexpress Cd39 and labeled with TdTomato (hereafter referred to as TIB-Cd39high). WT mice were injected intravenously with 1×10⁶ TIB-49 or TIB-Cd39high cells, respectively. BM cells were harvested from leukemic mice for single-cell RNA sequencing (scRNA-seq, CapitalBio Technology, Beijing, China) and flow cytometry (FACS) analysis when showing leukemic symptoms.
 Results: Transcriptomic profiling analysis showed a significant increase in neutrophil proportions in the BM of TIB-Cd39high-bearing mice (BMC2) when compared to TIB-49-bearing mice (BMC1), which was also confirmed by FACS analysis. Neutrophils were then classified into five major subpopulations based on the expression of known marker genes: G1 (Prtn3, Elane), G2 (Ltf, Camp, Ngp, Chil3, Fcnb), G3 (Ltf, Camp, Ngp), G4 (Mmp8, Retnlg), and G5c (Fgl2, Gm2a, Gngt2), corresponding to progressive stages of neutrophil development and maturation (PMID: 32719519). G3 and G4 were found to the predominant populations in BM. Gm26917, G6pdx, Clec2d, and Ifi27l2a were identified as upregulated differentially expressed genes (DEGs) in G3/G4 subsets from the BMC2 compared to the cells from BMC1. Notably, Clec2d has been found to be associated with immunosuppression, directly inhibiting CD4⁺ T cell activity and proliferation via interaction with the Cd161 receptor (PMID: 38153903). We next investigated interactions between AML cells and neutrophils. Cytokine-receptor pair analysis revealed reduced Spp1-Cd44 signaling in the BMC2. Given the critical role of Spp1-Cd44 in neutrophil recruitment and differentiation, its downregulation in the BMC2 may impair neutrophil maturation or promote a pro-tumorigenic, immunosuppressive phenotype.
 Additionally, a higher proportion of Cd4⁺ T cells (Th1 subset) was observed in the BMC2 than that in the BMC1, which was also validated by FACS analysis. GO and KEGG enrichment analyses of these cells showed enhanced leukocyte degranulation but attenuated responses to external stimuli and chemical stress. KEGG pathways associated with neutrophil extracellular trap formation were upregulated, while immune-related pathways (e.g., IL-17 and TNF signaling) were downregulated, suggesting suppressed T cell proinflammatory functions. Our prior work (EHA2025-2202) highlighted the functions of Spp1-Cd44 axis in the interactions between TIB-Cd39high cells and Th1 cells in the BMC2, suggesting its role in AML-mediated immune modulation.
 Beyond AML-immune cell interactions, we analyzed neutrophil-Cd4⁺ T cell crosstalk. The Lgals9-Cd44 signaling from neutrophils to T cells was significantly upregulated in the BMC2. Lgals9 (Galectin-9) was found to regulate T cell functions, including Th1 expansion and apoptosis, further implicating this axis in BM immunosuppression.
 Conclusion: Our findings demonstrated that Cd39 overexpression in AML blasts elicited an immunosuppressive BM microenvironment through the expansion of G3/G4 neutrophils and Th1 cells, which was mediated by three key mechanisms: (1) the Spp1-Cd44 axis, which drive AML-induced effects on neutrophils and Th1 cells; (2) Clec2d-Cd161 signaling, facilitating neutrophil-mediated suppression of CD4⁺ T cells; and (3) Lgals9-Cd44 crosstalk, connecting neutrophil dysfunction to impaired T cell activity. These results suggested that targeting Cd39 could disrupt the immunosuppressive BM microenvironment mediated by leukemic blasts, neutrophils and CD4⁺ T cells, thereby enhancing anti-leukemic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cde55e438575718386905fd8130a85f6e94ae0f1" target='_blank'>
              Cd39 overexpression in AML blasts elicits an immune suppressive bone barrow microenvironment via G3/G4 neutrophils and Th1 cells
              </a>
            </td>
          <td>
            Hanheng Mai, Hui Yuan, Yunqing Liu, Tan Sang, Zonghong Li, Xiuyan Chen, Jinming Yu, Y. L. Wang, Lili Feng
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors exhibit limited efficacy in metastatic cancers, especially in elderly patients. Innate immune agonists like STING and CD40 agonists have the potential to trigger systemic anti-tumor responses but remain clinically suboptimal. Strategies to fully exploit the therapeutic potential of intratumoral innate immune agonists remain under development. In this study, we demonstrate that intratumoral injection of the STING agonist cGAMP, in combination with CD40 agonists, effectively eradicates distant metastatic tumors in both young and aged mice—an effect not achievable with single-agent therapies. Mechanistically, cGAMP enhances antigen-presenting cell activation and promotes NK cell infiltration, leading to the regression of primary tumors, while CD40 stimulation facilitates DC1 migration to tumor-draining lymph nodes and primes tumor-specific T cells. Notably, the cGAMP-CD40 synergy reprograms the myeloid compartment into a distinct state marked by high production of IL-12, interferons, and GM-CSF. Deletion of CD40 or STING specifically in DC1 cells, rather than in macrophages, abolished these effects and impaired anti-tumor immunity. This reprogramming further promotes the robust induction of T-bet–expressing anti-tumor T cells and NK cells, culminating in effective tumor rejection. These findings reveal a novel localized therapeutic strategy that synergizes with existing immunotherapies and holds promising potential for advancing cancer treatment.



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/acf653c43ca927e80f1fae7a3a2b9fd485e4fd79" target='_blank'>
              Synergy of STING and CD40 agonists in DC1-mediated anti-tumor immunity and cancer immunotherapy 9387
              </a>
            </td>
          <td>
            Minglu Yan, Z. J. Chen
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Tumor-derived extracellular vesicles (tEVs) play a pivotal role in immune suppression within the tumor microenvironment (TME) by inducing T-cell senescence, a novel mechanism of dysfunction distinct from exhaustion. Here, we identify programmed death-ligand 1 (PD-L1) as a critical component of tEVs that promotes T-cell senescence through activation of the ATM-associated DNA damage response and subsequent CREB and STAT1/3 signaling. Functionally, tEVs suppress T-cell proliferation and effector activity, thereby contributing to resistance against immune checkpoint blockade therapies. Using in vitro and in vivo melanoma models, we demonstrate that targeting PD-L1, or inhibiting CREB signaling reverses T-cell senescence and enhances anti-tumor immunity. Furthermore, combining this strategy with immune checkpoint inhibitors significantly improves therapeutic efficacy. This study uncovers a novel molecular mechanism underlying tEV-mediated immunosuppression and provides a foundation for innovative combination therapies to overcome resistance and improve cancer immunotherapy outcomes.



 This work was partially supported by grants from the Melanoma Research Alliance (No. 621833 to G. P) and the NIH (CA184379, CA242188, CA237149, AI173260, AG078822, and AG067441 to G. P; GM128047 and GM141652 to Y. W).



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8702dc9583d2ff9ad9400aeaa6a78a7b6b31b7da" target='_blank'>
              PD-L1 in tumor-derived extracellular vesicles promotes T-cell senescence and suppression of tumor immunity 4555
              </a>
            </td>
          <td>
            Yuanqin Zhang, Feiya Ma, Xia Liu, Hazar Abusalamah, Yuqi Wang, Guangyong Peng
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Immunotherapy, including immune checkpoint inhibitors, antagonizes many hematologic malignancies, but has transient effects on acute myeloid leukemia (AML), as innate immune cells like macrophages remain inactive. Nucleotide metabolism is critical to regulate multiple cellular functions, and cytidine triphosphate synthase 1 (CTPS1), which catalyzes de novo CTP biosynthesis, is essential for cell proliferation. We previously (Liu, 2024, ASH) showed that high CTPS1 activity promotes cancer cell growth and suppresses anti-AML immunity. Accordingly, the administration of the CTPS1 inhibitor STP-B significantly extended the survival of immunocompetent leukemic mice, an effect requiring an immune response. Analysis of TCGA cohorts, including AML, glioblastoma, and non-small cell lung cancer, consistently demonstrated a negative correlation between CTPS1 expression and macrophage M1 signature. Herein, we show that targeting CTPS1 by STP-B exerts potent anti-AML activity by 1) promoting myeloid differentiation, in particular, macrophage M1 polarization triggered by dNTP imbalance, and 2) stimulating IFN-I signaling by inhibiting CTPS1-mediated deamidation of IRF3 and histone H1.
 To further define these mechanisms, we first employed a syngeneic MLL-AF9 (MA9) leukemia transplant model. Leukemic mice were administered STP-B orally (100 mg/kg/i.g./day) for 3 weeks. Then, full-spectrum flow cytometry revealed that treatment decreased leukemia burden and markedly increased CD11b⁺F4/80⁺ macrophage number and the frequency of the M1-like subset. Macrophage depletion by liposomal clodronate before STP-B treatment completely abolished survival advantages seen in STP-B-treated mice. Moreover, in the MA9 mouse model, treatment with STP-B and anti-CD47 in vivo synergized to antagonize AML, highlighting the significance of macrophage function. Transcriptomic profiling of MA9 cells (GFP+) and non-malignant myeloid cells (GFP-CD11b+) showed that STP-B treatment significantly upregulated macrophage M1_SIGNATURE_1 gene set, including Il6, Il1a, Cxcl9, and Cxcl10. As confirmation, we performed an ex vivo phagocytosis assay using STP-B–pretreated bone marrow-derived macrophages (BMDMs) co-cultured for 4 hours with MA9 cells and found that STP-B–treated BMDM cells showed significantly increased phagocytic activity.
 To assess how STP-B impacts human hematopoiesis, we transplanted CD34⁺ cord blood cells into sublethally-irradiated NSG mice and administered STP-B 8-12 weeks post-transplant. While total human CD45⁺ cellularity was unchanged, treatment markedly increased the size of myeloid (CD33⁺CD11b⁺) and monocyte (CD14⁺CD64⁺) subsets, and increased HLA-DR⁺CD86⁺ M1-like macrophages. RT-qPCR showed increased expression of myeloid transcription factors and human M1-associated genes in STP-B-treated NSG mice.
 We then performed metabolomic profiling of monocytic THP-1 cells, a model of myeloid differentiation, to assess intracellular NTP and dNTP levels. STP-B treatment drastically decreased intracellular CTP levels, suggesting nucleotide imbalance. Co-treatment with a ribonucleotide reductase (RNR) inhibitor partially rescued this imbalance and reversed THP-1 cell differentiation. Importantly, STP-B-mediatedupregulation of M1-associated geneswas reduced by RNR inhibition. These results support the idea that STP-B–mediated differentiation is driven by disrupted nucleotide metabolism, as we have proposed (PMID: 35439288).
 Moreover, GSEA indicated that STP-B treatment upregulates IFN-I-responsive genes, likely due to its DNA damage-inducing effects. CTPS1 is one of 11 glutamine amidotransferases, which catalyze histone H1 deamidation to promote DNA repair. STP-B inhibits these activities and promotes DNA damage, based on increased nuclear S9.6 staining and high γH2AX levels seen in STP-B-treated THP-1 cells. CTPS1 also deamidates IRF3, suppressing its transcriptional activity, an effect blocked by STP-B, enhancing expression of IFN-stimulatory genes (ISGs). To investigate these activities, we reconstituted CTPS1-knockout THP-1 cells with wild-type or glutaminase-deficient mutant CTPS1. Relative to wild-type CTPS1, expression of the mutant form exhibited ISG upregulation, suggesting that deamidation activity is critical to suppress IFN signaling.
 Together, these findings reveal that systemic STP-B treatment drives macrophage specification and innate immune activation, highlighting STP-B as a leukemia-ablating agent with immune-stimulatory potency.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5e67f75788626a6da21880fbbf0cb95e147dab25" target='_blank'>
              Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity
              </a>
            </td>
          <td>
            Meng Liu, Lei Zhang, Xin He, Haojie Dong, Yang Li, Shuaishuai Ge, Guohua Wu, Umesh Yadav, Wei Chen, Pinghui Feng, Guido Marcucci, Ling Li
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>29</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [4],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>